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Murine CD8α+ dendritic cells (DC) are antigen-presenting cells with tolerogenic properties, 
including ability to prolong allograft survival. Little is known, however, regarding their 
migratory ability, either in vitro or in vivo. Limited work to date has yielded inconsistent 
findings, and potential impediments to use of this subset to promote tolerance induction are 
reported discrepancies regarding their ability to “home” to secondary lymphoid tissue. Despite 
functional differences from classic CD8α- DC, the two subsets exhibit similar phenotypes and 
commonly coexist in the same tissues, suggesting expression of similar homing 
molecules/receptors. The central hypothesis underlying these studies was that CD8α+ and 
CD8α- DC have equal ability to respond to migration-inducing factors, both in vitro and in 
vivo. Our aim was to determine the factors and potential therapeutic targets that regulate CD8α+ 
DC migration. Herein we have employed an in vitro chemotaxis assay for the determination of 
which, if any, CC chemokines specifically regulate the migration of CD8α+ (and CD8α-) murine 
spleen DC. We also used this assay with the addition of endothelial cell layers, to assess the 
adhesion molecules that facilitate DC transendothelial migration. Two chemokines (CCL19 and 
CCL21) elicited CD54-dependent migration of both mature DC subsets, in the presence or 
absence of endothelial cells, but CD8α+ DC migrated in consistently fewer numbers than CD8α- 
DC in vitro. Our findings led us to investigate the importance of the in vitro migration-inducing 
chemokines in vivo. In these studies we compared the ability of DC subsets to migrate to T cell 
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areas of wild type and specific chemokine-deficient mice. Unlike our in vitro results, the DC 
subsets migrated with equal efficiency in normal recipients. After sc injection into 
CCL19/CC21-deficient mice, CD8α- DC trafficked more efficiently than CD8α+ DC to draining 
lymphoid tissue. The necessity of specific chemokine-directed DC migration in vivo for 
alloimmune responses was borne out in transplant studies in which impaired migration of DC 
resulted in significant prolongation of murine cardiac allograft survival. These studies 
demonstrate, for the first time, potential chemokine and adhesion molecule targets for 
manipulation of murine DC subset migration in vivo. 
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 1. INTRODUCTION 
1.1. Dendritic Cells 
Dendritic cells (DC) are the most potent antigen (Ag) presenting cells (APC) of the immune 
system. They are essential in both innate and adaptive immune responses. As pre-DC, they can 
activate anti-viral and anti-tumor NK cell-mediated responses through the release of IFNα (1). 
Mature (m) DC can also augment NK and NK/T cell activity through the release of IL-12, IL-15, 
and IL-18 (2-4). Unlike other APC—B cells and macrophages (Mφ), DC are capable of 
activating naïve T cells, and thus essentially are responsible for the initiation of adaptive immune 
responses. Though rare compared to the number of cells per tissue in which they reside, DC are 
found ubiquitously throughout the body, with specific concentrations of DC in the thymus and 
secondary lymphoid tissues. DC also are important in the regulation of autoimmunity, negatively 
selecting too-strongly-reactive self-recognizing T cells. Thus, though discovered just 30 years 
ago (5), DC are of major interest to cancer immunologists (as hopeful powerful anti-tumor 
immune initiators) and to transplant- and auto-immunologists and allergists (as regulators of T 
cell tolerance). 
 
1.1.1. Phenotype & Function 
In both the human and the mouse, DC typically are characterized by their expression of CD11c 
(4)[human plasmacytoid (p) DC are an exception – these DC are characterized (partly) by their 
lack of CD11c (6, 7)]. In the rat, DC are classified by their expression of CD11c, MHC II, and 
αε-integrin (OX62) (8). In non-human primates, DC are characterized by their expression of 
CD83, a feature they share with human DC (9). DC also express an array of other cell surface 
molecules not necessarily unique of their cell type, but typical to DC. They are considered to 
exist primarily in one of two states of maturation. Generally, immature (i) DC are CD11c+ and 
1
 characteristically express MHC I and low levels of MHC II (CD8+ and CD4+ T cell Ag-
presenting molecules, respectively), CD40, CD80, CD86 (classic costimulatory molecules), and 
inducible costimulator (ICOS) ligand (L), programmed death (PD)L-1 and 2 (neo-classic 
costimulatory molecules), with mid to high expression of CD31 and CD54 (adhesion molecules) 
(Table 1). iDC are also morphologically and functionally distinct. They exhibit short, “stubby” 
prolongations, possess multiple cytoplasmic vesicles (some of which contain Ag-laden MHC II 
molecules), and have manifest nucleoli (Fig 1a, c, and e). In this state, DC function primarily as 
environmental samplers, taking up soluble or particulate Ags (Fig 2a) and processing them for 
later presentation to naïve and memory B and T cells, making iDC poor immunostimulators in 
mixed leukocyte reactions (MLR) (Fig 2b). mDC maintain their levels of CD11c, CD31, and 
CD54, but upregulate Ag-presenting and costimulatory molecules, although the level of their 
upregulation can depend on the degree and type of stimulation (Table 1). mDC have extended 
cytoplasmic prolongations [dendrites, the initial observation of which gave DC their name (5)] 
and lobulated nuclei (Fig 1b, d, and f), do not phagocytose particulate Ags (Fig 2a), and are 
potent stimulators of T cell proliferation (Fig 2b). 
2
 
Fig 1. Morphology and ultrastructure of 
i(CD86-) and m(CD86+) murine (BM)DC.   
iDC possess short, blunt prolongations (A), a 
round nucleus with prominent nucleoli, multiple 
cytoplasmic vesicles, mitochondria, few 
lysosomes (C), and typical “veils” (E). After 
maturation, CD86+ DC show a typical dendritic 
morphology, with an eccentric, indented nucleus 
(B, D) and a veiled surface with delicate 
filamentous projections with knoblike tips (F, 
arrow). (A-B) May-Grünwald-Giemsa. (C-D) 
TEM x6000. (E-F) SEM x3500. Bar, 5 µm (10). 
Copyright America Society of Hematology, used 
with permission. 
 
 
Fig 2. i and m (BM)DC 
function.  
(A) FITC-dextran and FITC-
albumin uptake by murine 
CD11c+ bead-sorted CD86- 
(i) and CD86+ (m) BMDC. 
Only iDC internalized FITC-
dextran and FITC-albumin at 
37°C, a phenomenon down-
regulated at 0° C. Results are 
representative of 3 independent experiments. (B) Allostimulatory activity of γ-irradiated, FACS-sorted 
CD86- (i) (t) or CD86+ (m) B10 DC (?), assessed using C3H splenic T cells as responders. B10 (H2b) 
DC (d 7 of culture) were set up at graded concentrations with 2-3x105 responder naive C3H (H2k) T cells, 
and the cultures were maintained for 72 hours. [3H]TdR was added 18 hours before harvesting. The MLR 
stimulatory activity of freshly-isolated allogeneic (B10 [m]) or syngeneic (C3H [l]) bulk spleen cells is 
also shown. Results are expressed as mean cpm ± 1 SD and are representative of at least 3 separate 
experiments (10). Copyright America Society of Hematology, used with permission. 
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 Table 1. Typical Dendritic Cell Markers. 
state of 
maturation major ligand(s) cell surface 
molecule function iDC mDC 
subset(s) human/mouse/primate/rat molecule(s) cell(s) expressed 
CD1aa non-classic MHC ++ ++ LC h TCR T cells 
CD8α T cell marker ++ ++ CD8α+,b; m MHC I all cells 
CD11b 
(Mac-1; CR3) AM
a ++ ++ CD8α-c h,m,p,r CD54, iC3b, fibrinogen 
Mo, neutrophils, 
DC, FDC 
CD11c AM
a/DC 
marker +++ +++ 
all but 
human/primate 
CD45R+
h,m iC3b, fibrinogen N/A 
CD31 
(PECAM-1) AM ++ ++ all h,m,p,r CD31 
DC, B cells, 
T cells, Mo, EC 
neutrophils 
CD40 costim -/+ +++ all h,m,p,r CD154 activated T cells, NK cells 
CD45R 
(B220) 
signal 
transduction/
DC marker 
++ ++ pDC hd,m,p unknown N/A 
CD80 
(B7.1) costim ++ +++ all h,m,p,r 
CD86 
(B7.2) costim + +++ all h,m,p,t 
CD28/ 
CTLA4 
naïve/activated T 
cells 
CD83 
Ig 
superfamily/ 
DC marker 
- ++ all h,p (unknown) (unknown) 
CD123 
(IL-3Rα) IL-3R ++ ++ CD45R
+ h,p IL-3 
activated T cells, 
mast cells, 
eosinophils 
CD205 
(DEC 205) ER ++ ++ CD8α+e; LC m 
mannosylated 
proteins? 
(unknown) 
pathogens 
CD207 
(Langerin)f
induces 
BG/ER ++ ++ LC h,m,p,r 
mannosylated 
proteins? 
(unknown) 
pathogens 
ICOSL costim -/+ +++ allg h,m ICOS naïve T cells 
PD-L1 costim -/+ +++ allg h,m 
PD-L2 costim -/+ +++ allg h,m 
PD naïve T cells 
TLR4 microbial recognition ++ +++
h CD8α- DC h,m LPSi bacteria 
TLR9 microbial recognition ++ +++
h pDC h,m CpG viruses 
aAM—adhesion molecule; BG—Birbeck granules; CD – cluster of differentiation; costim—costimulatory 
molecule; CpG – cytosine poly-guanine; ER – endocytic receptor; F – follicular; Gr – granulocytes; ICOS 
– inducible costimulatory molecule; L – ligand; LC – Langerhans cell; Mo – monocytes; Mφ -- 
macrophages; PD – programmed death; PECAM – platelet and endothelial cell adhesion  molecule; TLR 
– toll-like receptor; awhen coupled with CD18; bupregulated on Langerhans cells (LC) after migration to 
the draining lymph node after activation; clow levels on CD8α-; dCD11c- DC only; elow levels on CD8α-; 
f(11); galthough the level of expression may vary according to tissue of isolation/subset (Lau and de 
Creus, unpublished observations); h at least when activated with LPS; ialthough LPS is the primary ligand 
for TLR4, other stimuli also activate this receptor (12). 
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 In response to the release of inflammatory – “danger” – signals [e.g., tumor necrosis factor 
(TNF)α, cytosine poly-guanine (CpG), and lipopolysaccharide (LPS), -- all of which are also 
used to mature DC in vitro] from injured tissues/pathogens, local iDC become activated. 
Activated DC begin to lose their ability to take up Ag, upregulate Ag-presenting and 
costimulatory molecules, and downregulate receptors for inducible chemokines and upregulate 
receptors for constitutive chemokines (further discussed in Section 1.2). Mature/semi-mature 
DC1 then traffic to the nearest draining (D) LN, spleen, or intestinal Peyer’s patch. Once in 
secondary lymphoid tissues, mDC enter (primarily) T cell areas for activation of naïve and 
memory T cells [while some DC also traffic to B cells areas for aid in the differentiation of B 
cells to memory and plasma cells (4, 13-15)]. 
 
Not all DC subsets (discussed further in Section 1.1.2) are capable of responding to the same 
stimuli (16). Toll-like receptors [TLR; so-called because of their conserved homology to toll 
receptors, first described in Drosophila (12)] are expressed specifically on various cell types and 
respond to specific microbial and autologous signals. TLR are restricted both by subset as well as 
state of maturation on DC. While TLR 1, 2, 4, and 5 are expressed at high levels on iDC, all are 
downregulated upon maturation (17). TLR3, on the other hand, is expressed only on mDC (18). 
Human blood-isolated, plasmacytoid DC (pDC), identified by their expression of CD123 and 
lack of CD11c (6, 7) express TLR7 and 9, and produce IFNα in response to binding of 
unmethylated CpG bacterial DNA fragments to TLR9 (19-23). “Myeloid” DC (CD11c+CD123-) 
reportedly express TLR1-5 (12, 16, 17, 20). Murine spleen-isolated DC show a slight different 
                                                 
1 Though “veiled cells” have been identified in lymphatic vessels (13-15), little is known about the order 
of the expression of cell surface molecules on and state of maturation of activated DC during their 
transition from the periphery to secondary lymphoid tissues. 
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 expression pattern for TLR. Interestingly, while TLR3 is expressed only on mDC in humans, it is 
selectively expressed on CD8α+ murine iDC and TLR5 and 7 are absent (24). Further, while the 
murine spleen pDC do express TLR7 and 9, CD8α- DC also express TLR7, a TLR exclusive to 
pDC in humans. However, this divergence from human DC may be more tissue-related than 
species-related, as murine bone marrow-derived DC express a similar TLR pattern to human 
blood-derived (25).  
 
Naïve T cells need three signals to become activated: (i) TCR/MHC ligation, (ii) 
CD28/CD80/CD86 costimulation, and (iii) secretion of T helper cell (Th)-inducing cytokines by 
DC, for example IL-12 (Fig 3). In the absence of signal one, naïve and memory T cells ignore 
DC, and thus do not become activated. In the absence of signal two and/or signal three, naïve T 
cells can become anergic or apoptotic. Memory T cells do not need all three signals and therefore 
can be activated by non-DC APC [such as B cells, Mφ, and, in rare instances, EC, none of which 
have the capacity to deliver signals two and three (26-28)]. 
2 
 Fig 3. DC are the only APC capable of delivering the three signals necessary for activation of naïve 
T cells.  
mDC present peptides to naïve T cells via MHC/TCR interactions (Signal 1). The interaction of CD80/86 
on mDC with CD28 on the T cell results in the delivery of Signal 2. Ligation of CD40 on DC with 
CD40L on the semi-activated T cell (for example, not shown here), in turn further activates the DC, 
resulting in secretion of IL-12 by the DC, inducing a Th1 phenotype in the formerly naïve T cell (Signal 
3). (29) Reprinted with the permission of Cambridge University Press. 
 
DC (principally CD8α+ DC) regulate central tolerance through negative selection of autoreactive 
T cells in the thymus. DC also are thought to regulate peripheral tolerance in the absence of 
inflammation through steady state trafficking from the periphery to DLN bearing self and 
“innocuous” non-self Ag, likely from engulfed apoptotic bodies (30-32). Interactions of  
(CD11c+CD8α+) DC bearing Ag with naïve T cells in the absence of danger have been reported 
to induce anergy (32), deletion (33), or both (34), or regulatory T cells (T reg) (30, 35, 36). 
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 1.1.2. Origin 
DC, like all leukocytes, arise from hematopoietic stem cells (HSC). The elusive DC-specific 
precursor that gives rise to DC only, however, is yet to be identified. DC can arise from 
progenitor cells as plastic as a BM precursor (pre)-DC (10) (which can give rise to a variety of 
cells of the myeloid lineage in the appropriate cytokine environment), or as differentiated as 
reverse-transmigrating monocytes  (which differentiate into macrophages if they remain in the 
subendothelial collagen) (37). Nevertheless, DC can be generated from pre-DC in in vitro culture 
systems or isolated directly from tissues. Human DC studies typically utilize DC derived from 
blood-derived CD34+ progenitor cells (38) or CD14+ monocytes (39, 40), or iDC emigrated from 
skin explants (Langerhans cells; LC) (38, 41). Non-human primate studies utilize blood- or 
lymph node-derived DC (42, 43). Rat DC can be generated from BM and secondary lymphoid 
tissues such as the gut associated lymph (GALT), Peyer’s patches, lamina propria, and the 
mesenteric lymph nodes (LN) (8). DC in murine studies commonly are generated from the bone 
marrow (BM). However, mouse DC have been reported to be directly isolated for study from the 
skin (4, 38), Peyer’s patches (44, 45), spleen (46-48), kidney (49, 50), liver (51-54), and blood 
(55). Derivation of murine DC subsets also has been reported for a variety of precursors, as 
discussed further below. 
 
Precursor cell populations require a variety of cytokines to differentiate into DC depending on 
the species and tissue of origin. Human CD34+ hematopoietic precursor cell (HPC) cultures give 
rise to CD1a+CD14- and CD1a-CD14+ cells which differentiate into LC [skin immature (i) DC 
which express Langerin (CD207) and E-cadherin and possess Birbeck granules (11)] and dermal 
(which lack these markers and express Factor XIIIa and CD2, CD9, and CD68) DC, respectively, 
after addition of granulocyte/macrophage-colony stimulating factor (GM-CSF) and tumor 
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 necrosis factor (TNF) (38). DC are generated from human and non-human primate blood 
mononuclear cells cultured in the presence of GM-CSF and IL-4 (9, 39, 40). Addition of 
transforming growth factor (TGF)β to GM-CSF and interleukin (IL)-4-cultured monocytes also 
yields LC (56). Interestingly, it has been shown that G-CSF, which reportedly selectively 
mobilized the pDC population in human blood (57), recently has been shown to augment pDC 
numbers in peripheral blood through downregulation of CD62L (and consequent prevention of 
pDC exodus into lymphatics), not through inducement of proliferation of blood pDC progenitors 
(58). After red blood cell lysis and complement depletion of other precursors (B, NK, red blood, 
and T cells and granulocytes), murine BM cells cultured in media supplemented with GM-CSF 
and/or IL-4 differentiate into iDC between days 4-6. Although GM-CSF alone is sufficient to 
produce DC, addition of IL-4 to BMDC cell cultures generally results in a more mature DC 
phenotype at an earlier stage than in cultures supplemented with GM-CSF alone (~6-7 d vs ~8-9, 
respectively) (59).  
 
It also has been reported that “lymphoid-related” DC [putative tolerogenic CD8α+-expressing 
mouse DC (60)] and pDC [interferon (IFN)α-secreting mouse, human, and non-human primate 
DC (6, 7, 42, 61, 62, 63 Coates, 2003)] both requiring addition of IL-3, and regulatory DC 
(putative T reg-inducing DC) requiring TNFα and IL-10 (64) (all discussed in Section 1.1.4) can 
be generated from BM cell cultures, but the complex cytokine cocktails [i.e., IL-1β, TNFα, IL-7, 
stem cell factor, IL-3, FL, and CD40L for CD8α+ DC (60)] necessary for the differentiation have 
led most investigators to isolate these DC directly from tissue.  
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 The belief that murine CD8α+ DC were of lymphoid lineage has lead to several investigations 
regarding the origin of these DC. Though the subject of debate, CD8α+ and CD8α- DC 
reportedly can arise from either committed lymphoid or myeloid progenitors [CLP or CMP, 
respectively, as discussed further in Section 1.3 (65, 66)]. The hematopoietic growth factor fms-
like tyrosine kinase 3 ligand (Flt3L; FL) also has been found to be useful in the generation of 
human and mouse DC both in vitro and in vivo, and it has been particularly useful in facilitating 
the growth of mouse pDC in vitro (25, 54). Rat DC can be generated under culture conditions 
similar to those for mouse BMDC (67). DC arise from in vitro culture systems from anywhere 
between 4-10 days, depending on precursor cell populations and culture conditions.  
 
As discussed in Section 1.1.1, early in vitro-generated DC are immature in phenotype, 
morphology, and function.  In vitro-generated DC continue to differentiate into mature (m) DC 
with extended culture or with the addition of inflammatory stimuli, such as TNFα, LPS, CpG, 
and/or CD40L, as evidenced by changes in their phenotype, morphology, and function, and 
concordant with the nuclear translocation of nuclear factor (NF)- κβ [the blocking of which 
impedes DC differentiation and maturation (68, 69)]. Freshly-isolated tissue DC are fully-
differentiated DC which resemble early iDC from in vitro-cell cultures, although due to their 
rarity, mice typically are pre-treated with a hematopoietic growth factor(s) such as FL (47, 70, 
71), GM-CSF (72), or the combination of both before harvesting (62, 73). Many investigators 
administer FL intraperitoneally (ip) into mice for 10 days before sacrifice, as FL reportedly 
expands both CD8α+ and CD8α- DC subsets, while GM-CSF selectively expands the CD8α- DC 
population (73). FL dramatically increases DC in the BM, GALT, liver, spleen, LN, lung, 
peritoneal cavity, thymus, and peripheral blood, in addition to stem cells and various leukocyte 
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 populations (74). Aside from their increased number, FL-DC are otherwise reportedly identical 
to DC from non-growth factor treated mice (48, 75).  Unlike in vitro-generated DC, however, 
tissue-isolated DC (from both FL- and untreated animals) mature after overnight culture (16-18 
h), without the addition of exogenous factors. GM-CSF, though not necessary for maturation, is 
typically added to overnight cultures of tissue-isolated DC to aid in the maintenance of cell 
viability (52). 
 
1.1.3. DC Subsets 
Another complication in determining the origin of DC is the existence of multiple DC subsets. In 
mouse secondary lymphoid tissue, and some non-lymphoid tissues [such as the kidney (50) and 
liver (53, 54, 76, 77)], at least three major DC subsets have been defined: CD11c+CD8α-CD11bh 
(immature “myeloid”), CD11c+CD8α+CD11blo (immature “lymphoid”), and 
CD11c+B220+CD11b+CD8α+/- (immature “plasmacytoid”) (54, 61, 62, 78). In the human and 
non-human primate, there are at least two: CD11c+CD123- (immature “myeloid”) and CD11c-
CD123+ (immature/pre-“plasmacytoid”) (6, 7, 42). These subsets are not only phenotypically 
distinct, but they can be classified functionally as well. 
 
1.1.3.1. Mouse DC Subsets 
CD11c+CD8α-CD11bhi DC (denoted henceforth by their common nomenclature, CD8α- DC) 
have been previously referred to as “classic” myeloid DC and generally describe any mouse DC 
from any tissue/culture condition that does not express/result in CD8α or B220 expression (Figs 
4 and 10 and data not shown). The best-studied of murine DC subsets, these DC are considered 
to reside in the marginal zone of secondary lymphoid tissues (31, 79) and generally are 
considered to be the immunogenic mouse DC subset (32, 47, 80-84), at least in the mature state 
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 (10, 47). In addition to their high expression of CD11b and the absence of CD8α on their 
surface, they also are frequently characterized by their low to non-existent expression of DEC-
205 (CD205) (Table 1). Early experiments with the CD11c+CD8α- DC subset suggested they 
were the Th1-inducing DC subset (75, 85), but almost immediately it was shown they can induce 
Th2 cells as well (86). 
Fig 4. Despite some phenotypic differences, 
CD8α- and CD8α+ DC are similar in 
morphology. 
 Metrizamide-enriched, splenic mDC were 
cytospun and then stained for expression of CD8α 
with biotinylated anti-CD8α and ABC/alkaline-
phosphatase (brown). Nuclei were stained with 
Giemsa (blue). Both mDC subsets exhibit similar 
dendritic extensions and lobulated nuclei (Amanda 
Schell, Summer 2001, unpublished data). 
 
 
Formerly known as lymphoid or “lymphoid-related” DC, CD11c+CD8α+CD11blo (CD8α+ DC) 
DC were first discovered in the thymus (78), spleen, and LN (46), but now are known to reside 
in the Peyer’s patches (44, 45), the kidney (50), and the liver (51, 52, 54) as well. 
Morphologically similar to CD8α- DC (Fig 4), CD8α+ DC express high levels of CD205 and low 
levels of CD11b (Table 1). Despite their presence in numerous tissues, even optimized isolation 
procedures require large numbers of animals to procure enough DC for study. Therefore, FL, 
which dramatically increases both CD8α+ and CD8α- DC numbers [as compared to GM-CSF, 
which selectively augments the expansion of CD8α- DC (72)], is frequently administered to the 
animals for 10 days prior to tissue harvest (42, 48, 50, 52, 71, 74).  
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 Early reports of these DC suggested that their expression of surface FasL (CD178) induced 
activation induced cell death in CD4+ T cells (84) and that they indirectly suppressed CD8+ T 
cell proliferation through suppression of IL-2 production (83) (both in an allo-MLR). However, 
neither these T cell suppressive properties nor the expression of FasL have been repeated by 
other groups. Nevertheless, O’Connell et al (47) found that CD8α+ DC, in both the immature and 
mature states, significantly prolonged mouse heart allograft survival, while only CD8α- iDC 
could delay graft rejection -- CD8α- mDC accelerate the rejection process. Further, another 
group has shown that populations of CD8α- DC containing only 3% CD8α+ DC are impaired in 
their ability to instigate an immunogenic response against a tumorigenic self-peptide due to 
CD8α+ DC secretion of indoleamine 2,3-dioxygenase (IDO), the first enzyme of the tryptophan 
degradation pathway. Interestingly, this ability of CD8α+ DC to suppress CD8α- DC 
immunogenicity can be itself abrogated by addition of IL-12 to cultures (82). However, further 
addition of IFNγ blocks the ability of IL-12 to overcome the CD8α+ DC-induced suppression 
(87). Additionally, the thymic DC population is nearly 95% CD8α+ (78), delegating this DC 
subset to what is likely an entirely tolerogenic role in this primary lymphoid organ. Therefore, 
despite confusion with early reports, these DC still remain of interest in the fields of 
transplantation and tumor immunology.  
 
CD11c+B220+CD11b+CD8α+/-, or pDC, are the most recently discovered mouse DC subset (61-
63) that appears to be good a candidate for the murine equivalent of human pDC (6, 7). pDC, 
despite one study implicating CD8α+ DC (88), are reportedly the major IFNα-secreting DC 
subset. Although nearly any cell type can produce IFNα in response to viral exposure, pDC 
produce a much higher concentration of IFNα at a much lower exposure of virus (6, 23, 42, 45, 
9 
 62, 89). pDC have been isolated from murine spleen (62), liver (54), blood (55), and even the 
thymus (90), and due to the rarity of pDC, these tissues are typically harvested from mice which 
have been pre-treated with FL (or FL + GM-CSF) to increase their numbers (54, 62). Freshly-
isolated pDC are fragile in culture and require IL-3 and CD40L (rather than GM-CSF) for 
survival. Despite the fact that IFNα is a Th1 cytokine (generally considered immunogenic), pDC 
appear to be replacing CD8α+ DC as the putative endogenous tolerogenic DC subset (42, 91). 
This theory is supported by the suggestion that pDC are capable of inducing T reg cells (61, 92), 
possible powerful tools for implementation of transplant tolerance and autoimmune regulation. 
Even more recently described (64, 93), the in vitro-generated “regulatory” DC may also be 
important candidates. 
 
Despite the correlation between these differences in phenotype and function, some investigators 
have suggested that molecules such as CD8α are markers of activation and not of lineage/subset 
demarcation (94). For example, LC, while not typically thought of as being/belonging to a 
particular subset, are especially interesting in regard to their expression of CD8α, CD11b, and 
CD205. As mentioned, CD11bhi cells characteristically express low (if any) levels of CD205 and 
CD8α. LC, however, express CD205 and have been shown to upregulate CD8α after 
phagocytosis of FITC particles taken up from painted skin and traffic to the DLN (95, 96). 
Further, it has been shown that a fraction of CD8α- DC express CD8α and CD205 after 
presentation of parvovirus virus-like particles to CD8+ T cells (97), and that splenic marginal 
zone CD8α- DC upregulate CD8α+ expression after uptake of iv-administered allogeneic 
apoptotic bodies (31). Recently, it even has been shown that monocytes/Mφ (cell lines) can 
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 differentiate into CD8α-expressing DC in vitro and in vivo (98), further blurring the distinction 
between distinct lymphoid/myeloid origins for CD8α+/CD8α- DC subsets. 
 
Reconstitution studies to elucidate the mouse precursor cell for DC subset lineages from Ken 
Shortman’s group have consistently suggested that CD8α+ and CD8α- DC arise from distinct 
progenitors [i.e., CLP for CD8α+ DC vs a CMP for CD8α- DC (99, 100)], while studies 
primarily from Ardavin’s group revealed that both CD8α+ DC and CD8α- DC can be generated 
from either progenitor cell type (101, 102). These latter studies have helped to shed some light 
on the confusing knockout (KO) mouse studies, in which both CD8α+ DC and LC are sometimes 
generated and sometimes not, in mice with depleted lymphoid or myeloid lineage cells (Table 2). 
As they are such essential regulators of the immune response, it is plausible to consider that DC 
can be derived from such a variety of progenitors as a part of the myriad of backup mechanisms 
built into the immune system to ensure their availability at any stage or site of an immune 
response. 
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 Table 2. Essential data on DC differentiation in KO mice 
a(103); b(104); c(105); d(106); e(107); f(108, 109); g(110, 111); h(112); i(113). 
 
1.1.3.2. Human and Non-Human Primate DC Subsets 
The pDC also has been defined in humans and is identified by lack of expression of CD11c, 
expression of IL-3Rα (CD123) [and the requirement for IL-3 in in vitro culture; reportedly, 
addition of IL-4 in precursor pDC cultures induces apoptosis in these DC (6, 114)], and the 
shared ability of mouse pDC to secrete IFNα (61-63). Also similar to mouse pDC, human pDC 
are considered the putative tolerogenic DC subset and are believed to induce the differentiation 
of T reg cells (92, 115). CD11c+CD123- DC are generally considered to be immunogenic and 
essentially refer to any DC that is not a pDC. These subsets have been defined in the rhesus 
macaque as well, in both the blood and LN (42). 
 
In humans, however, DC are often referred to not by their expression of specific cell surface 
molecules, but by the type of Th response they drive. Therefore, DC1 induce Th1; DC2 induce 
Th2. This method of classification is very useful when defining what type of an immune 
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 response a specific DC can initiate, but is very misleading when used to define subsets. For 
example, human pDC have been referred to as DC2 (114, 116), but as this subset secretes IFNα 
(a Th1 cytokine, as mentioned) (7), and as human non-pDC have been known to initiate Th2 
responses long before the pDC was discovered, this method of classification is flawed. By this 
same logic, it has been suggested that while tissue-isolated DC may in fact have some 
phenotypic differences (i.e., CD11c+CD8α+ vs CD11c+B220+ in mice and CD11c+CD123- vs 
CD11c-CD123+ in humans), what truly distinguishes DC subsets is their function in vitro and in 
vivo and that it is their microenvironment during differentiation from precursor to iDC and/or the 
kind of stimulation they receive to become mDC (either in culture or in situ) that defines their 
function (117-119). Thus LPS-stimulated DC induce Th1 responses (117), while DC matured in 
PGE2 induce Th2 responses (120). 
 
1.1.3.3. Follicular DC 
There are two distinct populations of primary and secondary follicle-residing DC: follicular DC 
(FDC) (121) and germinal center DC (GCDC) (122, 123). Human Follicular DC have a 
fibroblast morphology and express CD14, the complement receptors CD35 (CR1), CD21 (CR2), 
and CD11b (CR3), the adhesion molecules CD54, CD106 (VCAM-1), VLA-3-6, and VLA-β 
chain, and CD40, CD19, CD20, and CD24 (38), although the high expression of Fc receptors on 
FDC result in a lot of background staining, making phenotypic analysis difficult. Though the 
phenotype of FDC has been well characterized in humans, they have not been studied as well in 
mice or rats. FDC are essential for the organization of primary follicles (123, 124) and are 
believed to be important facilitating IgG, IgA, and IgM secretion by CD40-activated B cells 
(125). Though they share a somewhat similar dendritic morphology to classic DC, they do not 
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 share the classical DC functions (e.g., iFDC do not migrate to sites of inflammation in the 
periphery, take up Ag, and bear it so secondary lymphoid tissues for presentation to naïve T 
cells). 
 
Germinal center DC, while sharing a similar phenotype to FDC (CD16, CD32, CD64, CR1-3), 
are more classic mDC, with the ability to induce allo CD4+ T cell proliferation and enhance B 
cell growth and differentiation (38). It has been suggested that GCDC represent the mature form 
of CD11c+ blood precursors (126, 127) and may correspond with the memory T and B cell-
generating APC originally described by Szakal et al (128). 
 
1.1.4. DC in Transplantation 
Because of their strong Ag-presenting capacity (mDC are the most potent stimulators of T cell 
proliferation of all APC), DC are of extreme interest to cancer immunologists in their quest to 
develop tumor-specific vaccines. Therefore it almost seems counterintuitive to employ DC to 
diminish T cell responses to allogeneic Ag. However, DC are ideal target cells for regulating T 
cell responses to transplanted organs and tissues for several reasons: (i) DC are the only cells that 
can activate naïve (alloAg-reactive) T cells; (ii) DC are known regulators of central and (likely) 
peripheral tolerance; (iii) DC are easily influenced in vitro (and in some reported cases, in vivo) 
by exogenous factors (e.g., cytokines, viral transfection, lipofection, pharmacologic agents, 
blocking antibodies/antagonists); (iv) Some DC subsets have been purported to possess 
tolerogenic properties; (v) almost 10 years ago, it was discovered that iv administration of donor 
iBMDC one week prior to transplant results in significant prolongation of cardiac or pancreatic 
islet allograft survival, while mBMDC accelerate graft rejection (129, 130).  
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 As mentioned, DC can arise from different progenitor cell populations (i.e., CD34+, CLP, CMP, 
BM-precursors, etc), and the environment in which they are cultured can influence these 
progenitors. The knowledge that iBMDC can prolong allograft survival, indefinitely in one 
report (131), sparked a variety of investigations to maximize on the potential of using DC with 
similar properties to iDC to achieve tolerance to alloAg. 
 
1.1.4.1. DC Plasticity 
DC have been cultured in the presence of an assortment of pharmacologic and biologic agents, 
some of which are currently used clinically in transplant therapy protocols, which have been 
shown to regulate their ability to activate T cells, to differentiate into mature DC, and to migrate 
to secondary lymphoid tissues (Table 3; Fig 5a). For example, Hackstein et al (132) investigated 
the effects of clinically-relevant doses of aspirin on DC and found the drug maintained DC 
immaturity even after LPS-stimulation, due in part to impairment of NF-κβ activity. 
 
The natural ability of DC to secrete cytokines make them ideal targets for genetic manipulation 
for secretion of cytokines that would most greatly influence the desired T cell response. Adeno- 
and retroviral vectors and lipofection have been used to transfect DC with IL-4, IL-10, TGFβ1, 
IDO, or FasL, for example (Fig 5b), although with varying success in prolonging allograft 
survival [i.e., (133)], and to date, no genetically-modified donor DC used as a mono-therapy 
have induced donor-specific tolerance.  
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 As the enigmatic, rare (even for DC!), pDC has been suggested to be able to induce the 
production of T reg cells (92, 115), attempts are being made to optimize the propagation of this 
highly-sought after DC in vitro (115, 134). The recently-discovered murine “regulatory” DC (64, 
93), so-called because of their supposed ability to induce T reg populations, is also found in 
extremely low numbers in vivo. Culture of BMDC precursors in GM-CSF, TNFα, and IL-10 
leading to substantial numbers of regulatory DC in vitro (64) suggests these DC may be able to 
be studied more extensively, possibly leading to their manipulation for therapy. 
Table 3. Pharmacologic, biologic, and genetic engineering approaches to potentiation of DC 
tolerogenicity 
[Modified from (135)] 
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Fig 5. Manipulation of DC for enhancement of allograft survival.  
(A) Aspirin exerts its inhibitory effects on DC differentiation/maturation by an NF- κB-dependent, 
cyclooxygenase-independent, pathway such that NF-κB DNA-binding activity is reduced (132, 136). 
Aspirin profoundly inhibits expression of major histocompatibility complex (MHC) class II and 
costimulatory molecules such as CD80/86, and impairs expression of the potent allostimulatory cytokine 
interleukin 12 (IL-12); explaining the subsequent failure of aspirin-treated DC to stimulate T-cell 
proliferation. (B) Transfection of DC by genetically manipulated virus, such as replication-deficient 
adenovirus, can induce overproduction of specific immunomodulatory proteins (here represented by IL-
10, which elicits alloantigen-specific T-cell hyporesponsiveness) that may be beneficial for prolongation 
of graft survival. Human DC transduced with IL-10 show reduced cell-surface expression of 
costimulatory molecules, impaired production of IL-12 and are able to inhibit autologous human skin 
graft rejection in a human–murine skin graft model (137) [Fig modified from (48)] Reprinted with the 
permission of Cambridge University Press. 
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 1.1.4.2. DC Antagonists 
A number of cell surface molecules on DC are essential for regulating their response to 
inflammation (as well as steady state trafficking). Numerous methods to target these molecules 
have been employed. For instance, as the delivery of the second signal through CD80/CD86-
CD28 interactions is essential for activation of naïve T cells, investigators have attempted to 
interrupt this exchange of information by blocking functional CD80 and CD86 expression on the 
DC cell surface through cytotoxic T lymphocyte Ag (CTLA) 4Ig molecules (138-142) - an 
immunoglobulin (Ig) fused with CTLA4. The alternate receptor for the B7 molecules, CTLA4 
has about a 20-fold higher affinity for CD80 and CD86 than CD28 and reaches maximal 
upregulation on T cells 48-72 h after activation as a self-regulating mechanism (143, 144). Other 
attempts have been made through administration of blocking interactions of CD40 (expressed on 
mDC)/CD40L (CD154; expressed on activated T cells, the ligation of which with CD40 on DC 
activates DC to signal activation of CD8+ T cells) (145), with some success in mouse transplant 
models (142, 146) and non-human primate models (147-149), but in primate renal transplants, 
for example, all grafts eventually were rejected after anti-CD154 treatment was stopped (150, 
151). Further, there were thromboembolic complications in the human and primate renal models 
(152), which had not been evident in the murine studies. Currently, investigations are being 
undertaken to block chemokine receptors (important in directing leukocyte migration and 
discussed further in Section 1.2), [i.e., (153-155) and Fig 6] although analysis of the effects of 
chemokine antagonists on DC yet is to be explored.  
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Fig 6. DC antagonists.  
A chemokine receptor antagonist, such as BX 471 (155), might prevent immature DC expressing 
chemokine receptors (such as CCR1) for inflammatory chemokines from migrating to the graft and hence 
prevent the subsequent presentation of graft antigens to naive T cells. Similarly, binding of free 
chemokine by blocking antibody, such as anti-CCL5, can also potentially prevent inflammatory 
chemokine-induced migration of immature DC to the graft. Reprinted with the permission of Cambridge 
University Press. 
 
1.1.4.3. DC Subsets in Transplantation  
Donor iBMDC, used to prolong allograft survival in early DC/transplant studies (130, 131), do 
not express CD8α. Reports that CD8α+ DC are potentially tolerogenic led researchers in our 
laboratory to investigate whether these DC might be able to extend graft survival beyond that 
seen with iBMDC. In a comparative study between donor CD8α- and CD8α+ splenic DC, both 
subsets of iDC significantly prolonged murine cardiac allograft survival (47), as previously 
reported for murine iBMDC. Also like BMDC, CD8α- mDC accelerated graft rejection. 
Interestingly, mDC populations which were >95% CD8α+ by flow-sorting also significantly 
prolonged allograft survival. Both subsets were determined to be phenotypically mature before 
administration, and their maturation could not be further enhanced by exposure to LPS or 
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 CD40L (indicating both subsets were terminally mature upon administration). Both mDC subsets 
were equally capable of stimulating allo T cell proliferation in primary MLR, but T cells from 
allograft recipients which were pre-treated with CD8α+ DC 7 days prior to transplant were less 
responsive to donor Ag than those from CD8α- DC pre-treated animals. However, this 
prolongation of graft survival was found to be associated with neither immune deviation nor 
induction of T reg cells. Nor does it seem likely the tolerogenic effects of CD8α+ DC are due to 
IDO in this model as this effect was lost if the mDC population administered before transplant 
contained more than 5% CD8α- DC [as only 3% of CD8α+ DC are needed to abrogate the ability 
of CD8α- DC to activate naïve T cells against tumor/self-peptide (82)]. In early CD8α+ DC 
studies by Kronin et al (83), CD8α+ DC impaired CD4+ T cell proliferation through a FasL-
dependent mechanism, as evidenced by their lack of ability to suppress T cell allo-responses in 
gld (FasL-deficient) and lpr (Fas-deficient) mice. However, despite mRNA expression for CD95, 
vigorous attempts to detect this protein on the surface of either DC subset have met with failure 
thus far. Studies in our own laboratory using donor-derived apoptotic bodies injected 7 days 
prior to transplant showed prolonged allograft survival similar to injection of iBMDC (Morelli, 
AE, unpublished observations). That CD8α+ DC may be more susceptible to apoptosis than 
CD8α- DC (Moser, M, personal communication) offers a possible explanation as to how these 
cells are able to prolong allograft survival in either the mature or immature state, but do not 
explain why this ability is FasL dependent. Nevertheless, though the mechanism(s) by which 
CD8α+ mDC prolong cardiac allograft survival remains unknown, new theories regarding their 
alleged tolerogenic abilities continue to come to light. 
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 As mentioned, pDC have been proposed to promote T reg induction. Therefore our group, in 
collaboration with Dr. Pia Björck, investigated whether administration of freshly-isolated donor 
pDC prior to transplant would result in prolongation of graft survival. These iDC delayed murine 
cardiac allograft rejection significantly beyond that observed in control, untreated animals, and 
have in fact given the most marked extension of the mean graft survival of any unmanipulated 
donor iDC subset [MST 53 days for ipDC (156) vs MST 22 days for iBMDC (130)]. 
Experimental tests regarding T reg cell detection have been inconclusive, and further exploration 
of the mechanism by which ipDC prolong graft survival is necessary. The recent discovery of 
IDO expression (by RT-PCR) in freshly-isolated pDC suggests a possible suppression of 
recipient DC-mediated T activation (de Creus, unpublished observations). 
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 1.2. Chemokines2 
The immune response is strictly regulated. Though a diversity of inflammatory cytokines exists, 
each is specifically released in response to certain stimuli, resulting in elicitation of a tightly-
controlled immune response. A major player in immune response regulation is the secretion of 
specific chemokines by inflamed tissue and immune cells. Chemokines have roles in leukocyte 
activation, selectin/integrin up-regulation, hematopoiesis, angiogenesis, and adaptive immunity, 
but were first recognized for their ability to function as chemoattractants (157-159). All known 
chemokines bind to seven-pass, transmembrane-spanning, Gi/Go protein-coupled, Bordetella 
pertussis toxin-sensitive receptors (157, 160, 161) (Fig 7). The specificity and complexity of the 
chemokine system stem from the regulated expression of their receptors (CR). Not only does 
each chemokine family recruit only specific cell types, as discussed below (Section 1.2.1), but 
also frequently the expression of CR is controlled further by regulation of expression according 
to cell subsets (e.g., Th1 cells express CCR5 and CXCR3, although Th2-cells express CCR3 and 
CCR4) and/or the state of cell activation (e.g., iDC express CCR1–6, although mDC down-
regulate these six receptors and up-regulate CCR7 expression) (162-164). 
                                                 
2 Section 1.2 contains modified excerpts from reviews co-written by the author in the journals 
Transplantation and Expert Reviews in Experimental Medicine. 
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 Fig 7. The four known 
chemokine families (C, CC, 
CXC, and CX3C).  
All known chemokines bind to 
Gi/Go protein-coupled, 7-pass 
transmembrane spanning receptors, 
as shown for a generic CC 
chemokine. Both subsets of the 
CXC family are shown, and the 
CX3C chemokine, fractalkine, is 
depicted in its membrane-bound 
form (165). 
 
 
1.2.1. Classification 
Like most newly-discovered molecules, each chemokine was given a descriptive name 
implicating a biologic function(s) by its discoverer. As some were named according to structure, 
others to function, and still others according to favorite movie characters [Rantes, the protagonist 
from “Man Facing Southeast”, 1986, Film Dallas productions, inspired released upon activation, 
normal T cell expressed and secreted (Tom Schall, personal communication and (166)], Yoshie 
and Zlotnik (167) suggested a uniform nomenclature for chemokines based on structure and 
classical nomenclature that was presented and approved at the Keystone Symposium on 
Chemokines and Chemokine Receptors in 1999. The new nomenclature for CR proposed by 
Murphy et al (157) was presented to and approved by the Nomenclature Committee of the 
International Union of Pharmacology in 2000. These nomenclatures will be used herein. Classic 
chemokine names will be included upon first appearance (followed by the new nomenclature in 
parentheses) and the new nomenclature will be used thereafter. Readers are referred to Table 4 
[excerpted from (168)] for complete listings of chemokines and their receptors. 
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 Table 4. CXC, C, CX3C, and CC chemokine/receptor families 
Reprinted from IUIS/WHO Subcommittee on Chemokine Nomenclature. Chemokine/chemokine receptor 
nomenclature. Cytokine; 2003: 48-49 with permission from Elsevier. 
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 1.2.1.1. Family 
Chemokines make up a superfamily consisting of 8 to 11 kDa proteins subdivided into four 
families (C, CC, CXC, and CX3C) according to the position and separation of their first two 
amino-terminal cysteine (C) residues of a four-cysteine motif (157, 161) (Fig 7). The C family 
consists of only two members: lymphotactin-α [X chemokine ligand (CL)1] and lymphotactin-β 
(XCL2), which are homologous to the CC family at their carboxyl end, but lack the first and 
third cysteine residues found in the other three families. XCL1 and XCL2 recruit T lymphocytes 
only (169). The CC chemokine family evokes monocyte, lymphocyte, and DC migration (162, 
164, 170). The CXC family is further separated into two sub“families”: those that possess an 
additional glutamic acid(E)-leucine(L)-arginine(R) amino acid motif and primarily induce 
neutrophil migration, and those that are ELR- and recruit a more lymphocytic population (158). 
The CXC family also contains a unique member, CXCL16, which is predicted to be the only one 
of its family to possess a mucin-like stalk (171-173). The CX3C family contains only one 
member: fractalkine (CX3CL1). CX3CL1 was, previous to the discovery of CXCL16, the only 
known membrane-bound (via a mucin stalk) chemokine. Both CXCL16 and CX3CL1 are 
predicted to function, then, as both an adhesion molecule (possibly aiding DC-T cell 
interactions) and a chemoattractant (for IL-2 activated natural killer [NK] cells and CD8+T cells) 
(172-179). 
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 1.2.1.2. Expression 
Chemokines can be grouped again into categories reflecting their temporal and spatial 
expression: the inducible (or inflammatory) and the constitutive (or lymphoid) chemokines. The 
inducible chemokines are regulated by pro-inflammatory stimuli (e.g., IL-1, TNFα, IFNγ, LPS) 
and regulate innate and adaptive immune responses. These chemokines are released by injured 
endo- and epithelial cells, innate/early immune-responders such as neutrophils, monocytes/Mφ, 
and NK cells, and adaptive immune-responders such as iDC and activated T cells (159, 180). 
The constitutive chemokines are important for tissue homing of leukocytes, as well as for 
immune surveillance (159, 162, 170, 181). Lymphatic and high endothelial vessel cells, 
peripheral epithelial cells, and DC and EC in T cell areas express the constitutive chemokines 
(182-184). 
 
1.2.2. Chemokines & DC Recruitment 
Ubiquitously distributed throughout the body, tissue-resident DC likely arise from circulating, 
blood-borne pre-DC. LC precursors are attracted to residency in the epidermis by chemokine 
gradients expressed by keratinocytes (185-187). The skin recruits CD34+CD14+CCR6+ immature 
(i) DC through the constitutive expression of macrophage inflammatory protein (MIP)-3α 
(CCL20) (185, 188). The expression of TGFβ in the skin induces further differentiation of these 
precursors into LC (186) [and TGFβ KO mice lack LC (113)]. Less is known about DC 
recruitment into other tissues, but it has been suggested that recruitment into the kidney (for 
example) is by a similar method. Coates et al (190) have shown that blood iDC express CCR5 
mRNA, respond to at least one CCR5 ligand in vitro, and enter the kidney (an organ that 
expresses CCR5 ligands) after iv injection. Interestingly, the same chemokines that (apparently) 
recruit pre-DC (in vitro or in vivo) do not recruit tissue resident iDC. Neither kidney nor skin 
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 (LC) iDC migrate to CCR5 or CCR6 ligands, respectively (50, 185) and appear to be no longer 
functional despite receptor mRNA expression comparable to that of pre-DC. Mack et al (191) 
have reported CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES) downmodulate CCR5 
expression on murine NK cells in vitro (as well as CCR2 by CCL1 on monocytes) in a dose-
dependent manner. This aids weight to the suggestion that CR may become desensitized to their 
chemokine ligands after prolonged exposure in vivo. This also may explain the pluripotent ability 
of blood- and BM-derived iDC to respond to nearly any of the inducible CC chemokines 
typically tested in in vitro chemotaxis assays (192-194) – it is unlikely they remain in any one 
area long enough to become desensitized, and it seems more immunologically efficient to have 
semi-differentiated (non tissue-specific) iDC be capable of responding to inflammation anywhere 
in the body (and thus to a wide panel of chemokines), instead of just in the tissue in which they 
reside. 
 
Chemokines also are principal in directing DC migration during an immune response. CCL3, 
CCL4, and CCL5 are archetypal chemokines released by inflamed tissues (195), which have 
been reported to induce iBMDC migration in chemotaxis assays in vitro (192). The production of 
these chemokines by injured cells would eventually produce a chemokine gradient, with the 
maximal concentrations at the site of the inflammation. Circulating and resident peripheral iDC 
receiving these and other inflammatory signals (TNFα, IL-β, etc) likely follow this gradient to 
its source. At the site of injury, the iDC would phagocytose Ag as usual, receiving further signals 
from the wounded area to commence differentiation into mDC. During this process, activated, 
intermediately-matured (int) DC begin to downregulate Ag uptake as well as CR for inducible 
chemokines. As they upregulate their co-stimulatory and MHC I and II molecules, the DC also 
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 upregulate CCR7, the CR for the constitutive chemokines MIP-3β (CCL19) and secondary 
lymphoid chemokine (SLC; CCL21) (192-194, 196-199), as well as CXCR4 [which binds 
stromal-derived factor (SDF)-1α (CXCL12)] (193, 194). intDC are directed into lymphatic/high 
endothelial vessels by a CCL21 gradient, leading the DC into secondary lymphoid tissues (184, 
197, 198, 200, 201). Upon departure of the lymphatic vessel, int/mDC are directed to T cell areas 
by CCL19 (44, 197, 198) or to B cell areas, likely by CXCL13 (B lymphocyte chemoattractant; 
BLC) (202, 203). 
 
All mDC (based on phenotypic and some functional criteria) studied to date, regardless of tissue 
[e.g., skin (185), Peyer’s patches (44), BM (197), spleen (48), liver (54), kidney (50), and blood 
(204)] or species of origin [human (195), non-human primate (43), and mouse (192)] have been 
reported to migrate to either CCL19 and/or CCL21 (not all studies tested both chemokines). iDC, 
however, are not uniform in their response to inducible chemokines. As mentioned, iDC do not 
always migrate to the same chemokines as they do as pre-DC. Unlike mDC, iDC 
isolated/generated from different tissues have differing abilities to migrate to inducible CC 
chemokines [Chapter 1 and reviewed in (198)], although as yet no major differences have been 
reported between species. It has been reported, however, that human CD11c+CD123- “myeloid” i 
and mDC and (CD11c-CD123+) pre- and mpDC both express different CR on their surface, as 
well as respond to different chemokines (193, 205). Further, it was determined in these studies 
that pDC appear to express some CR that are non-functional (as determined by in vitro 
chemotaxis assays and changes in intracellular Ca++ levels). No comprehensive comparative 
studies of any of the DC subsets have been performed in the mouse previous to this work. 
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 Although it is well documented that iDC are directed to sites of inflammation by specific 
chemokines released by activated endothelial cells, and that mature DC are recruited to 
secondary lymphoid tissues by constitutively expressed chemokines, DC are also capable of 
influencing leukocyte trafficking via the same mechanisms important for their own localization. 
Chemokines secreted by DC (“dendrikines”) typically are involved in T cell recruitment. mDC in 
particular express CCL19 (182, 206-208) and CCL22 (macrophage-derived chemokine; MDC) 
(182, 206), aiding in the localization of both mDC and naïve T cells in T cell areas. 
 
Both human and mouse DC have been reported to secrete chemokines in response to 
inflammatory/maturation stimuli, important for initiating activated T cell migration, such as 
CCL9/10 (MIP-1γ) (mouse) (209), CCL18 [DC chemokine (DC-CK) 1] (human) (210), CCL3, 
CCL5 (human and mouse) (211, 212), CXCL8 (IL-8) (human) (212), CCL4 (human)(212), 
CCL22 (human and mouse) (179, 213, 214), CCL17 (thymus- and activation-regulated 
chemokine; TARC) (human and mouse) (163, 215, 216), and CXC3L1 (mouse) (178, 179). DC 
can selectively recruit Th2 cells: CCL17-expressing DC may be important for the recruitment of 
activated Ag-specific CD4+ Th2 cells but not naïve CD4+ T cells (162, 215, 216). Th1 cell 
recruitment may be suppressed by up-regulation of Th2-specific chemokines (e.g., CCL22) by 
DC exposed to PGE2 (217). DC also produce IFNγ (10, 218, 219), which can elicit the 
production of CXCL9 (monokine induced by IFNγ; Mig) and CXCL10 (IFN-γ–inducible protein 
of 10 kDa; IP-10) -- chemokines important in graft rejection (220).  
 
DC do not produce only T cell-attracting chemokines. CXCL12, CCL19, CCL20, and CCL21 
(221), all of which recruit B cells, are made by (human) DC. As with T cells, DC can specifically 
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 recruit B cell subsets. Dubois et al (221) have shown that supernatant from activated DC recruits 
naïve and memory B cells, but not germinal center B cells.  
 
1.2.3. Chemokines in Transplantation 
Organ transplant rejection is mediated largely by circulating peripheral leukocytes induced to 
infiltrate the graft by various inflammatory stimuli. The secretion of chemokines by inflamed 
graft tissues, as well as by early innate-responding leukocytes that infiltrate the graft, are 
responsible for the recruitment of phagocytic APC such as iDC and activated alloreactive 
leukocytes (165).  
 
1.2.3.1. Chemokine Expression in Transplanted Tissues 
Because leukocytic graft infiltration seems to be such a key event in graft rejection, recent work 
has investigated the expression of chemokines in rejecting versus accepted allografts (154, 161, 
222, 223) (Table 5). Early expression of inducible/inflammatory chemokines is most likely 
induced as part of the innate [i.e., graft-infiltrating NK cells (224, 225)] immune response to 
damaged graft vessels, as chemokines expressed in the first 4 days (peaking at day 3) 
posttransplant are expressed at similar levels in murine allo- and syngeneic skin grafts [Table 5 
and (220, 223)]. These early-expressed chemokines are no longer detectable by day 5 (with the 
exception of CCL2) and are replaced by a second set of chemokines (CCL5, CXCL9, CXCL10) 
in allogeneic grafts closer to the time of graft failure (3–4 days before rejection). This expression 
pattern is similar to that reported for rejecting human skin allografts, albeit in a human 
donor/SCID recipient model (226, 227). 
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 Murine cardiac grafts also show a temporal chemokine expression pattern [(225, 228, 229) and 
Table 5], although in heart grafts, CXCL10 is produced both early and late (whereas it is only a 
late-expressed chemokine in skin grafts). The late-expressed chemokines in cardiac allografts 
likely are induced by adaptive immune responses of graft-specific leukocytes [i.e., CXCL9 and 
CXCL10 are produced by CD8+ T cells (225)]. In rejecting human cardiac allografts, 
immunocytochemical analysis of endomyocardial biopsies for several chemokines/CR were 
found to have a high correlation between the incidence of CD3+ T cells, CXRC3 and CXCL10 (a 
ligand of CXCR3) expression, and acute rejection (230). 
 
Table 5. Summary of chemokine expression in transplanted organs 
a(220, 226, 227); b(225, 227-229); c(231, 232); d(233-235). 
 
Though murine heart and skin allografts express similar chemokines, temporally the pattern is 
dissimilar. In rejecting heart allografts, CCL3 and CCL4 are observed late (in skin they are early) 
and CXCL9 and CXCL10 are expressed both late and early, while for skin they are expressed 
only late (close to and during the time of rejection) (Table 5). Other analyses of human kidney 
(231, 232, 236) and lung (233-235) transplants have focused predominantly on the expression of 
CCL5, but other chemokines, such as CCL2 and CXCL10, also are expressed in rejecting kidney 
and lung grafts. Interestingly, in gallium nitrate-treated mouse recipients, long-term surviving 
heart allografts expressed low levels of CCL3 and CCL4 60 days posttransplant, although levels 
of CXCL10 and CCL5 remained high, indicating expression of “rejection-associated” 
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 chemokines does not necessarily indicate rejection (229). Clearly, the expression of chemokines 
in transplanted tissues and organs is complex, regulated both by time after transplant as well as 
by specific the type of tissue graft.  
 
Chemokines also may facilitate chronic cardiac allograft rejection, e.g., CCL5 production was 
found to correlate with leukocytic infiltration as well as to precede intimal thickening of arterial 
vessels (237). In a heart allograft model using CCR1 (a receptor for CCL5) KO mice, mAb 
depletion of CD4+ T cells resulted in permanent graft acceptance in both the KO and wild type 
(wt) recipients. Only CCR1 KO mice did not exhibit chronic rejection (238). Targeting of CCR5 
(via KO or neutralizing mAb) also leads to marked improvement of murine cardiac allograft 
survival that can result in permanent graft acceptance with no chronic rejection when used with 
cyclosporine (CsA) treatment (239). Further, transgenic overexpression on endothelial cells of 
the Duffy Ag (a non-signaling chemokine-binding protein that acts as a “sink” for CC and CXC 
chemokines) has recently been shown to have a negative effect on angiogenesis (240). 
Theoretically, this occurs through prevention of chemokine interactions with functional CR. As a 
consequence, efforts to block early chemokine expression to alleviate acute rejection may also 
have to be directed toward the later stages of allograft rejection.  
 
1.2.3.2. Chemokine Targeting Strategies in Transplantation 
There are several approaches to targeting DC migration for therapy of graft rejection. Several 
chemokines, which bind to multiple CR, are expressed in the graft. Although it is known that 
BM- and blood-derived iDC can express any of CCR1 to CCR6, it is not clear which CCR are 
expressed on tissue-resident DC, making it difficult to target DC specifically. Further, blockade 
32 
 of recipient iDC migration to the graft would block only the indirect pathway of graft rejection, 
as “passenger” donor-derived DC will mature under the influence of inflammatory signals in the 
graft and migrate to DLN, activating the direct pathway of rejection. Therefore, blockade of 
CCR7-CCL19/CCL21 interactions may be more suitable for effective targeting of DC migration 
for transplant therapy. However, some current strategies that block CCR (by means of KO mouse 
models for CCR1 or CCR5 or anti-CCR5 mAb) that bind inflammatory chemokines (blocking 
iDC, Th1 cells, monocytes, and NK cells) have succeeded in achieving indefinite graft survival 
in conjunction with CsA administration [(160, 170) and Table 6]. The advent of synthetic CR 
antagonists such as BX 471 (a CCR1 antagonist) may well prove to be an effective means for 
targeting specific DC-expressed CR [(155) and Fig 6]. Another strategy has been to use virally-
manufactured proteins [“virokines”: MC418 and vMIP-II, for example, (241, 242) further 
reviewed in (243-245)] that antagonize CR activity to block leukocyte–chemokine interactions 
within the graft for modest, but significant, prolongation of both non-vascularized and 
vascularized heart allograft survival (246). Strategies to enhance tolerogenic DC migration [i.e., 
through over-expression of important DC CR such as CCR7 (199)] may become important for 
maximizing DC–T cell interactions.  
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 Table 6. Summary of chemokine-targeting strategies in transplantation 
a(235); b(228); c(239); d(238); e(247); f(248); g(249); h(250); i(242); j(251); k(220) 
 
Despite the undisputed importance of DC migration to transplantation outcome and the responses 
of DC to a large number of CC chemokines, very little attention has been afforded to date to 
manipulating DC/chemokine interactions as a basis for antirejection therapy. The investigations 
mentioned above and in Table 6 regarding the effects of blocking chemokine/leukocyte 
interactions focus on preventing graft infiltration by activated T cells. Most discussions of DC 
immunobiology in transplantation, although acknowledging the necessity of DC reaching T cell 
areas to induce naïve T cell activation, refer instead to genetic/environmental manipulation of 
potential “stimulatory” DC to render them “tolerogenic” (170, 198, 222, 252, 253). Alternatively, 
they focus on the T cell aspect of chemokine-directed DC/T cell interactions (161). Previous to 
this work, no attention had been given to the role specific chemokines play in DC migration and 
in DC initiation of the activated T cell response against the allograft. 
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 1.2.3.3. DC, Chemokines, and Allograft Immunity 
Depending on their tissue of origin, iDC express several CR, most of which bind to 
inflammatory chemokines (170). Importantly, the early-expressed chemokines detected in skin 
and heart allografts are among those reported to induce iDC migration (170). Infiltration of graft 
tissues by iDC allows these DC to take up and process graft Ag for presentation to naive T cells 
in DLN, alerting graft-specific T cells to the presence of transplant Ag. Both donor- and 
recipient-derived, graft-Ag-bearing mDC are directed to DLN by CCL21 (and then to T cell 
areas by CCL19) upon maturation for direct and indirect activation of naïve, alloreactive 
recipient T cells. 
  
Strategies to prevent migration of (recipient and donor) mDC from organ allografts could allow 
would-be donor-specific T cells to remain immunologically “ignorant” of the “foreign” tissue 
(Fig 8) until the inflammatory phase of the transplant passes. Theoretically, in the absence of 
“danger” signals (254, 255), DC induce tolerance to peripheral Ag. Thus, mDC migration-
blocking therapies eventually could be withdrawn, putatively leaving the recipient immune 
system unimpaired while achieving donor-specific tolerance due to alloAg presentation in the 
absence of inflammation. The plt/plt mouse (paucity of lymph node T cells; which has 
spontaneous mutations in the expression of CCL19 and CCL21) (256), and the CCR7 KO mouse 
(the receptor for CCL19 and CCL21) (257), both of which have deficiencies in DC and T cell 
homing to LN, are ideal models for testing the effects that blocking mDC migration may have on 
allograft survival. No data using either mouse model have been reported before initiation of the 
present study.  
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 Fig 8. Targeting DC migration. 
Current efforts to prolong graft survival by targeting chemokines 
attempt to interdict activated T cell infiltration of the graft (black 
arrow and X). However, manipulating migration of alloAg-
bearing DC (either donor or recipient) from the graft to 2° 
lymphoid tissue (e.g., by targeting CCR7/CCL19/21) could 
potentially block both the direct and indirect pathways of 
allorecognition by preserving T cell ignorance of the graft. 
Alternatively, overexpression of DLN homing receptors [as 
accomplished by Takayama et al. (199) with retrovirally induced 
overexpression of CCR7 in murine DC] could enhance migration 
of specifically engineered/tolerogenic DC to the 2° lymphoid 
tissue to promote their interaction with/subversion of allospecific 
T cells (gray arrow and X). From (165). 
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 1.3. Migration 
As discussed in Section 1.2, leukocyte migration is essential for detecting and transporting Ag 
and initiating immune responses. Though this activity is largely directed by chemokines, other 
factors play equally important roles. Vascular EC regulate the trafficking of leukocytes from the 
blood into tissue through selective expression of chemokines, as discussed, but also through the 
expression of intercellular adhesion molecules, which bind to selectively-expressed ligands on 
blood vessel-trafficking leukocytes. In the absence of inflammation, during steady state 
conditions, there is normal turnover of blood-borne to peripheral tissue to DLN DC that monitor 
for possible incoming pathogens/Ag for maintenance of peripheral self-tolerance. When EC 
become activated during inflammation, depending on the type of inflammatory signals released 
by pathogens and/or the injured cells, they release specific chemokines and upregulate the 
expression of specific selectins and other ligands for integrins expressed on the appropriate 
leukocytes. This system allows tightly-regulated tailoring of an immune response for the 
recruitment of the appropriate leukocytes needed to eliminate specific foreign/pathogenic Ag. 
The emigration of leukocytes from the blood into peripheral tissues is a three-step process that 
involves rolling on selectins along the vessel wall, tethering to Ig superfamily members, and then 
extravasating (also called diapedesis) through the EC wall.  
 
1.3.1. Transendothelial migration 
The selectins are a three-member family of adhesion molecules that are key in the initial rolling 
and tethering steps of transendothelial migration. E-selectin (CD62E) is expressed on EC, P-
selectin (CD62P) is found on platelets as well as EC, and L-selectin (CD62L) was originally 
discovered on lymphocytes, but has since been determined to be expressed by monocytes, 
neutrophils, and granulocytes as well [reviewed in (258-260)]. CD62P and CD62E are 
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 constitutively expressed at low levels on EC and aid in iDC and memory T cell immunologic 
monitoring of peripheral tissues. Both are upregulated in response to inflammatory stimuli, and 
their increased expression aids in binding to P-selectin glycoligand (PSGL)-1 and E-selectin 
ligand (ESL-1) expressed on passing leukocytes, respectively, slowing down leukocytic travel 
through the blood, until the leukocytes literally are rolling along the blood vessel wall. This 
rolling allows ligation of CD62L with any of its 5 glycoprotein ligands on EC, signaling 
upregulation of integrins on leukocytes (260).  
 
The integrins are a family of heterodimeric α and β proteins [e.g., LFA-1 (CD11a/CD18), Mac-1 
(CD11b/CD18), VLA-4 (CD49d/CD29)] expressed on leukocytes that act together in varying 
combinations to bind to members of the Ig superfamily [e.g., ICAM-1 (CD54), ICAM-2 
(CD102), VCAM-1 (CD106)] expressed on EC constitutively, but upregulated in response to 
inflammatory signals (258). Interestingly, chemokines also play a role in migration before 
direction of chemotaxis – the secretion of chemokines by EC [or the transport of chemokines 
secreted within peripheral tissues across EC barriers (261)] and the sequential anchoring of 
chemokines onto the EC surface (262) triggers stronger adhesion of Ig superfamily molecules 
[i.e., VLA-4 (263) and ICAM-1(264)] to rolling leukocytes. Binding of integrins to Ig 
superfamily members slows rolling to a stop, allowing leukocytes to adhere to EC long enough 
to start the extravasation process. 
 
The exact mechanisms involved in diapedesis (discussed further in Section 1.3.1.1) have been 
long debated in the field of transendothelial migration. Some reports indicated passage of 
leukocytes through EC into inflammatory sites (265), but now most investigators agree that 
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 leukocytic emigration from the blood into peripheral tissues involves migration between EC 
(266). While heterophilic interactions (binding between two different molecules, i.e., CD54-
CD11b/CD18) between adhesion molecules on leukocytes and EC are essential for rolling and 
tethering of leukocytes, homophilic interactions (binding between two identical molecules, i.e., 
CD31-CD31) of adhesion molecules on the two cells types are key for facilitating the actual 
process of extravasation. 
 
Platelet-endothelial-cell adhesion molecule (PECAM)-1 (CD31), CD99, junctional adhesion 
molecule (JAM)-A, -B, and -C, and vascular endothelial (VE)-cadherin are believed to be 
involved in some way during the transendothelial migration process. These molecules are known 
to bind homophilically between either leukocytes and EC (all but VE-cadherin) or between EC 
only (all six molecules), although all three JAMs may also bind either of the molecules LFA-1, 
Mac-1, and/or VLA-4 (259). CD99 is a unique molecule (267), while VE-cadherin is a cadherin, 
and CD31 and the JAMs are members of the Ig superfamily. While VE-cadherin appears to be 
involved in regulating the adherens junctions between EC (268, 269), its absence apparently is 
essential during leukocytic emigration between EC (270, 271), as it is transiently relocated away 
from the EC surface at the site of contact with the transmigrating leukocyte. The presence of 
CD31 and CD99 at the site of leukocyte extravasation, however, is essential to transendothelial 
migration. Migration experiments in which CD31 was blocked resulted in a 90% reduction in 
leukocytic diapedesis in vitro and in vivo [reviewed in (259)]. Blocking both CD99 [blocking 
CD99 alone reduces transendothelial migration by >90% (272)] and CD31 has been shown to 
completely abolish transendothelial migration (272), although blocking of neither impairs the 
rolling or tethering of leukocytes along EC (272, 273). The role(s) of the JAMs in 
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 transendothelial migration is(are) less clear. All are reported to bind either heterophilically or 
homophilically to adhesion molecules involved in any of the three steps of transendothelial 
migration, but reports regarding their significance in emigration of leukocytes from the blood to 
sites of inflammation are varied [reviewed in (259)]. As the involvement of these molecules in 
transendothelial migration has only recently come to light, it is likely that as more in depth in 
vitro and in vivo studies emerge, their roles will become more clear. 
 
1.3.1.1. DC diapedesis 
As discussed earlier, pre- and iDC also can express CR appropriate for promoting the 
establishment of tissue residency (CCR6+ LC precursors leave the bloodstream in response to 
CCL20 expression in the skin) or for entrance into inflamed tissues for Ag uptake [blood-isolated 
and BM-cultured iDC chemotax in response to inflammatory chemokines in vitro (198)]. 
However, although CD11c (a ligand of iC3b and fibronectin) is the most common DC marker in 
mice, monkeys, and humans, and DC also commonly express CD11b (although the expression of 
this molecule is markedly decreased on CD8α+ DC, compared to other DC subsets [Table 1, Figs 
10 and 21, (47, 48, 78)]), very little attention has been given to the function of these adhesion 
molecules on DC [with de la Rosa et al (205) being the only current report of the effects of 
blocking CD11b on human monocyte-derived DC]. CD31 and CD54 are expressed at mid to 
high levels on DC, but little attention has been given to the importance of these molecules in 
DC/EC interactions. No doubt the expression of CD31 and CD54 on iDC facilitates entrance of 
pre- or iDC into peripheral tissues for steady state and immunologic monitoring, but while it is 
known which molecules are essential for T cell, neutrophil, B cell, and even monocyte [reviewed 
in (258, 259)] egress the bloodstream, studies on what adhesion molecules are critical for DC 
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 rolling, tethering, and extravasation are noticeably lacking (205, 274, 275). While it might be 
argued that as DC express CD31, for example, a key molecule in neutrophil and monocyte 
extravasation (276), and interactions between CD31 on DC and EC are highly likely to be 
fundamental in facilitating DC diapedesis. However, the expression of this same molecule by T 
cells has been shown to be unnecessary for their migration through EC (277). There have yet to 
be any accounts in the literature as to whether the difference in expression of specific adhesion 
molecules (CD11b, for example) between murine DC subsets may play a role in the reported 
differences in their migration. Studies later in this work have attempted to elucidate which, if 
any, of the aforementioned adhesion molecules play a role in DC migration in vivo. 
 
1.3.2. Reverse Transmigration 
For immune monitoring (by DC or memory T cells, for example) to be complete, leukocytes 
must be able not only to enter peripheral tissues, but to exit them as well. Reverse transmigration 
has been much understudied compared to transendothelial migration (37, 278). Leukocytes first 
interact with extracellular matrix proteins, rather than EC. CD54 is believed to be involved early 
in the process (279), similar to transendothelial migration, although, interestingly, CD31 is not 
(274). Tissue factor, a transmembrane member of the coagulation cascade (280, 281), also 
appears to be important in the navigation process of leukocytes from peripheral tissue into 
lymphatic vessels (280-282). Though not directly tested in vitro, it is likely CCL21 plays an 
important role in mediating mDC and T cell trafficking into lymphatic vessels. This supposition 
is further strengthened by the severe lack of T cells and DC in lymph nodes (which requires 
traffic through lymphatic vessels), but not the spleen (cells enter the spleen through the 
bloodstream), of CCR7 KO (257) and plt mice (200).  
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 Metalloproteinases [specifically matrix metalloproteinases (MMP) 2 and 9], enzymes important 
for “opening” the passageways between EC to facilitate leukocyte transendothelial migration 
(allowing exposure of intercellular adhesion molecules) (259, 266, 283), reportedly are expressed 
on the cell surfaces of human DC which have migrated out of skin explants, but not on human 
Mo-derived or CD34+ blood stem cell-derived mDC (284). Not surprisingly, then, 
metalloproteinases have been reported to be essential for mouse LC (284, 285) and dermal DC 
(284) and human LC (284, 286, 287) and dermal DC (284) exodus from the periphery into the 
lymphatic vessels, aiding their passage into secondary lymphoid tissues. Only one study has been 
reported utilizing non-skin-derived DC (288). In these experiments, investigators noted human 
Mo-derived DC expression of MMP 9, the upregulation of which was concurrent with an 
increase in mDC in vitro migration (both in response to CCL19). Thus, though DC migration 
(chemokine-directed, at least) patterns appear to vary according to tissues of origin/derivation 
[reviewed in Section 1.2 and Chapters 1 (Section 2) and 2 (Section 3)], as most reverse 
transmigration in vivo likely occurs with int/mDC and mDC appear to have similar migratory 
properties regardless of their ontogeny, it is possible that mDC from other tissues will also be 
determined to rely on metalloproteinases to aid in their exit from peripheral tissues, though this 
theory has yet to be tested in either the mouse or human DC model system. 
 
1.3.2.1. DC departure from peripheral tissues 
Peripheral int or mDC that have upregulated CCR7 acquire the ability to respond to CCL21, 
allowing them to leave the tissue enter draining lymphatic vessels to traverse to the nearest 
lymph tissue (43, 192, 194, 195, 198, 206, 257). As DC transmigration has been shown to rely on 
multidrug resistance I protein (274) and CD31 (205, 283), these adhesion molecules may play a 
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 role in their exit from peripheral tissues. Interestingly, there are no reported differences in the 
expression of adhesion molecules on (“resting”) i vs (“activated”) mDC suggesting, (i) a role for 
DC as environmental sentinels in both the steady and inflammatory states and (ii) that an 
increase of DC in peripheral tissues during inflammation is likely facilitated by upregulation of 
adhesion molecules on EC. Reverse transmigrating monocytes can be stimulated, purportedly by 
EC, to differentiate into DC during/following the process of reverse transmigration (37). 
Although several factors have been determined to be important for this in vitro [e.g., phagocytic 
material (37); IL-4 and IL-13 (289); CD40 ligation (290, 291); extracellular matrix components 
(292, 293)], the mechanism(s) by which monocyte to DC differentiation occurs in vivo is not yet 
known. Some of these same alleged factors involved in monocyte to DC progression also may be 
involved of the differentiation of pre-pDC into pDC in vivo [i.e., CD154 (6, 42, 57)], although to 
date only pre-pDC have been detected in vivo (6, 42, 57, 62, 89, 193). Not surprisingly, the 
presence of inflammatory cytokines (e.g., IL-1, TNFα) has been shown to enhance DC 
emigration from tissue both in vitro (279) and in vivo (294). It is not clear whether DC which 
have extravasated into peripheral tissues reverse transmigrate back into the blood, but at least 
one report has shown that passenger leukocytes detected in donor cardiac allografts (tissue 
resident DC) can be found in the spleen during the first four days after transplant, necessitating a 
re-entrance of these DC into the bloodstream [(295) and Fig 35].  
 
Though there have been a few reports regarding pDC migration in vitro (193, 205), the in vivo 
migratory patterns of pDC have remained much understudied, with the singular report on their 
trafficking patterns into inflamed tonsils being speculative at best (89). It was recently 
determined that human blood pDC require CD62L expression to enter secondary lymphoid 
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 tissues (58), and that they require β1 and β2 integrins for transendothelial migration, at least in 
vitro (205). However, whether reverse transmigration influences differentiation of pre-pDC into 
pDC or monocytes into pre/pDC is yet to be determined. 
 
1.3.3. EC and Transplantation 
The first interaction alloactivated-T cells have with graft tissue is with EC. EC that have been 
activated by IL-1 and TNFα (as alloEC are during the surgical, ischemia, and reperfusion 
processes imposed on grafts during transplantation) rapidly upregulate the expression of 
chemokines (296, 297) and adhesion molecules (298, 299) that recruit and secure activated T cell 
entrance into the transplanted organ. Alloactivated CD8+ T cells themselves further stimulate 
alloEC to produce CXCL9 and CXCL10, chemokines highly-selective for activated CXCR3+ T 
and NK cells (300), as well as CCL2-5, chemokines which recruit CD4+ T cells and monocytes 
(159). CD4+ T cells also induce chemokine secretion in alloEC, although a much more restricted 
set compared to CD8+ cells – only CCL5 and CXCL10 of the chemokines tested (300). Thus, 
interactions between activated T cells and EC facilitate the production/upregulation of factors 
essential for infiltration of peripheral tissues by the T cells, which, in the case of transplantation, 
also facilitate initiation of acute graft rejection. In addition, it has been suggested that the 
expression and anchoring of chemokines to EC could lead to the continual recruitment of passing 
immune effector cells, contributing to chronic rejection (238, 264, 301, 302). 
 
1.3.4. DC Migration and Transplantation 
Effector cells have specific routes by which they traverse the body to monitor for immunological 
targets, and they express specific adhesion molecules and CR according to their migratory needs. 
For example, as mentioned, memory and activated T cells express CD62L, while naïve T cells do 
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 not, allowing the former to travel through the blood and enter tissue during either steady state or 
inflammatory conditions and impairing the latter from doing the same. As discussed, pre- and 
iDC travel from the blood into tissues as well (although they do not express CD62L), and they 
leave peripheral tissues and enter the lymph as int or mDC. Therefore the expression of specific 
CR and adhesion molecules on DC is likely tightly-regulated according to their origin and tissue 
of residence. Thus it may be essential to consider these factors when determining the optimal 
route of injection of DC for immunotherapy, as not all DC express them same CR or the same 
level of adhesion molecules. 
 
1.3.4.1. Delivery of DC 
Although further discussed in Chapter 1, it is important to note that while donor iDC (47, 130, 
131) prolong allograft survival if administered iv 7 days prior to transplant, comparatively few 
reach their intended secondary lymphoid tissue (the spleen) (48). It is interesting to consider 
whether optimizing the delivery of exogenous DC to the thymus is an effective means of 
promoting tolerance. Inaba et al (303) injected donor DC into the thymus of allograft recipients 
differing in minor lymphocyte-stimulating Ag, resulting in anergy of alloreactive T cells and no 
evidence of graft versus host disease. Although we have detected some mDC in the thymus 24 h 
after sc injection (52), the reported lack of function of thymi in adult humans may delegate this 
type of therapy to pediatric transplant recipients only. Thus, efforts to manipulate DC in vitro in 
order to maintain their immaturity in vivo may be in vain if the injected iDC will never reach 
essential T cell areas. mDC, on the other hand, which express high levels of CCR7 are fairly 
efficient at trafficking to T cell areas of secondary lymphoid tissues (48, 304), although this 
ability is greatly affected by their route of administration [Chapters 1 and 4 and (48)]. However, 
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 (CD8α-) mDC also express high levels of co-stimulatory molecules and accelerate graft rejection 
(52, 130, 131).  
46 
 STATEMENT OF THE PROBLEM 
 
DC not only prime the immune system against transplanted tissues through presentation of 
alloMHC by donor (indirectly) and by recipient DC, initiating acute rejection, but they also are 
thought to be key players in chronic rejection, through indirect donor alloAg presentation. The 
ability of DC to regulate central and (putatively) peripheral tolerance also suggests a role for 
these APC in educating the immune system about the benignity of an allograft. We have been 
investigating the use of “tolerogenic” DC to prolong allograft survival and to achieve donor-
specific tolerance. Possible candidates are iDC, genetically-, pharmacologically-, or biologically-
modified DC, or discrete DC subsets, especially (at the time which these studies began) CD8α+ 
DC (in mice). Currently, in nearly all transplant studies in which DC are used as 
immunotherapeutic agents, the DC are administered via iv injection. In most of these studies, the 
donor heart is heterotypically transplanted into the abdomen, making the spleen the draining 
lymphoid tissue. Thus iv injection seems the most likely route for delivering the maximal 
number of DC into T cell areas. Studies with “tolerogenic” DC have had variable degrees of 
success in prolonging allograft survival utilizing this method of administration. 
 
Early reports of CD8α+ DC, identified initially as the constitutive DC within mouse thymus (≤ 
5% CD8α- DC), showed this subset of splenic APC to suppress both CD4+ and CD8+ T cell 
proliferation in an MLR, making them “ideal” candidates for transplant therapy. However, some 
groups reported that while (typically sc-) injected CD8α+ DC could prime an immune response 
in vivo (most likely through cross-presentation to migration-competent CD8α- DC), these DC 
were seriously impaired in their ability to migrate to secondary lymphoid tissues. Other groups, 
showed that (iv-injected) CD8α+ DC could migrate in small numbers to T cell areas of secondary 
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 lymphoid tissue, but each of the groups analyzed CD8α+ DC using different methods (Table 7). 
These differences no doubt highly influenced the results in each report, as aside from their few 
reported functional differences, both DC subsets have similar phenotypes and reportedly co-
habitat the same tissues (suggesting similar expression of CCR/adhesion molecules). Thus, we 
hypothesized that CD8α+ and CD8α- DC subsets have an equal ability to migrate in vitro 
and in vivo.  
 
If CD8α+ DC are candidate cells for use in transplant immunotherapy, it is essential to know 
whether they can reach T cell areas in order to exert their immunosuppressive effects on naïve 
alloreactive (and/or central memory cross-reactive) CD4+ and CD8+ T cells.  
 
Therefore we proposed to compare routes of injection, cell numbers injected, state of DC 
maturation, and time of detection of migrated cells. As we believe that CD8α+ DC are potential 
tolerogenic DC, capable of delaying, if not preventing, allograft rejection in an alloAg-specific 
manner, we also wanted to identify which chemokines, CR, and adhesion molecules play key 
roles in regulating their migration in vivo. These data will potentially allow specific 
augmentation (or impediment, if they are determined to be explicitly immunogenic) of (injected) 
CD8α+ DC migration to T cell areas in a transplant setting. Other groups have failed to repeat the 
work showing CD8α+ DC to suppress T cell proliferation. However our own work showing these 
DC to prolong allograft survival, coupled with reports that CD8α+ DC express IDO and may be 
key players in peripheral tolerance (through uptake and presentation of self-Ag from apoptotic 
bodies), indicate they remain at the forefront of immunological interest. In the studies presented 
and discussed herein, we employ a variety of experimental methods to resolve the question as to 
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 whether this important APC subset can traffic in vitro and in vivo, and which chemokines and 
adhesion molecules are principal in facilitating the migratory process. We also have applied 
these data in an experimental transplant model to evaluate whether our findings have potential 
clinical relevance. 
 
 
Table 7. Disparities between CD8α+ DC migratory studies. 
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 2. CHAPTER ONE3 
 
FACTORS INVOLVED IN SPLENIC DC MIGRATION IN VITRO 
 
The CC chemokines, CC chemokine receptors, and adhesion molecules likely to play a role in 
directing CD8α+ and CD8α- splenic DC trafficking in vivo are evaluated in this chapter utilizing 
an in vitro chemotaxis migration assay (novel to our lab previous to this work). These findings 
provide several possible explanations for splenic DC in vivo migration patterns, as detailed in the 
Chapter Discussion and in Chapter Two, which follow. 
 
 
   
 
 
 
 
 
 
 
 
 
 
                                                 
3 Data from this chapter are excerpted from (48) where indicated. 
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 2.1. ABSTRACT 
Murine CD11c+CD8α- and CD11c+CD8α+ DC differentially regulate T cell responses. Although 
specific chemokines that recruit immature (i) or mature (m) classic CD8α- DC have been 
identified, little is known about the influence of chemokines on CD8α+ DC. iDC and mDC 
isolated from spleens of FL-treated B10 mice were compared directly for migratory responses to 
a panel of CC chemokines. In vitro assays were performed using unmodified Transwell® filter 
chambers. iDC did not respond to any CC chemokines tested. Both subsets of mDC migrated to 
CCL19 and CCL21, with consistently lower percentages of CD8α+ DC migrating. Chemokine 
receptor (CR) mRNA and protein expression were analyzed, but no correlation between 
expression and function was demonstrated. Changes in intracellular Ca++ were not seen for iDC, 
suggesting that either CR are expressed only at the message level or that surface-expressed CR 
are non-functional on splenic iDC. mDC showed a striking morphologic response to exposure to 
chemokine in vitro, and correlative with their migration, CD8α+ DC showed a qualitatively 
reduced change in dendrite extension compared to CD8α- DC. These findings provide insight 
into the specific CC chemokines most likely to direct CD8α- and CD8α+ splenic mDC 
trafficking in vivo and suggest CCR7 may be at least partly essential for facilitating their 
differential migration, although the correlation between expression and function of CCR7 as well 
as that of CCR1-6 has yet to be determined. 
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 2.2. INTRODUCTION 
 
The immunobiology of CD11c+CD11bloCD8α+ murine DC (32, 47, 80, 305) has attracted much 
attention since these cells were first described (60, 78, 306). The high expression of the typically-
“lymphoid” marker CD8α (expressed as a homodimer, unlike on CD8+ T cells, which commonly 
express CD8αβ on their cell surface) coupled with the low expression of the “myeloid” CD11b 
led DC biologists to conclude initially that these DC were of lymphoid origin. Since then, 
various investigators have sought the elusive origin of this DC subset, invariably with 
contradictory reports [for exemplary reviews, see (66) vs (94)]. Presently, there still is no 
conclusive evidence to fully support either a lymphoid lineage for these DC or that the 
expression of CD8α is a marker of activation. Of particular interest to transplant- and auto-
immunologists, early reports suggested that CD8α+ DC might be specialized for tolerance 
induction since, unlike their so-called “myeloid” counterparts (CD11c+CD11bhiCD8α-), they 
suppressed both CD4+ and CD8+ T cell proliferation (83, 84) and enhanced the apoptotic death of 
activated T cells (305). Several groups have reported diverse functions for these cells, including 
selective Th cell subset activation in vivo in response to soluble (ovalbumin, keyhole limpet 
hemocyanin) or viral antigens (Ags) (75, 81, 304, 307), suppression of CD8α- DC-induced 
delayed-type hypersensitivity to tumor/self-peptide (87, 308), and prolongation of organ allograft 
survival (47). As with classic murine CD8α- DC, the ability of these APC to affect immune 
reactivity also depends on their tissue distribution and migratory properties, both of which are 
influenced by chemokines. 
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 The in vitro chemotactic responses of CD8α- (“myeloid”) i and mDC derived from murine bone 
marrow (BM) (192), skin (197), or lymph node (LN) (197), or from human skin (181, 185) or 
blood (201, 204, 207, 309), or from non-human primate blood (43) have been well documented. 
The few reports regarding CD8α+ DC have examined either only their in vivo trafficking (71, 86, 
304) or their in vitro migration -- CD11b-(CD8α+) (Peyer’s patch; PP) DC in response to a 
restricted set of chemokines (CCL19, CCL20, and CCL21) (44) -- and have not adequately 
considered all the factors that might influence their migration. Until the studies discussed in this 
chapter [(48) and two others from our laboratory (50, 54) stimulated by these investigations] and 
aside from one PPDC study (44), the majority of DC migration assays have been performed on 
in vitro-propagated DC. The relationship between maturation status and migratory potential of 
murine DC in vivo has not been resolved, - a discrepancy underlined by the fact that in non-
human primates, iDC and mDC migrate with equal efficiency to DLN after intradermal injection 
(despite the fact that rhesus mDC express CCR7 and iDC do not) (43). Nor have there been any 
reports investigating the adhesion molecules involved in murine DC transendothelial migration, 
the two studies having been performed with human monocyte-derived and blood-isolated DC 
(205, 283). Furthermore, there has there been no thorough investigation of the chemokine 
receptor expression of murine secondary tissue derived-DC, although this likely is partly due to 
the paucity of reliable reagents for murine studies. 
 
Leukocyte recruitment in vivo is mediated largely by chemokines. Each of the four families of 
chemokines (C, CC, CXC, and CX3C) attract specific leukocytes (159, 164, 167, 169, 177, 178, 
195, 310, 311). Inducible CC chemokines recruit iDC to inflamed peripheral tissues, while 
constitutive CC chemokines attract mDC to secondary lymphoid organs. There is also recent 
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 evidence that chemokines within organ allografts may influence the outcome of transplant 
survival (220, 229, 230, 247, 251). In this context, it appears that chemokines elicit migration of 
cells important in facilitating rejection (i.e., iDC or alloAg-specific T cells); conversely, 
chemokines may recruit cells for suppression of rejection (i.e., T reg cells or 
“tolerogenic”/regulatory DC). Manipulation/targeting of those chemokines may promote graft 
survival. In this chapter, we have analyzed factors that influence the in vitro trafficking of 
splenic DC subsets. We show for the first time that murine spleen iDC fail to respond to the 
same panel of inducible CC chemokines as has been reported for iBMDC, despite a similar 
expression pattern of mRNA for CCR (192, 196). Additionally, we show that this lack of 
migration is due to a lack of functional CCR expression on splenic iDC (through a failure of 
these DC to show a change in intracellular Ca++ in response to CC chemokines). Ca++ flux studies 
with mDC also revealed that CD8α+ DC do not respond as positively to CCR7 ligands as do 
CD8α- DC, suggesting one possible explanation for the lower percentage of migrating CD8α+ 
DC.  
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 2.3. MATERIALS AND METHODS 
2.3.1. Mice 
Male C57BL/10J (B10; H2b), 8-12 wk of age, were purchased from The Jackson Laboratory (Bar 
Harbor, ME). They were maintained in the specific pathogen-free facility of the University of 
Pittsburgh Medical Center and fed Purina rodent chow (Ralston Purina, St. Louis, MO) and tap 
water ad libitum. Experiments were conducted under protocols approved by the Institutional 
Animal Care and Use Committee (IACUC). 
 
2.3.2. DC isolation and maturation 
Spleen DC were isolated as described (47). Briefly, B10 mice were treated with r huFL 
(Immunex; now Amgen, Seattle, WA) for 10 days (10 µg mouse/day intraperitoneally) to 
increase the number of DC (60). This approach allowed isolation of a greater number of DC 
from fewer mice than isolation of DC from untreated animals. On day 11, spleens were excised, 
gently mascerated through wire mesh, and red blood cells lysed. No digestive procedures were 
employed in order to minimize possible perturbation of cell surface Ag expression. To generate 
mDC, cells were incubated overnight (18 h) in RPMI-1640 (Life Technologies Inc, 
Gaithersburg, MD) supplemented with antibiotics, 10% heat-inactivated FBS (Life 
Technologies, Inc.), and r mouse GM-CSF (1000 U/ml, Schering Plough, Kenilworth, NJ) at 
37°C, 5% CO2 in air. BM-derived DC (BMDC) were generated as previously described (10). 
Briefly, BM was extracted from the femurs and tibias of FL-treated B10 mice, and iBMDC were 
harvested after one day of culture and defined by the same criteria as spleen iDC. For enrichment 
of iDC and mDC for phenotypic analyses, chemotaxis assays, and RPA, a 16% or 14.5% v/v 
metrizamide (Sigma-Aldrich, St Louis, MO) solution were used, respectively. Spleens from 
untreated mice were digested with 100U collagenase (which did not affect their phenotype as 
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 assessed by flow cytometric analysis; data not shown), teased apart, and then further digested in 
400U collagenase for two 30 min incubation periods in order to maximize DC recovery. Bulk 
spleen cell cultures were then enriched for i and mDC with 16% or 14.5% w/v metrizamide as 
for cells from FL-treated mice. Too few cells were recovered from spleens of untreated animals 
to sort the subsets by fluorescence activated cell sorting (FACS) or magnetic beads, so bulk 
populations were used in experiments with these cells.    
 
2.3.3. DC purification 
Bulk DC were incubated with magnetic beads coupled to anti-CD8α mAb (Miltenyi Biotec, 
Auburn, CA) at 4°C for 15 min (according to the manufacturer’s instructions). Half of the bulk 
DC was then passed through a positive selection column (Miltenyi Biotec) to obtain a purified 
population (60-90%) of magnetically labeled (CD8α+) DC; the remainder was passed through a 
depletion column (Miltenyi Biotec) to select for a purified population of unbound (CD8α-) DC 
(75-95%). Freshly-isolated CD8α- iDC were further enriched for CD11c by incubation of 
depletion column-eluted DC with magnetic beads coupled to anti-CD11c mAb at 4° for 15 min, 
then passed through a positive selection column. iBMDC were further purified via anti-CD86 
(depletion) and anti-CDllc (selection) mAb bead separation after metrizamide enrichment. DC 
were then used for both phenotypic and functional analyses.  
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 2.3.4. Extracellular flow cytometric analyses 
Cell surface phenotypic analysis was performed by flow cytometry using an EPICS Elite ESP 
analyzer (Beckman Coulter, Hialeah, FL). All flow cytometric experiments were done at 4°C. 
Leukocytes were first blocked with 10% normal goat serum for 10 min and then stained with 
mAb for 30 min. DC purity after immunomagnetic bead sorting was assessed by determining the 
expression of CD11c and CD8α using flow cytometry. Phenotypic analysis of cell surface 
markers was performed with the following Abs: phycoerythrin (PE)-CD11b, -CD40, -CD54, -
CCR5, -IAb, -H2k, -CD80, -CD86 (mAb, 1-2 µg/ml, BD PharMingen, San Diego, CA); 
biotinylated-CCR1 (C-terminus reactive), -CCR1 (N-terminus reactive), -CCR5 (C-terminus 
reactive) -CCR7 (C-terminus reactive) (goat anti-mouse polyAbs), secondary fluoroscein 
isothiocyanate (FITC)-conjugated donkey anti-goat (Santa Cruz Biotechnology Inc, Santa Cruz, 
CA); FITC-CCR3, -CCR6 (mAbs, R&D Systems, Minneapolis, MN); biotinylated-CCR4 
(donkey anti-mouse polyAb), secondary FITC-conjugated goat anti-donkey (Capralogics Inc, 
Hardwick, MA) [Attempts to titrate CCR Abs (1-50 µg/ml) failed to render reproducible results 
in >25 experiments]. Cells stained with the appropriate isotype-matched Ig (BD PharMingen; 
Santa Cruz; Capralogics; R & D Systems) were used as negative controls. After staining, the 
cells were fixed with 4% paraformaldehyde (PFA). For some experiments, CD11c
+
CD8α+ and 
CD11c
+
CD8α- iDC and mDC were flow-sorted according to their positivity for CD11c and 
CD8α.  
 
2.3.5. Intracellular flow cytometric analyses 
Intracellular staining was performed according to the standard PharMingen protocol: after Fc-
block with CD16/32, DC were surface stained with PE-CD11c and Cy-chrome CD8α (all mAbs, 
1-2 µg/ml, PharMingen) for 30 min and then fixed for 20 min with 4% PFA. Cells were then 
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 permeablized in the presence of biotinylated-CCR5 or -CCR7 (polyAbs, 3-5 µg/ml, Santa Cruz) 
for 30 min, washed, and then resuspended in permeablization buffer in the presence of the FITC-
conjugated secondary goat anti-donkey polyAb (1-2 µg/ml, Santa Cruz). Cells stained with the 
appropriate isotype-matched Ig (Santa Cruz) were used as negative controls. After staining, cells 
were fixed again with 4% PFA.  
 
2.3.6. Chemotactic agents 
Mouse recombinant CC chemokines CCL2, CCL3, CCL4, CCL5, CCL9/10, CCL7, CCL12, 
CCL19, CCL20, CCL21, CCL22 and CCL25 for the chemotaxis assay experiments (please refer 
to Table 4 for original nomenclature). Complement factor (C)5a and the bacterial formyl peptide 
N-formyl-methionyl-leucyl-phenylalanine (fMLP) (both from Sigma), both non-chemokine 
chemoattractants, also were tested. 
 
2.3.7. Chemotaxis assays 
Assays were performed as previously described (194), with minor modifications. Purified 
CD8α+ or CD8α- iDC or mDC, iBMDC, or bulk iDC or mDC from untreated mice (1-4 x 105) 
were resuspended in 100 µl 0.5% BSA RPMI 1640 (no FBS, without chemokine) in Transwells® 
(5 µm pores for mDC, 5 or 8 µm pores for iDC; Costar, Cambridge, MA) were placed in 24-well 
plates with 600 µl of chemokine dilution in 0.5% bovine serum albumin RPMI 1640 per well and 
incubated for 2 h at 37° C in 5% CO2 in air. After the incubation period, the Transwells® were 
removed and migrated DC from the 24-well plates were collected and enumerated using a 
Coulter Counter (Coulter). For accurate comparison between experiments, results were expressed 
as the percentage of migrated DC. Migration assays were performed in duplicate; experiments 
were repeated at least 3 times. 
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2.3.8. Calcium flux 
Ca++ flux was analyzed as described previously (196), with minor modifications. DC were 
loaded with 2 µM fura-2/AM (Molecular Probes), incubated for 30 min at 37°C in PBS without 
Mg++ or Ca++ supplemented with 4 [mM] probenecid (Sigma) in the dark, washed twice in PBS 
(BioWhittaker), and resuspended in PBS containing 1.2 [M] Ca++ and 1.5 [M] Mg++ at 2-3 x 106 
cells/ml. For iDC (BM and splenic), chemokines were added at a concentration of 10 [nM] at 
indicated times in a continuously stirred cuvette at 37°C in a Model MS-III spectrofluorimeter 
(Photon Technology, South Brunswick, NJ). Fig 15 only: after fura-labeling, mDC were placed 
on poly-D-lysine coated coverslips for 30 min at room temperature in PBS containing 1.5 [mM] 
Ca++ + 1% BSA. DC-coated coverslips were mounted on a ACAS 570c confocal microscope 
(Meridian Instruments, Okemos, Michigan) for measurement and data was collected and 
analyzed by the C*IMAGING Systems-Simple PCI program (Compix Inc, Imaging Systems, 
Cranberry Township, PA). Basal levels of intracellular Ca++ were measured for approximately 1 
min, then Ca++ PBS + 1% BSA was removed and 10 [nM] chemokine of CCL19 or CCL21 was 
added. The imaging system used in these studies consisted of a Nikon Diaphot 300 microscope 
(Nikon, Melville, NY) fitted with a 40quartz objective, a Dage-MTI cooled-CCD camera with 
640 480-pixel resolution (Dage-MTI, Michigan City, IN). For both iDC and mDC, the relative 
ratio of fluorescence emitted at 510 nm following sequential excitation at 340 and 380 nm then 
was recorded.  
 
2.3.9. RNase protection assay 
The RNase protection assay (RPA) was performed as described (69). Briefly, RNA was isolated 
from ~5x106 flow-sorted DC using a total RNA Isolation Kit (BD PharMingen). RPA was 
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 conducted using the RiboQuant mCR-5 Multi-Probe Template Set with anti-sense RNA probes 
that target CCR1, 1b, 2, 3, 4, and 5, and the housekeeping genes L32 and GAPDH (BD 
PharMingen). CCR6 and 7 probes were included in a customized RiboQuant Multi-Probe 
Template Set (BD PharMingen). The corresponding antisense RNA probe set was included as 
molecular weight standards. Mouse RNA and RNA degradation controls were included. Yeast 
tRNA served as a negative control. Quantification of bands was performed by densitometry 
followed by assessment using Image QuantNT software (Molecular Dynamics, Sunnyvale, CA). 
The signals from specific mRNA were normalized to signals from the housekeeping genes run 
on each lane to adjust for loading differences. 
 
2.3.10. Statistical analysis 
Results are expressed as means ±1 SD. Comparisons between means were performed by analysis 
of variance and then by the Newman-Keuls test. Comparison between 2 means was performed 
by the Student t-test. A “P” value ≤ 0.05 was considered to be significant. 
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 2.4. RESULTS 
 
2.4.1. Isolation and identification of splenic DC subsets 
Although most murine DC in vitro studies have utilized BM-derived DC, this culture system 
does not produce the CD8α-expressing DC subset. Therefore, for these studies, we chose to 
isolate DC from the spleens of FL-treated mice, as the ratio of CD8α- to CD8α+ DC averages 1:1 
[(46, 47) Colvin: unpublished observations] and FL treatment greatly increases both DC subsets 
without apparent significant differences in phenotype or function (as compared to DC from non-
FL-treated spleens) [Fig 9 and (47, 70)]. While flow sorting typically results in highly-purified 
cell populations (> 95%) at the cost of time and limited cell recovery, we employed 
immunomagnetic bead sorting to recover CD8α+ and CD8α- freshly-isolated (iDC) or overnight-
GM-CSF-cultured (mDC) B10 splenic DC enriched on a 16% (iDC) or 14.5% (mDC) 
metrizamide solution from bulk spleen cells, a method recently adopted by other groups for DC 
subset isolation (82, 304). Metrizamide separation yielded >60% of CD11c+CD86-/lo iDC (Figs 
9A and 10) and >90% of CD11c+CD86hi mDC (Figs 9B and 10). Forty to 60% of iDC or mDC 
were CD8α+ (Fig 9A and B). Purification of DC by immunomagnetic bead sorting yielded ~80% 
i and >90% m CD8α+ DC and ~80% i and ~90% m CD8α- DC populations (Fig 9C and D). As 
expected, both subsets of iDC exhibited immature DC morphology, were CD40/80/86-/lo and 
MHC IIlo, and were poor stimulators of allogeneic naïve T cells in MLR [Fig 10 and (47, 52)], 
while mDC of both subsets showed abundant dendritic prolongations, were MHC IIhi and 
CD40/80/86hi (Figs 6 and 11 and data not shown), and exhibited potent naïve T cell 
allostimulatory capacity, as previously reported by our group (47, 52).  
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Fig 9. Immunomagnetic bead sorting yields ample numbers of highly-purified DC populations. 
(A, B) Freshly-isolated or overnight (18h), GM-CSF-cultured spleen cells from 10 d-FL-treated B10 mice 
were layered on 16% w/v or 14.5% w/v (for iDC or mDC, respectively) metrizamide/PBS. (C, D) This 
CD11c+ DC-enriched population was then immunomagnetic bead-sorted according to CD8α expression, 
typically yielding ~80% CD8α+ and ~80% CD8α- iDC (C) and >90% CD8α+ and >90% CD8α- mDC 
(D). Appropriate isotype controls (Ig) were use for gating (data not shown); numbers indicate percentage 
of cells (48). 
 
 Fig 10. Phenotype of splenic iDC and m DC.  
Metrizamide-enriched, magnetic bead-sorted i and mDC were gated on CD11c and CD8α and stained for 
the adhesion molecules CD11b and CD54, the co-stimulatory molecules CD80 and CD86, and the Ag-
presenting molecule MHC II. CD8α+ DC are low, but not completely negative for CD11b and express 
high levels of CD205, while CD8α- DC express high levels of CD11b, but low levels of CD205 (CD205 
data not shown). Both subsets expressed (typical for iDC) low levels of co-stimulatory and MHC 
molecules when freshly-isolated (top two rows), and upregulated these after overnight culture (showing 
typical mDC phenotype) (bottom two rows) (312). Mean fluorescence intensity (MFI) follows the percent 
expression of each molecule in parentheses. Open histograms represent isotype control Ig; filled 
histograms represent protein expression. 
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 2.4.2. Freshly-isolated spleen CD8α+ and CD8α- DC do not migrate in vitro in response 
to previously-defined iDC migration-inducing CC chemokines 
Various mouse CC chemokines were tested in chemotaxis assays to determine the in vitro 
migratory response of CD8α+ and CD8α- iDC. Surprisingly, although both human and mouse 
BM- and blood-derived and skin iDC have been reported to respond to several CC chemokines 
(44, 192, 204, 309), neither murine spleen iDC subset migrated to any of the CC chemokines 
tested (CCL2, CCL3, CCL4, CCL5, CCL7, CCL9/10, CCL12, CCL19, CCL20, CCL21, CCL22, 
or CCL25) (positive migration was considered ≥10% migration above control wells without 
chemokine) (Table 8, Fig 11A, and data not shown). We also tested the non-chemokine 
chemoattractants C5a and fMLP, which have been reported to elicit human skin (313) and blood 
(314) iDC migration in vitro (although blood iDC responded to higher concentrations than those 
tested by us: 1000 and 10,000 [nM]), but these factors did not induce migration of either splenic 
iDC or mDC (data not shown). To control for possible impairment of migration due to the 
presence of anti-CD8α or anti-CD11c magnetic beads on iDC, iDC subsets were sorted by 
fluorescence activated cell-sorting (FACS), but this did not increase iDC migration (data not 
shown). Finally, we increased the incubation up to 4 h, but this increased migratory period 
merely resulted in an equal increase of iDC kinesis in all wells, including the control well (data 
not shown).  
 
To confirm that our assay was appropriate for analysis of chemotaxis of immunobead-sorted, FL-
treated, spleen iDC migration, we replaced the spleen iDC with BM-derived iDC as positive 
controls. The iBMDC exhibited reproducible migration to CCL4 (MIP-1β) and CCL5 
(RANTES) (Fig 11B), as reported previously (164, 195, 204, 315). As expected, neither CCL19 
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 (MIP-3β) nor CCL21 (SLC) (both chemoattractants for mDC) elicited migration of splenic 
CD8α+ or CD8α- iDC or iBMDC (Table 8, Fig 11A and B, and data not shown).  
 
Table 8. Assessment of migratory responses of immature and mature CD8α+ and CD8α- DC to CC 
chemokines. 
 
 
(48) 
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 Fig 11. DC migration to specific CC chemokines in vitro is dependent on both tissue of origin and 
state of maturation.  
Immunobead-sorted (unless otherwise noted) DC were placed in the upper wells of Transwell® chambers 
over graded concentrations of CC chemokines. (A) Freshly-isolated CD8α+ or CD8α- iDC from either 
non-FL- (non-immunobead-sorted) or FL-treated spleens failed to migrate to any CC chemokines tested 
(positive chemotaxis was considered ≥10% migration over control without chemokines). (B) iBMDC 
migrated to CCL4 and CCL5, but to neither of the constitutively expressed chemokines CCL19 and 
CCL21 (data not shown). (C) Splenic CD8α+ or CD8α- mDC migrated only to CCL19 and CCL21 (data 
not shown). To assess whether immunomagnetic beads interfere with DC chemotaxis, the migratory 
response to CCL19 and CCL21 of negatively-selected CD8α- mDC (unbeaded) was compared to that of 
negatively-selected CD8α- mDC incubated with anti-CD11c magnetic beads. CD8α- mDC migrated 
equally well with or without magnetic bead attachment. Three examples of the 12 CC chemokines tested 
are shown (for a complete list of chemokines tested, the reader is referred to the text). Data are from a 
single experiment representative of at least 3 performed; each chemokine dilution was tested in duplicate. 
(48) 
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 2.4.3. Spleen CD8α+ and CD8α- mDC migrate in vitro in response to mDC migration-
inducing chemokines 
The constitutively-expressed chemokines CCL19 [by DC and endothelial cells (EC) in secondary 
lymphoid tissues] and CCL21 [by EC in lymphatics and high endothelial venules (HEV)] (182-
184) have been reported to induce migration of human and murine mDC (44, 192, 197, 204, 
315). In keeping with these reports, both CD8α+ and CD8α- splenic mDC migrated in response 
to CCL19 and CCL21, but not to the inflammatory CC chemokines tested (CCL2, CCL3, CCL4, 
CCL5, CCL7, CCL9/10, CCL12, CCL20, CCL22, CCL25) (Table 8 and Fig 11C, and data not 
shown). CD8α+ mDC consistently migrated in fewer numbers in response to CCL19 and CCL21 
compared to CD8α- DC (Fig 11C). Since after cell purification, CD8α+ DC (unlike CD8α- DC) 
may have retained magnetic beads on the cell surface, we ascertained whether the presence of 
magnetic beads on the cell surface would affect CD8α+ DC migration. As shown in the last panel 
of Fig 11C, CD8α- DC bearing anti-CD11c magnetic beads migrated equally well to both 
CCL19 and CCL21 as compared to unbeaded CD8α- DC. Therefore, the presence of 
immunomagnetic beads on the cell surface did not affect migration. 
 
To ensure FL-mobilization of the spleen DC was not a factor influencing their ability to migrate, 
bulk spleen i and mDC were isolated from untreated mice and their chemotactic responses were 
tested to a select group of CC chemokines. Because it required a large number of mice to isolate 
enough iDC for one chemotaxis assay, and because only a very few non-FL-treated iDC could be 
isolated, even from a large number of spleens, the iDC were not separated into CD8α+ and 
CD8α- populations. Like iBMDC, whose migration in response to CC chemokines is not affected 
by exposure to FL (192, 196), spleen iDC from non-FL-treated mice did not migrate to CCL4, 
CCL19, CCL20, CCL21 (data not shown), or CCL5 (Table 8 and Fig 11A), and non-treated 
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 spleen mDC migrated to CCL19 and CCL21 (but not CCL4, CCL5, or CCL20), in a similar 
manner to their FL-mobilized counterparts (Table 8 and data not shown). 
 
2.4.4. CCR mRNA and protein expression in spleen CD8α+ and CD8α- DC does not 
correlate with (apparent) functional CCR expression 
The lack of available cell surface-staining murine CCR Abs coupled with the absence, in vitro, 
of migration to inflammatory CC chemokines, led us to analyze the pattern of CCR mRNA 
expressed by splenic DC using RPA. CD8α+ and CD8α- iDC showed the typical pattern of 
down-regulation of inflammatory CCR mRNA expression (CCR1, 2 and 5), especially CCR2 
upon maturation, with concomitant upregulation of CCR7 (Fig 12A and B), similar to that 
reported for murine BMDC [both in the presence (192) and absence (196) of FL]. Despite the 
expression of mRNA for CCR 1, 2, and 5, both spleen iDC subsets failed to migrate in response 
to any of their ligands (Table 8 and Fig 11), although iBMDC migrated to the CCR1 and CCR5 
ligands CCL4 and CCL5. Interestingly, expression of mRNA for CCR6, a CR typically 
expressed on precursor/iDC populations (44, 181, 185), was low in iDC but increased in mDC. 
We therefore then analyzed untreated spleen CD8α+ and CD8α- i and mDC mRNA to determine 
if this unexpected CCR6 expression pattern was due to FL-treatment. i and m spleen CD8α+ and 
CD8α- DC from non-FL-treated mice expressed an identical pattern of mRNA for CR receptors 
1-7 (data not shown) as compared to all spleen DC subsets from FL-treated mice, indicating that 
the pattern of CCR6 mRNA was not due to treatment of the mice with the growth factor. 
Nevertheless, neither subset at either stage of maturation (with or without FL-mobilization) 
exhibited a positive migratory response to the CCR6 ligand CCL20.  
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Fig 12. CCR mRNA expression in spleen i and mDC. 
CD8α+ and CD8α- iDC and mDC were flow-sorted for maximum purity (>95%). (A) Both iDC subsets 
s CCR mRNA expression did not correlate with spleen iDC migration, and since CD8α+ mDC 
downregulated CCR1, CCR2, and CCR5 mRNA expression and upregulated CCR6 and CCR7 message 
upon maturation into mDC. (B) Densitometric analysis for quantitation of cytokine mRNA expression. 
Analysis of each lane was performed on scanned autoradiographs, and all values are expressed relative to 
corresponding housekeeping gene transcripts (L32). Data are from 1 experiment representative of 3 
performed. (316) 
 
A
migrated in consistently fewer numbers than CD8α- DC (possibly indicating lower expression of 
CCR7), we attempted to measure DC surface protein expression of CCR 1, 3, 4, 5, 6, and 7 by 
flow cytometry. However, in >25 experiments, CCR detection was not reproducible. We 
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 therefore endeavored to measure intracellular protein production using anti-CCR1, -CCR5, and -
CCR7 polyAbs. Though these CCR were detected consistently in iDC and mDC of both subsets, 
no conclusions could be drawn regarding their differential surface expression, as apparent 
intracellular protein production showed little variation among the cell subtypes analyzed (Fig 
13).  
 
Fig 13. Intracellular staining 
of CCR1, 5, and 7 revealed 
 
grate to any of the ligands for 
these CR. We performed a Ca++ flux assay to determine if the DC expressed CR that could be 
activated, even if they were unable to induce migration of DC after binding their ligand(s). 
Spleen iDC did not exhibit any Ca++ flux in response to CCL4, CCL5, CCL19, CCL20, or 
CCL21, although they did release Ca++ in response to a non-specific Ca++ flux inducer, 
no significant difference in 
the production of CCR 
between either subset of 
either state of maturation.  
Metrizamide-enriched i or 
mDC were stained for CD11c 
(PE) and CD8α (Cy-chrome), 
washed, permeablized, and 
then stained for intracellular 
protein production of CCR 
(FITC). MFI is presented in 
parenthesis after the percent 
expression of each molecule. 
(316) 
 
 
iDC contained mRNA and protein for CCR1 and 5, but did not mi
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 ionomycin (Fig 14 and data not shown), somewhat similar to human blood-isolated plasmacytoid 
iDC (193). Freshly-isolated human blood pDC express CXCR3, and CXCR4 (for example) but 
migrate only to SDF-1α (CXCL12), the ligand for CXCR4, and to no ligands for CXCR3. Nor 
do they exhibit changes in intracellular Ca++ levels in response to the CXCL10 (a ligand for 
CXCR3), but they do flux in response to CXCL12 (193). iBMDC, however, which migrated in 
response to CCL5, also fluxed after exposure of the DC to CCL5 (Fig 14). 
 
Fig 14. Despite mRNA and intracellular protein production of CCR1 and 5, but in correlation with 
in vitro migration data, spleen iDC do not show a change in intracellular Ca++ in response to CCL4 
or CCL5.  
 
eft and middle). However, iBMDC (right) responded to exposure to CCL5. A positive change in Ca++ 
onsistently migrated in greater numbers than CD8α  DC. One possibility for this difference is a 
Neither CD8α+ (left) nor CD8α- (middle) spleen iDC exhibited a change in intracellular Ca++ after 
exposure to CCL4 (data not shown) or CCL5, although a Ca++ flux was seen after exposure to ionomycin 
(l
flux is indicated by a change in the overall flux ratio, as seen after spleen iDC exposure to ionomycin or 
iBMDC exposure to CCL5: an initial spike in the flux ratio was observed initially each time chemokine or 
ionomycin was added to the DC, but immediately returned to baseline in negative reactions. (316) 
 
mDC expressed similar levels of CCR7 mRNA and intracellular protein, although CD8α- DC 
+c
lesser ability of CD8α+ DC to respond to CCR7 ligands. The current lack of Abs which bind the 
extracellular portion of CCR7 prevents direct detection of protein levels on the surface of DC, 
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 therefore we were unable to ascertain whether CD8α+ DC simply express less CCR7 than CD8α- 
DC. However, as both mDC subsets showed changes in intracellular Ca++ levels upon exposure 
to CCL19 and CCL21, we attempted to compare the function of CCR7 on CD8α+ and CD8α- 
DC indirectly. Yanagawa and Onoé (317) reported that LPS-matured BC1 cells (a spleen-derived 
murine iDC line) extend their dendrites in response to CCL19 after an hour, but not to CCL21. 
Interestingly, we found that both mDC subsets rapidly (less than 1 min) extended their dendrites 
in response to 10 [nM] CCL19 and CCL21. While the morphologic response of CD8α- DC to 
these chemokines was more striking (compare Fig 15A and B to C and D), the mDC subsets 
showed a similar change in intracellular Ca++ levels after exposure to chemokine (Fig 15E), 
making quantitative comparison of their expression of CCR7 unachievable.  
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 Fig 15. Splenic mDC morphologic and intracellular responses to CCR7 ligands.  
Immunomagnetic bead-sorted CD8α+ and CD8α- mDC were labeled with fura-2 and allowed to adhere to 
poly-D-lysine-coated glass coverslips. Basal levels of Ca++ flux were measured in DC immersed in PBS + 
Ca++ and 0.1% BSA (A-D first panels; E black bars), and the change in flux was measured again after 
addition of 10 [nM] chemokine (A-D second panels; E white bars). (A-D) DC exhibited dendrite 
extension after 1 min of exposure to either chemokine, with slightly more drastic extension in response to 
CCL21 (B and D), and with CD8α- mDC showing slightly more apparent extension than CD8α+ mDC 
(compare A and B to C and D). Arrowheads highlight mDC that exhibit an increase in dendrite extension 
after exposure to CCR7 ligand. (E) Despite a more obvious extension of dendrites by CD8α- mDC, 
neither subset appeared to have a more drastic quantifiable change in intracellular Ca++ levels. Bars 
represent the mean ± SD change in intracellular Ca++ in n = 20 DC averaged from three separate 
experiments. 
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 2.5. DISCUSSION 
In this study, we have compared the migratory ability of murine CD8α+ spleen DC to their more 
extensively studied CD8α- counterparts. Previous data regarding “classic” myeloid DC, 
generated from BM or blood precursors or isolated from the skin or LN, suggest that iDC are 
capable of responding to diverse inflammatory CC chemokines. This is not surprising, given the 
role iDC play during immune responses. However, unlike in vitro generated BM- or blood-
derived DC, here we have shown that iDC isolated directly from spleen are more restricted in 
their chemotactic reactivity. While iBMDC exhibited positive (albeit weak, compared to mDC) 
migration to iDC migration-inducing CC chemokines, as previously reported (159, 167, 192, 
195, 204, 309, 311, 315), freshly-isolated spleen CD8α+ and CD8α- iDC failed to respond to any 
of the CC chemokines tested. Preliminary studies in our laboratory with FL-mobilized murine 
liver (54) and kidney DC (49) reveal this phenomenon is not restricted to spleen iDC, as iDC 
isolated directly from these non-lymphoid/parenchymal organs also appear to have restricted 
chemotactic responses to CC chemokines. We consider it unlikely that this phenomenon is 
related to DC mobilization by FL treatment, as FL-DC have been reported by several groups to 
be phenotypically and functionally identical to DC from non-treated animals (47, 60, 307). 
Studies using iBMDC from FL-treated mice showed iBMDC responded to the same CC 
chemokines as those reported by groups using non-FL-mobilized murine BMDC (192), and our 
own data using spleen iDC from non-FL-treated mice were comparable to those from FL-treated 
DC (Fig 11A). Further, our in vivo migration data for freshly-isolated, FL-mobilized DC (Figs 26 
and 27) are consistent with those reported by Ruedl and Bachmann (304), who used untreated 
iDC  and with those reported by Drake et al (71), who used FL-treated mDC. 
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 It seems likely that spleen iDC do not express functional CR, as evidenced by their lack of Ca++ 
flux (Fig 12D) and lack of migration to their ligands (Fig 11A). At least one study has reported 
CCR5 expression on murine CD8α+ iDC [through binding of FITC-labeled CCL4 (MIP-1β)] 
(318), although we did not observe spleen CD8α+ iDC migration or 
Ca++ flux to CCR5 ligands (e.g., CCL4 or CCL5; Fig 11A and 13D). A possibility for the lack of 
detected activity is that the CCR on iDC have been downregulated by constitutive expression of 
CC chemokines in the spleen. By RPA, we have detected low levels of CCL3 and CCL4 and 
high levels of CCL5 in the spleens of FL-treated mice (50). Mack et al (191) have shown that 
these three chemokines downmodulate CCR5 expression on murine NK cells in vitro (as well as 
CCR2 by CCL1 on monocytes) in a dose-dependent manner, suggesting that CCR expression 
downmodulation on iDC in situ is a distinct possibility. No studies to date have reported CR 
expression on murine DC using poly- or mAb. Despite the availability of several such reagents, 
we were not able to demonstrate differential expression of CCR on mouse DC subsets, as has 
been reported for mouse Th1 and Th2 cells (159) and human DC (193, 205). The eventual advent 
of reliable Abs for detection of mouse extracellular CR will aid in determining whether iDC 
express no, non-functional [like human i pDC (193)], desensitized (or any combination of the 
three) CCR. 
 
Whereas spleen iDC responses to the CC chemokines essentially were lacking, spleen mDC 
reacted as predicted from all other studies with mDC, regardless of tissue or species of origin 
(44, 49, 50, 54, 163, 164, 190, 195, 198, 309, 316). Perhaps analogous to in vivo data (86, 304) 
however, CD8α+ mDC migrated in consistently fewer numbers, a fact apparently unaffected by 
the chemokine tested (Figs 11C, 16-18) or method of sorting (Fig 11C). Without reliable anti-
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 CCR7 mAbs, it is not possible to know for certain whether fewer CD8α+ DC overall express 
CCR7, or whether less CCR7 is expressed by CD8α+ DC overall, only that fewer migrate (as 
compared to CD8α- mDC) and the change in intracellular Ca++ is (surprisingly) similar to CD8α- 
mDC. Though these data do not provide conclusive evidence as to why CD8α+ DC migrate in 
fewer numbers, they give further insight into this consistent pattern: though both DC subsets may 
receive the same intracellular message to migrate, CD8α+ mDC exhibit decreased prolongation 
of dendrites as compared to CD8α- mDC. As we discuss in Chapters 2 and 3, both mDC subsets 
migrate with equal agility to secondary lymphoid tissues in vivo (Figs 29 and 30), but not 
through EC-layered Transwell filter chambers (Figs 20, 21, 23-26), suggesting CD8α+ mDC may 
require further stimulus (beyond CCL19 or CCL21) for full extension of their dendrites that has 
not been provided in our in vitro models. We have shown DC matured overnight in culture 
rapidly (in less than 1 min) extend their dendrites in response to both CCL19 and CCL21, unlike 
the LPS-matured iDC cell line previously investigated by Yanagawa and Onoé (317) (which 
exhibit prolongation of dendrites after 1 h exposure to CC19 only). Perhaps indeed the 
rapidity/ability with which mDC extend their dendrites depends on more factors than just 
chemokine. Thus, the advent of cell surface-specific murine anti-CCR mAbs will benefit greatly 
the investigations of CCR expression on both i and mDC. 
 
In conflict with previous studies, we report here that spleen DC upregulate CCR6 mRNA 
expression after overnight culture (concomitant with phenotypic and functional maturation), 
although neither iDC nor mDC responded to CCL20 (the natural ligand of CCR6). Iwasaki and 
Kelsall (44), on the other hand, demonstrated that CD11b+(CD8α-) freshly-isolated PPDC 
migrated in response to CCL20, while neither CD8α+ PPDC nor either subset of spleen DC did 
77 
 so. Despite the fact that the freshly-isolated DC in their experiments appeared to be 
phenotypically immature, all the DC subsets evaluated migrated to CCL19 and CCL21, 
inconsistent both with the present findings and those of others [Fig 11A and B and (164, 185, 
192, 194, 196, 197, 204, 309, 315)]. Kucharzik et al (319) detected EGFP/CCR6 on 
CD11b+(CD8α-) PP and spleen freshly-isolated (untreated or FL-mobilized) DC, although they 
did not attempt in either case to determine whether the receptor was functional or whether its 
expression changed with maturation. Varona et al (320) also describe a lack of CD11b+ PPDC in 
CCR6-/- mice, although they did not investigate whether this population was also absent in the 
spleen. Further, in the studies of Kelsall et al (44), DC were isolated from spleens of BALB/c 
mice, while our DC were isolated from the spleens of B10 mice. It has been reported that DC 
from C57BL/6J mice express mRNA for TRL9 only, while DC from BALB/c mice express 
mRNA for TLR2, 4, 5, and 6 (321). Perhaps CR mRNA expression is strain- as well as tissue of 
origin-dependent. If indeed CCR6 is expressed on mouse spleen iDC or mDC, it appears to be 
non-functional and unable to be activated (as assessed by Ca++ flux and migration assays) (Table 
8, Fig 12, and data not shown). 
 
In summary, here we have compared, for the first time, the in vitro migration of CD8α- and 
CD8α+ (spleen) DC, taking into consideration the effect the state of DC maturation has on 
migratory capacity. Here we also show the first Ca++ flux assays performed to determine CR 
activation in response to specific chemokines with in vitro-generated (iBMDC) and tissue-
isolated (spleen i and mDC) mouse DC. All other DC Ca++ flux studies previous to this one have 
been undertaken with human DC (193, 322) or a murine iDC cell line (196). Taken together with 
the migration data, these findings strongly suggest that unlike peripheral iDC, (i)DC within 
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 secondary lymphoid tissues (in particular, the spleen) do not respond to (inflammatory) CC 
chemokines. They also offer the beginnings of an understanding as to why some groups have 
reported poor CD8α+ mDC migration in vivo.  
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 3. CHAPTER TWO4 
 
MIGRATION OF SPLENIC DC SUBSETS THROUGH EC: MIMICKING THE IN VIVO 
ENVIRONMENT 
 
In Chapter One, CCL19 and CCL21 were determined to selectively induce the migration of 
splenic mDC in vitro through unmodified Transwells®. Thus we analyzed whether these same 
chemokines were still able to induce mDC migration through a more “in vivo-like” environment 
by layering resting and activated endothelial cells (EC) across the Transwells®. Because of the 
differential migration pattern seen for CD8α+ vs CD8α- mDC through both unmodified and EC-
layered Transwells®, in this Chapter we attempted to determine which, if any, adhesion 
molecules expressed on mDC might be responsible for this difference. These findings also were 
important in determining which intercellular adhesion molecules may be important in facilitating 
splenic mDC migration in vivo, as considered in the Chapter Discussion. 
                                                 
4 Data from this chapter have been submitted independently in manuscript form for peer review and 
publication (312) where indicated. 
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 3.1. ABSTRACT 
Immature DC are induced to migrate to sites of inflammation by inducible (“inflammatory”) 
proteins called chemokines. Upon uptake of antigen and maturation, DC then are directed by 
constitutively-expressed (“lymphoid”) chemokines to draining secondary lymphoid tissues, 
wherein they present these antigens to naïve and memory T cells, initiating the immune response. 
We have previously shown that mature murine CD8α+ mDC are able to migrate, albeit poorly 
compared to their CD8α- counterparts, in response to CCL19 and CCL21 (constitutively 
expressed in T cell areas and HEV, respectively) using in vitro chemotaxis assays through 
unmodified Transwell® filters. One reason for this decreased migration may be the lower surface 
expression (compared to CD8α- mDC) of the adhesion molecule CD11b, which may hamper the 
ability of CD8α+ mDC to adhere to/extravasate through filter pores in vitro and/or endothelial 
cells in vitro/in vivo. To test whether expression of this adhesion molecules plays a role in 
regulating the ability of CD8α+ DC to migrate, we analyzed whether incubating CD8α- mDC 
with blocking monoclonal antibodies against CD11b would reduce their migration to the level of 
CD8α+ DC. We further tested whether blocking adhesion molecules reported to be expressed on 
mouse and human DC (e.g., CD31, CD54, CD62L) would have an effect on their 
transendothelial migration. Resting or TNFα-activated mouse endothelial cells (EC) were 
layered on 5 µm Transwell® filters, and overnight-matured splenic, magnetic bead-sorted DC 
were placed into the upper wells of Transwell® filters for 2 h (with resting EC) or 4 h (with 
activated EC). Migrated DC then were removed from the lower chamber and enumerated using a 
Coulter counter. Both DC subsets had slightly impaired migration to CCL19 through resting EC 
(compared to absence of EC), but both DC subsets migrated through TNFα-activated EC as well 
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 as in the absence of the EC monolayer. Contrary to reports concerning human DC, 
transendothelial migration of the murine DC subsets was not dependent on CD11b, CD31, or 
CD62L expression by these cells. CD54, however, was determined to be at least partly involved 
in DC/EC interactions. This is the first report to examine adhesion molecules involved in 
transendothelial migration of murine DC subsets. The data implicate CD54 in facilitating DC 
transendothelial migration, suggesting a potential target for manipulation of DC trafficking in 
vivo. 
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 3.2. INTRODUCTION 
DC trafficking in vivo requires interactions between DC and EC. In both steady-state and 
inflammatory situations, iDC leave the bloodstream, aided by interactions between integrins on 
DC [reportedly, for human monocyte-derived DC, CD11b/CD18 but not CD11c (283)] with Ig 
superfamily members on EC [e.g., CD54 (37, 283)] for rolling and tethering, and likely through 
homophilic engagement of CD31 for transendothelial extravasation (273, 276, 283). Upon 
entrance into the peripheral tissue, the iDC endo/phagocytose Ag, begin to mature, and modify 
their CCR expression. The concurrent downregulation of CR for inflammatory chemokines and 
the upregulation of CR for lymphoid chemokines initiates recruitment of the DC to secondary 
lymphoid tissues, requiring their reverse transmigration through EC into lymphatic vessels, a 
process which reportedly requires CD29 (β1-integrin), CD49d (VLA-4), and CD49e (VLA-5) 
(283), and tissue factor and multidrug resistance protein 1 (274, 278, 282). 
 
Leukocyte rolling and tethering have been studied comprehensively in both the mouse and 
human. The adhesion molecules that regulate these processes have been elucidated for T cells, 
NK cells, and monocytes (258, 259). Recently, even the inscrutable transendothelial migration 
process has been illuminated (259) by studies that revealed both the physical means by which 
leukocytes transverse EC [most researchers now agree leukocytes (with the exception of one 
study with NK cells, which suggests migration through EC) wedge between two EC (265)] and 
the adhesion molecules [as mentioned above (259)] involved. However, these studies have not 
been extensive regarding DC. Presently, very few reports have considered which adhesion 
molecules may be important in directing DC extravasation, and these studies have been limited 
to human DC that differ in state of maturation as well as in origin of the DC analyzed (205, 283).  
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As observed in Chapter One, CD8α+ mDC appear to have a reduced ability to migrate in vitro as 
compared to CD8α- mDC. As also discussed, one possibility for this discrepancy may be related 
to their expression of functional CCR7. Another possibility is their expression of adhesion 
molecules. CD8α+ DC frequently are further characterized by their lack/low expression of 
CD11b, while CD8α- DC are classically identified as “myeloid” by their high expression of this 
integrin [Fig 10 and (46-48, 52)]. CD54, constitutively expressed on resting (albeit low/moderate 
levels) and (upregulated on) activated EC (258), is a major ligand of CD11b. Therefore it is 
conceivable that the reduced expression of CD11b on CD8α+ DC may correlate with their 
reduced migration in vitro (Fig 11C) and reported in vivo trafficking (86, 304). Data concerning 
murine DC/EC/adhesion molecule interactions currently are lacking, leaving a discernible gap in 
the knowledge of a potential means by which to manipulate DC migration in vivo. In addition to 
questions concerning differences in CD8α+ and CD8α- DC migration, basic information 
regarding which adhesion molecules permit DC to exit from the bloodstream into peripheral 
tissues is essential for optimizing their therapeutic delivery. 
 
In Chapter Two we describe our creation of a more “in vivo-like” chemotaxis environment 
through layering of resting or activated EC over the Transwell® filters. This system allowed 
further evaluation of the ability of CCL19 and CCL21 to regulate mDC migration and provided a 
controlled environment in which the specific adhesion molecules thought to be important for DC 
extravasation could be examined. Thus in this Chapter, we evaluate, also for the first time, which 
adhesion molecules are essential for facilitating murine splenic DC subset transendothelial 
migration. 
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 3.3. MATERIALS AND METHODS5 
3.3.1. DC isolation 
mDC were prepared as described in Chapter One (Section 2.3.2), except that 14.5% w/v 
nycodenz (Sigma) was used for DC enrichment (instead of 14.5% w/v metrizamide). 
 
3.3.2. Endothelial cells 
EC from the Mile Sven 1 (MS1) SV40-transformed pancreatic cell line derived from a C57BL/6 
(B6; H2b) background were generously donated by Timothy Carlos MD, PhD, Department of 
Medicine, University of Pittsburgh Physicians Faculty (who acquired the cells from ATCC). EC 
were grown to confluence in normal, uncoated cell culture flasks in EC media: RPMI-1640 
supplemented with 5% FBS, antibiotics, fungicide® (an anti-fungal supplement; Sigma), and 1% 
sodium bicarbonate, as recommended by Dr. Carlos. The MS1 cell line requires no exogenous 
growth factors/cytokines (ATCC). EC were split at confluence (to prevent overgrowth) and for 
phenotypic and chemotaxis assays. Excess EC cultures were frozen down as available to provide 
backup cultures: EC were frozen in 90% dimethyl sulphoxide (9 parts DMSO: 1 part EC media) 
in liquid N2. The MS1 cell line is not susceptible to activation by IL-1β, but overnight exposure 
to TNFα (10 ng/ml) elicits the expression/upregulation of typical activated EC markers (with the 
exception of mucosal addressin cell adhesion molecule (MadCam)-1, which is not expressed by 
this cell line, T Carlos, personal communication). For chemotaxis assays, EC confluence was 
determined by Giemsa staining of 5-7.5 x 104 EC layered on uncoated 5 µm Transwells® filters 
for 24-48 h. Optimal EC numbers were found to be 6.5 x 104 overnight or 5 x 104 for 48 h. 
 
                                                 
5 The reader is referred to Chapter One Materials & Methods for any repeat methods not covered here. 
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 3.3.3. Extracellular flow cytometric analysis 
Confluent EC were exposed to 0, 5, 10, or 20 ng/ml TNFα in EC media for 0, 4, 8, 18, or 24 h in 
uncoated 6 well plates, washed thoroughly with PBS, trypsinized, washed in PBS, and then 
stained by normal flow cytometric analysis protocol. EC were first blocked with 10% v/v normal 
goat serum and then stained for the following cell surface molecules: FITC-/biotinylated-CD11a 
(LFA-1), CD11b (Mac-1), CD11c (p150/95), CD31 (PECAM-1), CD54 (ICAM-1), CD62L (L-
Selectin), CD62E (E-Selectin), CD102 (ICAM-2), and CD106 (VCAM-1) (all from 
PharMingen). Cells stained with the appropriate isotype-matched Ig (BD PharMingen, San 
Diego, CA) were used as negative controls. After staining, cells were fixed in 4% v/v PFA. 
 
3.3.4. Chemotaxis assays 
For chemotaxis assays with EC, 5 (activated) -6.5 (resting) x 104 EC were layered over 
Transwells® with 5 µm pores 48 or 24 h, respectively, before the experiment. In assays with 
activated EC, 5 x 104 EC were layered 48 h preceding the migration assay, so that 10 ng/ml 
TNFα could be added 24 h after layering and 24 h before the chemotaxis assay. DC + EC were 
incubated for 4 h for resting EC and 2 h for activated EC. After the appropriate incubation 
period, the Transwells® were removed and migrated DC from the 24-well plates were collected 
and enumerated using a Coulter Counter. For accurate comparison between experiments, results 
were expressed as the percentage of migrated DC. Migration assays were performed in duplicate; 
experiments were repeated at least 3 times. 
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 3.3.5. Statistical analysis 
Student’s unpaired t-test was performed to determined statistical significance using Statview and 
Microsoft Excel for the Macintosh. A “P” value < 0.05 was considered to be significant. 
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 3.4. RESULTS 
 
3.4.1. Phenotypic analysis of resting and activated EC 
Primary mouse EC cell cultures are difficult to procure as well as to maintain. Therefore, we 
employed an established EC cell line. Although they appeared to be morphologically normal EC, 
we analyzed their cell surface phenotype (namely, adhesion molecules) to confirm there 
“resting” EC status. As expected, they expressed low levels of CD31, CD54, and CD62L, with 
high levels of CD62E, CD102, and CD106 (Fig 16), similar to normal EC (323, 324). Since EC 
are activated by exposure to TNFα (258, 279, 294), we used this cytokine to analyze CD11b 
(negative control), CD31, CD54, and CD106 expression after 0, 4, 8, 16, and 24 h exposure to 
TNFα. This allowed us to determine the minimum period of exposure of EC to TNFα for 
optimal upregulation of these adhesion molecules (Fig 17). Twenty-four h of exposure to 10 
ng/ml TNFα resulted in maximal upregulation of all the molecules analyzed except CD102, 
which already was expressed by nearly 100% of the EC at 0 h (Fig 16). Flow cytometric analysis 
of adhesion molecule expression after 24 h exposure of EC to either 5 or 20 ng/ml of TNFα 
revealed no significant upregulation of adhesion molecules compared to that seen in the presence 
of 0 or 10 ng/ml, respectively (data not shown). 
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 Fig 16. TNFα induces upregulation of various integrins and Ig superfamily members on EC.  
EC were washed in PBS, trypsinized, and removed from plates after overnight culture (18h) with 
(“activated” EC; right histograms) or without (“resting” EC; left histograms) 10 ng/ml TNFα for staining 
of cell surface adhesion molecule expression. Open histograms represent appropriate isotype controls; 
grey histograms represent adhesion molecule expression (312). 
 
Fig 17. Optimal expression of adhesion molecules on EC occurs after 24 h exposure to 10 ng/ml 
TNFα.  
EC were grown to confluence in EC media in 6-well plates and exposed to 10 ng/ml TNFα for 0, 4, 8, 18 
or 24 h. EC were then washed in PBS, trypsinized, washed in fresh media, and then stained with 
appropriate adhesion molecule (grey histograms) or isotype control mAbs (open histograms) (312).  
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 3.4.2. Spleen mDC subset migration is affected by the state of activation of EC  
Normally it is iDC, not mDC, which extravasate through EC-walled blood vessels into peripheral 
tissues. However, our in vitro chemotaxis experiments with splenic iDC revealed that they were 
unable to migrate in response to any of the chemoattractants tested (either the CC chemokines or 
C5a or fMLP) (Table 8 and Fig 11A). Nor did they exhibit a change in intracellular Ca++ levels 
in response to any of the CC chemokines tested (Fig 14) or migrate in significant numbers to T 
cell areas of secondary lymphoid tissues in in vivo trafficking studies (as discussed further in 
Chapter Three). Thus, we chose not to pursue analysis of iDC in vitro migration through EC. 
Rather, we focused attention on overnight-cultured DC subsets (CD8α+ and CD8α-) since these 
“mature” DC both migrate to secondary lymphoid chemokines in vitro (Table 8 and Fig 11C) 
and migrate to secondary lymphoid tissue following their iv administration (Fig 28). 
 
Maximal chemotactic mDC migration occurs between 2 and 2.5 h after addition of DC to the 
upper wells of the Transwell® filters (after 2.5 h, random DC movement in wells with no 
chemokine increases, giving a false positive migratory response: original time course performed 
by Dana Faratian, MD, Summer 1999; data not shown). Because the EC layer adds an additional 
barrier for mDC to transverse, we did time course assays to determine the optimal time to 
evaluate mDC transendothelial migration. As expected, maximal mDC migration through resting 
EC required an extended incubation period (after approximately 4 - 4.5 h of incubation) (Fig 
18A). Somewhat unexpectedly, maximal mDC migration through activated EC occurred with 
slightly more rapidity than through unmodified Transwell® filter chambers (after approximately 
1.5 - 2 h) (Fig 18B).  
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 Fig 18. Time course of mDC migration to CCL19 through EC-layered Transwells®.  
10 [nM] of (A) CCL19 or (B) CCL21 was added to the lower wells, and immunomagnetic bead-sorted 
CD8α+ or CD8α- mDC were added to the upper well of Transwells® layered with (A) resting/(B) 
activated EC. The plates were incubated at 37° C in 5% CO2 for the times indicated, at which point the 
Transwells® were removed and cells in the bottom well enumerated. To control for random movement of 
DC through EC over time, DC were also seeded in the upper wells of Transwells® that had no chemokine 
in the lower well. (A) Maximal mDC migration occurred after 4 - 4.5 h through resting EC. (B) Although 
from these data it appears maximal mDC migration occurred as early as 90 minutes, further chemotaxis 
assay experiments revealed 2 h to be the optimal incubation period for mDC migration through activated 
EC. Data are from a single experiment for each time course assay; one well per time point. 
 
As expected from previous reports of their reactivity to the CC chemokines tested (e.g., Chapter 
1), mDC migrated through unmodified Transwell® filter chambers only in response to CCL19 
and CCL21 (Table 8 and Fig 11). We found both mDC subsets retained this ability, even in the 
presence of resting EC (Fig 19). Interestingly, despite the increased incubation period (from 2 h 
to 4 h), both mDC subsets displayed an overall decrease compared to migration through 
unmodified Transwell® filters in the percentage of cells that migrated through the EC barrier into 
the lower chamber (compare Fig 19 A to B and C).  
91 
  
Fig 19. mDC subset migration through resting EC displays a similar pattern to mDC migration 
through unmodified Transwells® filter chambers, but with an overall decrease in the number of 
migrating DC.  
Immunobead-sorted CD8α- and CD8α+ DC were placed in the upper wells of unmodified (A) or resting 
EC-layered (B, C) Transwell® chambers over graded concentrations of CC chemokines. DC migration 
through unmodified Transwells® solely to 10 [nM] chemokine was analyzed in parallel, to ensure that the 
decreased percentage of migrating DC was due to the presence of EC and not to a decreased ability of the 
DC to migrate in general (data not shown). Data are from a single experiment representative of at least 3 
performed; each chemokine dilution was tested in duplicate (312). 
 
mDC migration through activated EC (Fig 20) was greater than that through resting EC (Fig 19B 
and C) and equal or superior to that through unmodified filters (Fig 19A). This was likely due to 
the upregulated expression of intercellular adhesion molecules on the surface of activated EC 
(Fig 17), thus facilitating their migration through interaction with counter-receptors expressed on 
the DC. 
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 Fig 20. mDC subset migration through activated EC mimics mDC migration through unmodified 
Transwells® filter chambers and does not exhibit the decrease in migration seen through resting 
EC.  
Immunobead-sorted CD8α- and CD8α+ DC were placed in the upper wells of activated EC-layered 
Transwell® chambers over graded concentrations of CCL19 (A) or CCL21 (B). DC migration through 
unmodified Transwells® solely to 10 [nM] chemokine was analyzed in parallel, to ensure that the 
decreased percentage of migrating DC was due to the presence of EC and not to decreased ability of the 
DC to migrate in general (data not shown). Data are from a single experiment representative of at least 3 
performed; each chemokine dilution was tested in duplicate. *, P < 0.05, significant difference between 
CD8α- and CD8α+ DC (312). 
 
3.4.3. Murine spleen mDC transendothelial migration in vitro does not require the same 
adhesion molecules as reported for human monocyte-derived and blood DC 
CD31, CD54, and CD62L were all expressed at low levels on resting EC and upregulated upon 
EC activation (Fig 17). Both LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) (on CD8α- DC) 
expressed on human and murine DC are ligands of CD54, whereas CD31, its own homophilic 
ligand, is expressed on some human DC (205, 275). There is evidence that CD11b and CD31 are 
involved in human monocyte-DC/EC binding (CD11b and CD18) and extravasation (CD31) 
(278, 283) to/through EC. CD62L is involved in homophilic binding between EC and activated 
and memory T cells, and may facilitate T cell exit from the blood into lymph (325, 326). 
Therefore we investigated whether blocking interactions between these adhesion molecules and 
their counter-receptors would affect transendothelial migration of murine splenic DC subsets. 
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 Since the influence of blocking specific molecules on EC is dependent on the state of activation 
of the EC barrier (205, 283), we chose to analyze both resting and activated EC conditions in 
these experiments. 
 
3.4.4. Blocking of CD11b expression does not effect transendothelial migration of CD8α- 
mDC 
CD8α+ DC express lower levels of CD11b than do CD8α- DC [Figs 10 and 21 and (46, 47, 52, 
190) (316)]. Thus, another possible explanation for the apparent difference in mDC subset 
migration may be the level of expression of CD11b on CD8α+ DC. We incubated CD8α- mDC 
with anti-CD11b mAbs to determine whether blocking this adhesion molecule would reduce 
CD8α- mDC migration to the level of CD8α+ mDC. Despite reports that blocking CD11b or 
CD18 on human DC impairs their adhesion to/transmigration through EC (205, 283, 327), 
CD8α- DC were not impaired in their migration through resting or activated EC (Fig 22). 
 
Fig 21. Blocking of specific 
adhesion molecules on mDC 
subsets.  
Nycodenz-enriched, 
immunomagnetic bead-
purified, overnight-cultured, 
CD8α- and CD8α+ mDC were 
incubated with appropriate 
(purified or biotinylated) 
blocking or isotype control Ig for 30 min at 4° C. mDC were then washed and split for staining with 
FITC-conjugated mAbs to measure the extent of blocking or used in chemotaxis assays. Events were 
gated for CD11c+CD8α- (top row) or CD11c+CD8α+ (bottom row) cells. Shaded histograms indicate 
detection of protein expression in the presence of isotype control Ig; bold outlined histograms represent 
isotype controls; dotted histograms represent detection of protein expression in the presence of blocking 
mAb. Data are from one experiment representative of at least 3 performed (312). 
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Fig 22. Blocking of CD11b expression does not influence CD8α- DC migration in vitro.  
Nycodenz-enriched, bead-sorted CD8α- mDC were treated with either blocking anti-CD11b or isotype 
control Ig for 30 min at 4° C. Blocking was confirmed by both phenotypic (Fig 21) and functional 
analyses [phagocytosis of apoptotic bodies as described (31); data not shown]. After washing to remove 
excess mAb, DC were placed in the upper well of (A) resting or (B) activated EC-layered Transwells® 
and allowed to migrate for either 4h (resting EC) or 2 h (activated EC). Results are expressed as percent 
of transmigrated cells, mean ± SD of at least two experiments (two replicates per experiment) performed 
(312). 
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 3.4.5. Lack of CD31 expression on murine spleen DC subsets precludes the necessity of 
this adhesion molecule in their transendothelial migration 
CD31 also has been implicated in human DC (205, 283) and monocyte (278) transendothelial 
migration. Despite preliminary data suggesting a moderate level of expression of this adhesion 
molecule on mDC, incubation with blocking mAbs against CD31 did not affect the migration of 
CD8α+ or CD8α- mDC through resting (Fig 23) or activated EC (data not shown), which we 
later determined correlated with the low-to-no CD31 expression on spleen mDC (Fig 21).  
 
Fig 23. Unlike human monocyte-derived and 
blood-isolated DC, CD31 does not facilitate 
murine spleen DC transendothelial 
migration.  
Nycodenz-enriched, bead-purified CD8α+ and 
CD8α- mDC were incubated with purified anti-
CD31 blocking or control isotype mAb for 30 
min at 4° C (Fig 21). DC then were washed, 
resuspended in migration media, and their ability 
to migrate through resting and activated (data 
not shown) EC was analyzed as described. Data 
are from a single experiment representative of at 
least 2 performed; each chemokine dilution was 
tested in duplicate. 
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 3.4.6. Blocking of CD54 expression inhibits transendothelial migration of DC subsets in 
response to CCL19 
Although blocking of CD11b had no apparent effect on the migration of CD8α- mDC through 
resting or activated EC, blocking of CD54 significantly reduced the migration of both mDC 
subsets through resting EC (Fig 24A) and, to a lesser extent, through activated EC (Fig 24B). 
Interestingly, whereas DC migration through either resting of activated EC in response to CCL19 
was impaired after blocking CD54 (Fig 24A), CD54 blocking appeared to affect mDC subset 
migration to CCL21 only through resting EC (Fig 24B). 
Fig 24. Blocking of CD54 expression reduces murine spleen CD8α- and CD8α+ mDC subset 
chemotaxis through resting or activated EC.  
mDC incubated with control isotype Ig or CD54-blocked mDC (Fig 21) were washed, resuspended in 
migration media, and then incubated for 4 h (for resting EC) or 2 h (for activated EC). Both subsets 
exhibited reduced migration through resting (A) and activated EC (B), although the effect was more 
marked through resting EC. Results are expressed as percent of transmigrated cells, mean ± SD of at least 
two experiments (two replicates per experiment) performed. *, p < 0.02, compared with control Ig (312). 
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 3.4.7. Blocking of CD62L expression does not impair transendothelial migration of DC 
subsets 
Although CD62L-blocking studies have been performed primarily on T cells and neutrophils 
(325, 326, 328-330), a recent report showed impaired in vivo migration of human blood CD123+ 
DC after G-CSF-induced downregulation of this selectin (58). We show here for the first time 
that it also is expressed in moderate levels on FL-treated murine spleen DC (Fig 21). Thus we 
investigated the effect of blocking this selectin on DC on their chemotaxis through resting and 
activated EC (Fig 25A and B). Despite blocking of CD62L on both DC subsets with anti-CD62L 
mAb (Fig 21), neither their migration through resting nor activated EC was consistently impaired 
(Fig 25). 
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Fig 25. Blocking CD62L on CD8α- and CD8α+ mDC does not impair their migration through 
resting or activated EC.  
Nycodenz-enriched, bead-sorted CD8α- and CD8α+ mDC were treated with either blocking anti-CD62L 
or isotype control IgG for 30 min at 4° C. Blocking was confirmed by phenotypic analysis (Fig 22). After 
washing to remove excess mAb, DC were placed in the upper well of (A) resting or (B) activated EC-
layered Transwells® and allowed to migrate for either 4 (resting EC) or 2 h (activated EC). Results are 
expressed as percent of transmigrated cells, mean ± SD of at least two experiments (two replicates per 
experiment) performed (312). 
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 3.5. DISCUSSION 
In the course of these studies, we have set up an environment in which to examine the cell 
surface-expressed molecules involved in murine mDC transendothelial migration in vivo, while 
still using a tightly-controlled system in vitro. We first established that mDC indeed were 
capable of extravasation through resting EC in response to CCL19 and CCL21, but that their 
migration to these chemokines is visibly less compared to through unmodified Transwell® filter 
chambers or activated EC, despite a more prolonged (doubled) incubation period (Figs 18 and 
19). Likely due to the upregulation of adhesion molecules on the EC (Fig 17), mDC trafficked 
with little to no impairment through activated EC, and did so within the same time frame as DC 
migrating in the absence of EC (Figs 11C, 19, and 20). Though it seemed initially that the results 
of our adhesion molecule blocking experiments were in direct conflict with reports of human 
DC-EC interaction, in depth review of these reports in comparison to the present findings (as 
discussed below) yielded insightful conclusions. As we have shown for BM-derived and spleen-
isolated iDC responses to chemokines, differences in adhesion molecule requirements may be 
related as much to the state of maturation of the DC as to their tissue of origin/method of 
isolation/propagation. 
 
Ca++ flux experiments with CD8α+ and CD8α- mDC implicated a difference in their extension of 
dendrites (Fig 15), which may provide a partial explanation for the disparity seen in CD8α+ 
mDC migration. However, evidence that blocking of CD11b inhibits human monocyte-derived 
DC adhesion to EC by >60% (283) coupled with the differential expression of the integrin 
CD11b [Fig 10 and (46-48, 52)] by the two subsets suggested an alternative explanation as to 
why the CD8α-expressing subset showed a decreased migratory ability to the CC chemokines 
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 CCL19 and CC21 compared to their CD8α- counterparts (Figs 11C and 19-25). Despite a lower 
expression of the adhesion molecule CD11b by CD8α+ mDC, it does not appear that this integrin 
plays a critical role in regulating murine splenic mDC migration. Thus blocking CD11b on 
CD8α- mDC had no apparent effect on their transendothelial migration through either resting or 
activated EC (Fig 22), similar to human skin explant emigrated-DC, which also express CD11b 
but do not exhibit impaired migration in the presence of anti-CD11b blocking Ab (274). The 
differential pattern of migration seen for CD8α+ and CD8α- mDC indeed may be explicitly 
related to their expression of functional CCR7/prolongation of dendritic extensions. A third 
explanation (not mutually exclusive) may be the high expression of CD205 by CD8α+ DC. 
CD205 (DEC-205) is a comparatively large glycoprotein and might prevent interactions between 
with adhesion molecule on CD8α+ DC and EC. Unfortunately, as we know of no way to induce 
CD205 expression on CD8α- DC (without genetic modification), and coating CD205 on CD8α+ 
DC would merely increase its size, furthering increasing its interference, we were unable to test 
the degree to which this molecule may be involved (or not) in CD8α+ DC migration within the 
scope of these studies. 
 
In contrast to these findings, blocking of a major ligand of CD11b (CD54) considerably reduced 
CD8α- mDC extravasation and even further reduced an already weak migratory response of 
CD8α+ mDC through resting EC. The same effect (though not as marked) was seen with 
activated EC (Fig 23B). While the overall numbers of mDC that migrated through resting EC 
were lower than those that traversed activated EC (one explanation for the less apparent 
reduction), the differences between control IgG-blocked and CD54-blocked DC groups in each 
system was greater in the presence of resting (~20% average inhibition) vs activated EC (~10% 
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 average inhibition) (Fig 23A and B). Thus it is possible that one or more adhesion molecules on 
the activated EC may have compensated for the loss of functional CD54 on the DC (i.e., 
CD102/CD11a interactions were not investigated, as CD102 expression on EC does not change 
after activation, however, it may have facilitated DC migration in the absence of CD54). 
 
While CD11b and CD54 likely are involved almost exclusively in leukocyte rolling and tethering 
to EC (the blocking of which would prevent further attachment to and extravasation through 
EC), CD31 has been reported to be a significant molecule in leukocyte (T cells, neutrophils, 
monocytes, human DC) migration between EC (37, 205, 273, 276, 277). Therefore it seemed 
surprising that it apparently had no involvement in murine spleen DC transendothelial migration. 
However, while a preliminary experiment indicated moderate expression of CD31 on both mDC 
subsets, consequent analyses proved this not to be the case. Indeed CD31 is expressed at very 
low levels on murine spleen mDC (4-5%; Fig 22), which makes it an unlikely candidate for 
involvement in DC/EC interactions after all. This low expression of CD31 on murine spleen DC 
likely is due to tissue rather than species of DC origin, as mouse BMDC express CD31 (~25%; 
Yuk Yuen Lan and An de Creus, unpublished observations). Human skin explant-emigrated DC 
do express CD31, but have no decrease in their migration in the presence of blocking Ab (274), 
while human blood-isolated CD11c+ and CD123+ have reduced migration when CD31 is blocked 
through activated but not resting EC (283). Thus the role of CD31 in DC transendothelial 
migration appears to be tissue specific. 
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 It has been reported (259) that a leukocyte to EC ratio >10:1 can result in the destruction of 
integrity in an EC layer, due to the disproportionately high number of transendothelial migrators. 
Such an effect could eliminate any measurable influence of blocking mAb on DC migration. We 
typically use between 2.5-4 x 105 DC for our chemotaxis experiments to minimize deviations 
between paired wells. In our early blocking experiments, this resulted in a DC to EC ratio close 
to 10:1. These first experiments were with anti-CD11b and anti-CD31 mAb, and we saw no 
impairment of DC migration. The experiments were repeated with 1-2 x 105 DC, and as no 
change in the percent of DC migration through the EC was seen, we utilized this lower ratio in 
subsequent experiments to ensure the DC:EC ratio would not be a factor in other Ab blocking 
experiments. 
 
Between 50% (58) and 90% (205) of human blood-isolated DC express CD62L, but there is little 
information on expression of CD62L by murine DC. It recently has been shown that 
administration of G-CSF induces upregulation CCR7 on human blood pDC, with a concomitant 
downregulation of CD62L, effectively preventing the exodus of the pDC from the blood into 
lymphatic vessels (58). Prior to this latter study, it was believed that G-CSF selectively enhances 
the generation of the CD11c-CD123+ pDC over the “classic myeloid” CD11c+CD123- DC (57). 
In fact, it selectively impairs their emigration, resulting in an accrual of pDC in the blood, while 
CD11c+ DC continue their normal trafficking patterns (not affecting their numbers in blood). 
Thus we felt it appropriate to investigate the expression of this molecule on murine spleen DC. 
In fact, approximately 50% of both CD8α+ and CD8α- mouse spleen DC subsets express 
CD62L, and its expression is not subset specific, as in humans (although the expression of 
CD62L murine pDC has not yet been investigated). Similar to CD11b and CD31, shown to be 
103 
 important in human (205, 283) but not murine (Figs 22 and 23) DC transendothelial migration, 
blocking of CD62L on either mDC subset did not impair their migration through resting or 
activated EC. 
 
Upon first assessment, the results from our blocking Ab experiments appear to be in conflict with 
those reported for human DC. However, as for freshly-isolated spleen and immature BM-derived 
(murine) DC, it appears the factors that regulate DC migration may be specific to the 
source/subset/state of activation of DC and the activation status of the EC being analyzed. 
Blocking of CD31 on resting EC before their interaction with human monocyte-derived DC 
(mature DC; as indicated by their strong induction of naïve T cell proliferation in MLR) has been 
reported to reduce transmigration by 40% (283). However, incubation of CD31-blocked human 
blood-isolated immature DC subsets (CD11c+ and CD123+) with EC showed significant 
reduction only in transendothelial migration through activated EC,- their migration through 
resting EC was unaffected after blocking of CD31 on their cell surface (205). Moreover, whereas 
human CD11c+ iDC transmigrate normally through resting and activated EC after CD54 is 
blocked on their cell surfaces, CD123+ iDC show impaired migration through activated but not 
resting EC (205). Blood-isolated human CD11c+ and CD123+ (i)DC also apparently need a 
chemotactic agent to elicit significant migration through EC (205), while monocyte-derived DC 
migration through EC was detected even in the absence of exogenous chemoattractants (283). 
Thus while some of our data may not match exactly those reported for human DC from different 
tissue compartments, it appears likely that as more DC/EC interactions in each species are 
examined, patterns will emerge regarding DC tissue source, subset, and state of maturation, as 
well as EC state of activation. Further understanding of the influence of these variables will 
prove invaluable in optimizing appropriate means by which to administer target DC 
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 therapeutically. In summary, herein we demonstrate for the first time adhesion molecules that 
appear to be important in regulating murine spleen DC transendothelial migration. 
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 4. CHAPTER THREE6 
 
FACTORS INVOLVED IN REGULATION OF SPLENIC DC MIGRATION IN VIVO 
 
In this chapter, we evaluate how the stage of maturation and route of administration of splenic 
DC affects their ability to traffic from the site of injection to secondary lymphoid tissues. 
Concomitantly, we examine the dependence of DC subsets on CCL19 and CCL21 for their 
directed migration in vivo. These findings offer insight into optimizing the delivery of DC for 
therapeutic applications, through manipulation of their state of maturation and route of 
administration, and possible exploitation of their chemotactic signals in vivo, as detailed in the 
Discussion and Chapter 4. 
 
 
                                                 
6 Data from this chapter are excerpted from (48) where indicated. 
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 4.1. ABSTRACT 
Several groups have reported disparate findings regarding the ability of murine CD8α+ DC to 
migrate in vivo. As these groups have employed diverse methods for monitoring CD8α+ DC 
trafficking, and since our goal is to exploit their purported tolerogenic properties therapeutically, 
we evaluated the two most common routes of DC administration in an attempt to optimize 
delivery of these DC to T cell areas. To examine the in vivo significance of CCL19 and CCL21 
in eliciting mDC migration, we utilized paucity of lymph node T cells (BALB/c plt/plt; H2d) 
mice, which lack expression of CCL21-serine (ser) and have severely impaired expression of 
CCL19. Metrizamide-enriched, iDC and mDC subsets isolated from spleens of FL-treated B10 
(H2b) mice were separated by magnetic bead-sorting into CD8α+ and CD8α- populations and 
labeled with chloromethylfluorescein diacetate (CMFDA). In vivo trafficking of the 
fluorochrome-labeled DC was assessed by immunohistochemistry (for in situ localization) and 
by rare event, flow cytometric analysis (for quantitation) of allogeneic recipient [control wt 
BALB/c ByJ (H2d) and plt] draining lymph node (DLN) and spleen cells. As observed in our in 
vitro trafficking studies, labeled mDC were detected in draining secondary lymphoid tissues in 
greater numbers than iDC. Both mDC subsets were detected in greatest numbers in normal mice 
after iv injection, and considerably fewer CD8α+ mDC were detected in DLN than CD8α- DC. 
Conversely, in the plt mouse, sc injection proved to be the more efficient route of administration, 
with CD8α- DC still trafficking the most competently. These data correlate well with the in vitro 
migration data presented in Chapter One. They also confirm the importance of CCL19 and 
CCL21 in regulating mDC trafficking to T cell areas of secondary lymphoid tissues and further 
suggest that CD8α+ mDC may indeed respond to higher concentrations of chemotactic ligands 
than do CD8α- mDC. 
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 4.2. INTRODUCTION 
 
Four groups (52, 71, 86, 304) directly or indirectly have studied CD8α+ DC migration in vivo. 
Each has reported disparate results regarding the ability of this DC subset to traffic to secondary 
lymphoid tissues. With careful consideration of the methods employed in each investigation 
(Table 7), it becomes clear that differences in experimental protocol for migration analysis in 
vivo are responsible for the disparate findings. Two groups have reported that spleen-derived, sc-
injected CD8α+ iDC fail to migrate to DLN (86, 304), whereas another has observed reduced 
(compared to CD8α- DC) CD8α+ iDC migration to the spleen after their iv injection (304). 
O’Connell et al (52) found that in vivo-mobilized, liver-derived CD8α+ mDC trafficked to DLN 
and spleen after sc injection, while Drake et al (71) detected in vivo-mobilized spleen-derived 
CD8α+ mDC in DLN after their sc administration in a mixed population together with CD8α- 
mDC. Two of these studies (52, 71) used FL-expanded mDC (both groups reported migration to 
the DLN); two (86, 304) used non-FL-mobilized iDC (both reported no detection of iDC in 
DLN). The two groups (52, 304) that investigated DC migration to the spleen after injection both 
detected DC, although Ruedl and Bachman (304) used non-FL-treated spleen iDC and iv 
injection, and O’Connell et al (52) used FL-treated liver mDC and sc injection. Further, the 
groups differed in their methods to sort (or not) the subsets, in their technique for detection of the 
injected DC in secondary lymphoid tissues, and in the time points at which they excised the 
spleen or DLN. These inconsistencies in experimental protocol have not been previously 
compared directly, nor has the route or number of cells for delivery of DC subsets been 
evaluated and optimized, despite frequent discussion about their potential therapeutic use [e.g., 
(29, 253, 331)].  
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 The plt/plt mouse lacks CCL21-ser (the lymphoid tissue-expressed gene of CCL21; the non-
lymphoid tissue-expressed form [CCL21-leucine (leu)] is not impaired) and exhibit a severe 
reduction in CCL19 expression compared to wild-type mice (200, 256, 332, 333). Early reports 
of these mice showed that there was a drastic reduction in the number of DC and T cells in LN 
(200, 332). In the spleen, however, normal numbers of DC and T cells are found, but with poorly 
formed or virtually absent T cell area structures. The plt mouse can mount a delayed but 
enhanced response to contact sensitization and sc immunization to OVA (334) and can clear 
some viral infections (eg, Vesicular stomatitis-Indiana virus) (334, 335) but is highly susceptible 
to other viral infections [eg, mouse hepatitis virus (MHV)] (200). Its counterpart, the CCR7 KO 
mouse, is similarly deficient in T cell and DC numbers/T cell structure in secondary lymphoid 
tissues (257). These mice fail to mount primary T cell responses in contact sensitivity or DTH 
reactions, and their humoral responses are delayed but eventually as vigorous as wt (257). Thus, 
the natural mutation in chromosome 4 in plt mice that appears to be responsible for the absence 
of CCL19 and CCL21 (63) makes them ideal candidates for evaluating the importance of these 
two chemokines for regulating mDC trafficking in vivo. 
 
Although all in vitro studies with mDC, regardless of species, subset, or tissue of 
origin/derivation have reported positive migration to CCL19 and/or CCL21, no studies previous 
to these have tested the importance of these chemokines for DC subsets in vivo. The natural 
mutation in chromosome 4 in plt mice that appears to be responsible for the absence of CCL19 
and CCL21 (63) makes these mice ideal candidates for examining the importance of the two 
chemokines in DC subset in vivo trafficking (the CCR7 KO mouse would be an equally 
interesting model to investigate these issues, especially in parallel with the plt mouse, but our 
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 efforts to obtain these mice from Germany for our studies was not successful). Both Gunn et al 
(200) and Förster et al (257) examined activated DC migration to T cell areas after skin contact 
sensitivity reactions (to FITC-painting) and found that a reduced number of DC trafficked to 
DLN of plt compared to wt mice. However, neither group injected normal DC into their mutant 
mice (or their mutant DC into normal mice) to confirm that the impaired migration was indeed 
due to lack of CCL19/CCL21 or CCR7 and not due to an inherent lack of ability of the DC in 
each model to migrate to secondary lymphoid tissues. Nor did they phenotype the DC that 
migrated to the DLN post FITC-painting to ascertain whether the DC subsets were differentially 
affected by the deficiency in chemotactic signaling.  
 
In this chapter, we build on the studies of Chapters One and Two, investigating whether the 
failed migration of spleen iDC subsets in vitro is seen also in vivo [one possible explanation for 
some of the disparate findings between groups for CD8α+ DC migration (86, 304)]. We also 
examined to what degree DC migration is affected by route of administration (Table 7), and 
whether the differences in mDC subset migration in vitro carries over into in vivo trafficking. We 
further investigated how the drastic reduction in CCL19/CCL21 concentrations would affect 
CD8α+ mDC in vivo migration, given the poor in vitro chemotaxis responses and decreased 
dendritic extension exhibited by these DC in high concentrations of chemokine. 
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 4.3. MATERIALS AND METHODS 
 
4.3.1. Mice 
Male B10 (H2b) and BALB/c ByJ (H2d) mice, 8-12 wk of age, were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Breeding pairs of BALB/c plt/plt (H2d) mice were obtained from 
Dr. Hideki Nakano at Duke University Medical Center, NC. They were maintained in the 
specific pathogen-free facility of the University of Pittsburgh Medical Center and fed Purina 
rodent chow (Ralston Purina, St. Louis, MO) and tap water ad libitum. Experiments were 
conducted in accordance with the National Institutes of Health guide for care and use of 
laboratory animals and under an Institutional Animal Care and Use Committee protocol. 
 
4.3.2. DC isolation 
Pooled spleens from 3-4 plt or normal BALB/c mice were digested with 100 U/ml collagenase, 
teased apart, and then further digested in 400 U/ml collagenase for two 30 min incubation 
periods in order to maximize DC recovery. Bulk spleen cell cultures were then enriched for mDC 
with 14.5% (w/v) nycodenz (Sigma) as with metrizamide as reported for cells from FL-treated 
mice (Chapter One; Materials and Methods). As 16% (w/v) nycodenz (as used with metrizamide) 
resulted in a substantial loss of recovery of DC, iDC were enriched over a 0.3055 g/ml (stock 
solution) nycodenz gradient (resulting in cell recovery similar to the enrichment experienced 
with 16% metrizamide). Too few cells were recovered to sort the subsets by FACS or 
immunomagnetic beads, so bulk populations were used in experiments with these cells. Pooled 
popliteal and inguinal LN from plt and BALB/c mice were gently mascerated over a nylon filter, 
and due to the extremely low number of cells in plt LN, no further enrichment was performed. 
4.3.3. Flow cytometric analyses 
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 For subset ratio determination of plt spleen and LN DC, cell surface phenotypic analysis was 
performed by flow cytometry, using an EPICS Elite ESP analyzer (Beckman Coulter). All flow 
cytometric assays were done at 4°C. Leukocytes were first blocked with 10% v/v normal goat 
serum for 10 min, then stained with mAb for 30 min. Cells stained with the appropriate isotype-
matched Ig (BD PharMingen) were used as negative controls. Phenotypic analysis of cell surface 
markers was performed with the following Abs: FITC-CD11b, -CD31, -CD40, -CD54, -CD62L, 
-CD80, -CD86, and -IAb, -H2k; PE-CD11c; and Cy-Chrome-CD8α (mAbs, BD PharMingen). 
After staining, the cells were fixed with 4% v/v paraformaldehyde (PFA).  
 
4.3.4. Labeling of DC for ex vivo detection 
CD8α+ and CD8α- (B10, H2b) DC were cytoplasmically labeled with the green fluorescent dye 
chloromethylfluorescein diacetate (CMFDA; Molecular Probes, Leiden, The Netherlands) (15 
µM; 45 min at 37° C) according to the manufacturer’s instructions. After two washes, 2-4x106 
CD8α+ or CD8α- DC were injected either iv into the lateral tail vein or sc into one hind footpad 
of allogeneic recipients (BALB/c ByJ or BALB/c plt/plt; H2d). Spleens or popliteal DLN were 
removed 24, 48, or 72 h after iv or sc injection.  
 
4.3.5. Rare event, flow cytometric analysis 
Quantification of in vivo DC migration was performed by enumerating the percentage of green 
fluorescent cells in 105 whole spleen/DLN cells as compared to control spleens/DLN from age-
matched mice that had not been injected with DC. 
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 4.3.6. Immunostaining of tissue sections 
In situ localization of injected DC was ascertained by immunohistochemistry. Tissue samples 
were embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, IN), snap-frozen in isopentane 
(pre-chilled in liquid N2), and stored at -80°C until use. Ten µm cryostat sections were mounted 
on slides pretreated with Vectabond (Vector Laboratories Inc, Burlingame, CA), air-dried, and 
fixed in cold 4% v/v PFA for 10 min. Sections were blocked with 5% v/v normal goat serum, 
followed by avidin blocking solution (Vector Laboratories Inc). Biotinylated anti-CD3ε (T cells), 
-CD11c (DC), and -CD19 (B cells) mAbs (BD PharMingen) and biotinylated F4/80 (red pulp 
macrophages), and MOMA-1 (marginal zone metallophillic macrophages) mAbs (Bachem 
Bioscience Inc, King of Prussia, PA) followed by Cy3-streptavidin (Jackson Laboratories) were 
used to localize, T cell, DC, B cell, red pulp, and marginal zone areas, respectively.  
 
4.3.7. 2-photon confocal microscopic analysis 
FACS-sorted, CMFDA-labeled CD8α+ and CD8α- splenic mDC were injected either iv or sc into 
BALB/c recipients. 48 h later, the spleens and LN were removed and imaged using a multi-
photon laser scanning confocal microscope system comprising a titanium-sapphire ultrafast 
tunable laser system (Coherent Mira model 900-f), Olympus Fluoview confocal scanning 
electronics, an Olympus IX70 inverted system microscope, custom-built input power attenuation, 
and external photomultiplier tube detection systems (Olympus, Melville, NY). Dual photon 
excitation was at 870 nm, with fluorescence emission detected using a HG510/50 steep passband 
emission filter (Chroma, Brattleboro, VT). 
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 4.4. RESULTS 
 
4.4.1. CD8α+ and CD8α- iDC do not localize to the spleen after iv injection 
Iv injection is not the most direct measurement of chemokine-elicited trafficking of leukocytes to 
secondary lymphoid tissues as it deposits cells directly into the bloodstream, thus eventually 
conveying the injected leukocytes through the spleen. However, this route of injection is 
appropriate for the study of the ability of leukocytes to extravasate through EC walled blood 
vessels into peripheral tissues. It also is a valuable method for determining the localization of 
leukocytes in lymphoid tissues, an activity that is regulated/organized (at least partly) by 
chemokines. It is also a common route for therapeutic delivery of DC [i.e., infectious disease 
(336), transplantation (47, 130, 131), autoimmunity (337, 338), and cancer (339, 340) studies]. 
 
We have reported previously that allogeneic liver-derived CD8α+ mDC migrate to the DLN of 
recipients within 24 h of sc injection (52). However, two other groups have been unable to detect 
fluorochrome-labeled spleen CD8α+ iDC administered subcutaneously to syngeneic recipients in 
DLN (86, 304). Differences in protocols between studies, coupled with the present findings that 
at least both subsets of mDC apparently express the cellular machinery necessary for in vitro 
migration, led us to investigate further the disparity in the reports regarding the ability of CD8α+ 
DC to traffic in vivo. Since the two groups that reported CD8α+ DC are incapable of migration 
used freshly-isolated DC, we first examined the migration of iDC to the spleen after iv injection. 
However, surprisingly [although perhaps in correlation of our in vitro data (Fig 11A)], neither 
CD8α+ nor CD8α- splenic iDC could be detected in the T cell areas of spleens of normal 
recipients, 24 or 48 h after iv injection (Fig 26), despite the reported ability of these DC to prime 
114 
 naïve T cell responses via this route of administration (71, 75, 86, 304, 307). These results were 
confirmed by rare-event, flow cytometric analysis (Fig 29). To determine whether the pattern of 
splenic iDC traffic was related to their origin [as in in vitro chemotaxis assays (Fig 11A)], 
iBMDC were injected iv as controls. We were unable to detect iBMDC in the spleen after 24 h, 
but these cells could be detected in the liver and lung 24, 48, and 72 h their after injection 
(Morelli, AE, personal communication).  
 
Fig 26. iDC are not detected in T cell areas of the spleen 24 or 48 h after iv injection. 
Immunomagnetic bead-sorted, CMFDA-labeled (green) CD8α- (upper panels) or CD8α+ (lower panels) 
B10 iDC (3-5 x 106) were injected iv into BALB/c mice. Twenty-four or 48 h later, spleen sections were 
stained with biotinylated mAb anti-CD3 (T cell), -CD19 (B cell), -F4/80 (red pulp Mφ), -MOMA-1 
(marginal zone Mφ), -CD11c (DC), followed by Cy3-streptavidin (red). Neither subset appeared to 
migrate in significantly greater numbers. The near total absence of iDC at 24 and 48 h precluded further 
investigations at later time points (i.e., 72 h). DAPI (blue) indicates nuclear staining. x 200. [modified: 
(48)] 
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 4.4.2. CD8α+ and CD8α- iDC do not localize in DLN after sc injection 
As some of the studies of CD8α+ DC trafficking in vivo injected DC into the footpad (52, 71, 
86), we also examined the ability of CD8α+ and CD8α- mDC to reverse transmigrate out of 
peripheral tissues into lymph vessels in order to reach DLN. Despite data obtained in the rhesus 
macaque with blood iDC that suggest otherwise (43), iDC injected sc into the hind footpad of 
allogeneic recipient mice also did not localize to the DLN, 24 h or 48 after injection (Fig 27). 
Nor were the iDC detected after rare-event flow cytometric analysis (Fig 30) or in the footpad, as 
assessed by two-photon confocal microscopy (data not shown). 
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Fig 27. iDC do not colocalize with recipient DC and T cells after sc injection.  
Immunomagnetic bead-sorted, CMFDA-labeled (green) CD8α+ or CD8α- B10 iDC (3-5 x 106) were 
injected sc into one hind footpad of BALB/c mice. Twenty-four and 48 h later, DLN sections were 
stained with biotinylated mAb anti-CD3 (T cell), -CD19 (B cell), -F4/80 (red pulp Mφ), -CD11c (DC) 
followed by Cy3-streptavidin (red). Few CD8α- iDC localized to T cell areas after sc injection; no CD8α+ 
iDC were visualized. Blue: DAPI indicates nuclear staining. x 200. [modified: (48)] 
 
117 
 4.4.3. CD8α+ and CD8α- mDC colocalize with splenic T cells after iv injection  
Unlike iDC, both mDC subsets migrated to T cell areas (CD3+) and colocalized with (recipient) 
DC (CD11c+) at 24, 48, and 72 h after iv injection (Fig 28). Administered mDC were not found 
in B cell follicles (CD19+), red pulp (F4/80+), or marginal zone (MOMA-1+). In keeping with the 
quantitative rare-event data (data not shown), fewer DC were visualized over time. The 
comparatively inferior CD8α+ to CD8α- DC migration seen in the in vitro chemotaxis studies, 
however, was not borne out in the in vivo experiments, as both DC subsets were detected in 
similar numbers in the spleen at 24, 48, and 72 h after injection (Fig 30 and data not shown).  
 
4.4.4. CD8α+ and CD8α- mDC localize with DLN DC and T cells after sc injection 
Unlike previous reports (86, 304), we detected both CMFDA-labeled CD8α+ and CD8α- mDC in 
the popliteal DLN [no DC were detected in inguinal LN at any time point tested (data not 
shown)] 24 h after sc footpad injection (Fig 29). Immunohistochemical analysis of the DLN 
revealed DC localized in recipient DC T cell areas, as seen in the spleen, and again the DC did 
not colocalize with B cells (CD19+) or macrophages (F4/80+) [MOMA-1+ cells were not found in 
the LN (data not shown)]. CD8α+ DC were furthered identified at 24 h by their faint co-staining 
for PE, – residual from flow sorting on CD8α expression immediately before injection (Fig 30). 
Only CD8α- DC were detected in DLN at 48 h, and neither subset was detected 72 h after sc 
injection. Unlike rhesus macaque blood-derived mDC (43), neither murine mDC subset was 
detected in the injected footpad mice as assessed by 2-photon confocal microscopy (data not 
shown).  
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Fig 28. mDC of both subsets are found in T and DC areas of the spleen after their iv injection and 
at all time points investigated.  
Immunomagnetic bead-sorted, CMFDA-labeled (green) CD8α+ or CD8α- B10 mDC (3-5 x 106) were 
injected iv into BALB/c mice. Twenty-four, 48, or 72 h later, spleen sections were stained with 
biotinylated mAb anti-CD3 (T cell), -CD19 (B cell), -F4/80 (red pulp), -MOMA-1 (marginal zone), or -
CD11c (DC) followed by Cy3-streptavidin (red). Unlike in vitro experiments, CD8α- mDC (upper panels) 
did not appear to migrate with more efficiency than CD8α+ mDC (lower panels). DAPI (blue) indicates 
nuclear staining. x 200. [modified: (48)] 
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Fig 29. mDC colocalize with recipient DC and T cells 24 h after sc injection. 
Immunomagnetic bead-sorted, CMFDA-labeled (green) CD8α+ or CD8α- B10 mDC (3-5 x 106) were 
injected sc into one hind footpad of BALB/c mice. Twenty-four, 48, or 72 h later, DLN sections were 
stained with biotinylated mAb anti-CD3 (T cell), -CD19 (B cell), -F4/80 (red pulp), or -CD11c (DC) 
followed by Cy3-streptavidin (red). While both subsets of mDC were detected in T cell and DC areas 24 
h after sc injection, CD8α+ mDC (lower panels) were found in fewer numbers than their CD8α- 
counterparts (upper panels) at 48 h. Blue: DAPI indicates nuclear staining. x200. [modified: (48)] 
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 Fig 30. Efficient DC delivery is dependent 
both on the route of administration as 
well as the state of maturation of the DC.  
Flow-sorted, CMFDA-labeled DC (3-5 x 
106) were injected iv or sc and spleens or 
DLN excised 24, 48, or 72 h later. Spleen 
DC-enriched suspensions (iv) and LN cell 
suspensions (sc) were analyzed by flow 
cytometry for CMFDA-positive cells. Only 
CD8α+ and CD8α- mDC were detected in 
spleens after iv injection, with the greatest 
number of DC at 24 h of the 72 h (data not 
shown) follow-up period. Though fewer 
CD8α+ mDC were visualized by 
immunohistochemistry at 24 h, these DC 
were apparent by flow cytometric analysis, 
and in similar numbers to those for CD8α- 
mDC. Non-injected spleens or lateral LN 
were used as controls. The data are from a 
single experiment representative of at least 3 
performed. Numbers indicate the percentage 
of CMFDA positive cells. (48) 
 
4.4.5. 2-photon confocal microscopic analysis of mDC in vivo trafficking to secondary 
lymphoid tissues  
Originally, we planned to quantify each individual migrated DC in the spleen and non-migrating 
DC retained in the footpad using 2-photon confocal microscopy. Unfortunately, due to technical 
difficulties this method did not prove as useful as we had hoped. The thickness of the tissue 
prevented full penetration by the laser, and there appeared to be hair on the footpad, which also 
prevented penetration. These few studies did provide, however, further morphological evidence 
that the labeled cells detected by immunohistochemistry and rare-event analysis were in fact DC 
(Fig 31). 
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Fig 31. CMFDA-labeled cells detected 
in spleens after iv or sc transfer are 
morphologically DC.  
Nycodenz-enriched, magnetic bead-
sorted CD8α- (A and B) and CD8α+ (C 
and D) spleen mDC from B10 mice were 
injected iv or sc (data not shown) into the 
lateral tail vein or footpad of normal 
BALB/c recipients. 48 h later, the 
secondary lymphoid tissues were excised, 
fixed, and CMFDA-labeled (green) cells 
were detected via 2-photon confocal 
microscopy. CMFDA-labeled cells with 
distinct mDC morphology were identified 
in both the spleen (A-D) and DLN (data 
not shown). x100. 
 
4.4.6. Dependence on CCL19 and CCL21 for mDC trafficking in vivo is affected by both 
subset and route of delivery  
Though in some sections, fewer CD8α+ than CD8α- DC were detected by fluorescence 
microscopy [Figs 28 (48 h) and 29], quantitative rare-event flow cytometric analyses revealed 
both subsets of mDC migrated in similar numbers to the appropriate secondary lymphoid tissue. 
Their overall proficiency was dependent on the route of administration (Fig 30). This finding is 
somewhat unexpected considering the consistent pattern of lower CD8α+ mDC migration to 
CCL19 and CCL21 in vitro. Therefore we utilized the plt mouse to determine whether these CC 
chemokines were key factors in directing CD8α+ and CD8α- mDC migration in vivo (as iDC did 
not migrate efficiently in vitro or in vivo, we did not pursue further migration studies with DC at 
this stage of differentiation). 
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 4.4.7. CD8α- mDC are detected in greater numbers in DLN than CD8α+ mDC after sc 
injection in plt recipients 
Gunn et al (200) painted the skin of plt mice in order to determine whether there was normal DC  
(LC) trafficking to DLN during inflammation, as in the steady state, plt mice are severely 
deficient in LNDC. The experiment did not verify, however, whether the lack (vs wt mice) of 
FITC+ DC in the DLN in plt mice was due to an inherent inability of plt DC to migrate, or 
whether the poor migration was due directly to the lack of CCL19 and CCL21. Nor did they 
determine whether DC subset migration to the DLN was differentially affected. Though plt mice 
lack CCL19 and CCL21-ser in DLN, there is normal expression of CCL21-leu in lymphatic 
vessels. This suggests that mDC should be able at least to enter the lymph from peripheral 
tissues, such as the skin. This, in turn, should result in accumulation of normal numbers of DC in 
DLN during inflammation (although likely within poorly-formed T cell areas as seen in the 
spleen). As this was not the case in the FITC-painting experiments (200, 257), it may be that the 
lack of CCL19 and CCL21 in secondary lymphoid tissues may not be the only factor influencing 
the decreased number of leukocytes in these tissues. Thus, we injected sc CMFDA-labeled, 
normal B10 DC [which we have shown migrate normally to T cell areas of secondary lymphoid 
tissues (Figs 28-30)] into BALB/c plt/plt footpads and examined their migration to DLN (Fig 
32). 
 
As predicted, mDC were able to reach the DLN after sc injection, but did not localize exclusively 
with T cells. Interestingly, while both subsets migrated with equal efficiency to DLN after sc 
injection into the footpads of normal BALB/c, CD8α+ mDC were detected in much fewer 
numbers compared to CD8α- mDC in plt mice (Fig 32), somewhat similar to CD8α+ mDC in 
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 vitro migration. Nor did DC of either subset localize exclusively with recipient DC and T cells, 
but were found dispersed throughout the tissue. 
Fig 32. CD8α- mDC are less impaired in their ability to reach the DLN 24 h after sc injection.  
Immunomagnetic bead-sorted, CMFDA-labeled (green) CD8α+ or CD8α- B10 mDC (3-5 x 106) were 
injected sc into one hind footpad of BALB/c plt/plt mice. Twenty-four or 48 h later, DLN sections were 
stained with biotinylated mAb anti-CD3 (T cell), -CD19 (B cell), -F4/80 (red pulp), or -CD11c (DC) 
followed by Cy3-streptavidin (red). While both mDC subsets were found in T cell areas of normal 
BALB/c mice 24 h after injection, only CD8α- mDC (upper panels; lower panels: CD8α+ mDC) were 
detected in DLN. As expected, the mDC were found in DC and T cell areas, but were also found 
dispersed throughout B cell (CD19+) and red pulp (F4/80+) areas. x 200. 
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 4.4.8. Few mDC of either subset remain in/localize with T cells in spleens of plt mice 
after iv administration 
As CD8α+ mDC migrated to the T cell areas of the spleen with equal, even superior, efficiency 
as CD8α- mDC in normal mice (Figs 28 and 30), we wanted to ascertain whether the reduced 
CD8α+ mDC migration after sc injection in plt mice would be reproduced after iv injection. 
Therefore, we injected CD8α+ or CD8α- mDC into the lateral tail vein of plt mice to compare the 
ability of the subsets to enter the spleen and colocalize with host DC or T cells in the absence of 
CCL19 and CCL21. 
 
Unlike in normal BALB/c mice, iv injection was a less efficient route of injection than sc 
injection. mDC frequently were found near blood vessels (Fig 33, arrowheads), but they were 
neither localized with DC nor with T cells [as seen in wt mice (Fig 27)] nor dispersed throughout 
the tissue [as seen in the DLN after sc injection of plt mice (Fig 32)]. Nor did there appear to be a 
differential ability in mDC migration, as neither subset was detected in substantial numbers (< 1 
DC/tissue section, on average). 
 
As few iv-injected DC were detected in the spleen of plt recipients, and as only CD8α- DC were 
detected in DLN after sc injection, we considered whether endogenous CD8α- and CD8α+ DC 
subsets were present in a normal ratio in plt secondary lymphoid tissues. Despite their near 
absence in LN and their poor distribution in spleens, there were no significant phenotypic 
differences in DC isolated from LN or spleens of plt and wt mice (data not shown). DC 
expressed comparable levels of CD11b, CD31, CD40, CD54, CD62L, CD80, CD86, MHC I, and 
MHC II. Nor was there a drastic difference in the ratio of CD8α- to CD8α+ DC (an average of 
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 1:1, accounting for inter-experimental variance) in the spleen (too few DC were isolated from the 
LN to determine their expression of CD8α). 
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 Fig 33. CD8α- and CD8α+ CMFDA-labeled mDC are difficult to detect in spleens of plt mice after iv 
injection.  
Immunomagnetic bead-sorted, CMFDA-labeled (green) CD8α+ or CD8α- B10 mDC (3-5 x 106) were 
injected iv into the lateral tail vein of BALB/c plt/plt mice. Twenty-four, 48, or 72 h later, DLN sections 
were stained with biotinylated mAb anti-CD3 (T cell), -CD19 (B cell), -F4/80 (red pulp), MOMA-1 
(marginal zone), or -CD11c (DC) followed by Cy3-streptavidin (red). While both mDC subsets were 
found in T cell areas of normal BALB/c mice at all time points 24 h after injection, almost no CD8α- 
(upper panels) or CD8α+ (lower panels) mDC were detected at any time point, and they did not 
specifically co-localize with either DC or T cells. Arrowheads indicate blood vessels near injected DC. x 
200. 
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 4.5. DISCUSSION 
 
The lack of in vitro migration of freshly-isolated splenic iDC to CCL19 and CCL21 and their 
low expression of CCR7 mRNA are consistent with what has been reported for in vitro-
generated (cultured) iDC. This unresponsiveness to constitutive lymphoid CC chemokines is 
further supported by the lack of retention of iDC by the spleen after iv injection, presumably 
because of the inability of these DC to respond to CCR7 ligands. The lack of functional CCR7 
on the cell surface of DC before injection, then, appears to preclude directed migration to 
secondary lymphoid tissue, which may also explain the absence of iDC in DLN 24 h after sc 
injection.  Interestingly, rhesus macaque blood iDC do not express CCR7, but after their id 
injection, they apparently upregulate the molecule as they can be detected in the DLN with a 
concurrent upregulation of expression of surface CD83 and CD86 (341). Thus a possible 
explanation for the failure of murine iDC to do the same is that id injection may induce a greater 
degree of inflammation than sc injection, resulting in a level of rhesus iDC activation sufficient 
for their subsequent activation and emigration from the tissue that does not occur after sc 
injection in mouse recipients. After iv injection, i(BM)DC become dispersed throughout the lung 
and liver (Morelli, AE, personal communication). It is not clear whether these circulating iDC 
are capable of entering secondary lymphoid tissues after their activation by foreign 
Ag/inflammatory signals, or if they are fated to recirculate until they die. Splenic mDC, on the 
other hand, exhibit the migratory patterns of other mDC reported thus far. In the present study, 
upregulation of CCR7 mRNA expression in mDC correlated with the ability to respond to 
CCL19 and CCL21 in vitro. This responsiveness was further borne out by not only the retention 
of mDC in the spleen (up to 72 h after injection; Fig 28) but by their mobilization to T cell areas. 
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 Comparatively fewer mDC reached the T cell areas of DLN after sc infusion and their 
persistence appeared more transient, with only CD8α- DC evident up to 48 h.  
 
In the mature state, CD8α+ DC and to a greater extent CD8α- DC, responded to CCL19 and 
CCL21 in vitro. This disparity seen with in vitro migration studies did not correlate with the 
level of in vivo traffic to the spleen and apparently is not necessarily an index of a cell’s ability to 
mobilize to secondary lymphoid tissue. In vivo migration requires interaction with adhesion 
molecules and extravasation through lymphatic or blood vessel endothelia, and may be affected 
by other as yet unknown in vivo factors. Comparison of the two DC subsets clearly underlines 
the superior ability of CD8α- mDC to traffic in vivo, as strikingly fewer CD8α+ than CD8α- 
mDC were apparent in the DLN of plt recipients at all time points tested. In Chapter One, we 
attempted to investigate whether the inferior ability of CD8α+ mDC to migrate in vitro and in 
vivo compared to CD8α- mDC correlated with surface expression/function of CCR7 (Figs 12, 13, 
and 15). Conceivably, lower expression/function of CCR7 would impair the ability of CD8α+ 
mDC to migrate from peripheral to secondary lymphoid tissues. As blocking of CD11b on 
CD8α- mDC did not reduce their migration to the level of CD8α+ mDC (Fig 22), it is unlikely 
the low expression of this molecule on CD8α+ mDC detrimentally affects their migration. Nor 
does it appear that any of the other adhesion molecules evaluated plays a role in their differential 
migration, as both blocking CD54 inhibited mDC subset migration to the same degree (Fig 24). 
Thus, chemokine-induced dendrite prolongation data (Fig 15) coupled with the in vivo migration 
data in plt mice (Fig 32) implicate a requirement for both high expression of CCR7 ligand(s) as 
well as another as yet unknown endogenous factor (apparently absent in our in vitro systems) for 
elicitation of efficient traffic by CD8α+ mDC. 
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 In normal BALB/c recipients, both mDC subsets exhibited equal ability to migrate to secondary 
lymphoid tissues, although their overall efficiency was dependent on their route of 
administration (Figs 28-30). While few mDC were detected in the DLN after sc injection (Figs 
28 and 30), a comparatively large number of mDC were identified in the spleen after iv injection 
(Figs 29 and 30). Both CD8α+ and CD8α- mDC also clustered almost exclusively with host DC 
or T cells (Figs 28 and 29), with only a few CD8α+ mDC dispersed in areas other than T cell 
after sc injection (Fig 29 and data not shown). On the contrary, after iv injection into plt 
recipients, few, if any, mDC were found in spleen tissue sections, and consistent with the lack of 
normal T cell areas in plt mice (200), the DC did not appear to be localized specifically with any 
particular cell type. Interesting, what few DC were found were located frequently close to blood 
vessels, suggesting recent immigration. However, unlike in normal CCL19/CCL21-expressing 
recipients, there were no chemotactic “roadmaps” to direct the mDC to their “proper” areas of 
residency. As iv-administered mDC are carried to the spleen shortly after injection [at least as 
early as 6 h after injection (31)], and as we have established that mDC from normal B10 mice are 
capable of extravasation from the bloodstream into the spleen, it seems likely that mDC enter the 
spleen normally, but the deficit in CCL19 and CCL21 expression prevents their retention in the 
spleen. This proffered explanation correlates well with the failed retention of iDC [which 
purportedly do not express CCR7, as they do not respond to its ligands in vitro (Table 8 and Figs 
11A and 14)] after iv injection (Figs 29 and 30). 
 
Surprisingly, sc injection proved to be the more efficient route of administration of DC in plt 
recipients (Fig 32) as compared to iv injection (Fig 33), whereas the opposite was true in normal 
BALB/c recipients (Figs 28 and 29). Perhaps even more interestingly, while both mDC subsets 
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 migrated (on average) in equal numbers to the DLN after sc injection in normal mice (Figs 29 
and 30), almost no CD8α+ mDC were detected in plt recipients by the same route of 
administration (Fig 32). Unlike iv injection (which deposits injected DC directly into the 
bloodstream), sc injection deposits injected DC into the tissue of the footpad. Thus the DC must 
traverse the peripheral tissue, reverse transmigrate lymphatic vessel walls, enter the LN, and then 
locate the T cell area. Though HEV express normal levels of CCL21 in plt mice (256), in the 
absence of concomitant expression of CCL19 and CCL21 in LN, this level may not be high 
enough to attract CD8α+ mDC out of peripheral tissues to the DLN. Another possibility is that 
CD8α+ mDC may be able reach lymphatic vessels, but again, the lack of CCL19 and CCL21 
expression by DLN may prohibit retention of CD8α+ mDC. A third possibility is that murine 
spleen mDC exhibit a differential expression of CXCR4. CXCR4 reportedly is expressed on 
mature monocyte-derived mDC (194, 315, 322) and on human blood-isolated CD11c+ and 
CD123+ iDC (193), but while neither CD11c+ nor CD123+ ex vivo-matured blood DC express 
CXCR4, CD11c+ DC still exhibit migration to CXCL12, while CD123+ DC do not. Thus 
suggesting a possible selective recruitment of CD8α- mDC to CXCL12-expressing HEV and 
DLN (342). Finally, if CD8α+ mDC require two stimuli (chemokine and another unknown in 
vivo factor) to fully extend their dendrites, the low expression of CC19 and CCL21 may an 
impediment to their prolongation. 
 
Finally, we investigated whether the number of DC injected affected their ability to be detected 
in vivo. Most of the groups injected 1 x 106 or less (52, 86, 304). We found that injecting less 
than 3 x 106 DC, regardless of route of administration, state of maturation, or subset, made 
detection of DC by immunohistochemistry or rare event analysis extremely difficult (data not 
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 shown). Thus, it is possible that in experiments where CD8α+ DC Ag presentation was evident, 
but the DC themselves were not detected in secondary lymphoid tissues (86, 304), simply may 
be due to the fact that the number of DC injected were below the threshold of detection of the 
method used.  
 
To summarize, these data indicate that CD8α+ mDC can traffic to secondary lymphoid tissues in 
vivo, and reveal that previous reports that they are incapable of doing so (86, 304) likely are due 
to a combination of lower number of DC injected and their state of maturation (iDC), as we have 
shown iDC migrate with poor efficiency regardless of subset (Figs 27 and 28). However, we also 
report for the first time that there is differential migration of mDC subsets in plt mice, possibly 
due to differential prolongation of dendritic extension.  
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 5. CHAPTER FOUR7 
 
THE ROLE OF DC RECRUITMENT TO SECONDARY LYMPHOID TISSUES IN THE 
OUTCOME OF ORGAN TRANSPLANTATION 
 
In this chapter, we exploited the CCL19/CCL21-deficient plt mouse to assess the necessity for 
DC recruitment to secondary lymphoid tissue for (initiation of) graft rejection. As the absence of 
these two chemokines delayed, but did not prevent, (cardiac) allograft rejection, we also 
investigated whether administration of a blocking Ab directed against a T cell-specific 
chemokine (CXCL9) would have an additive or synergistic effect on graft survival. As 
considered in the Discussion, differences in mean survival times between different types of 
allografts may be related to the migration patterns seen for mDC in the in vivo trafficking studies 
summarized in Chapter 3. The results also raise questions about both the number of mDC 
required to activate a naïve T cell response against alloAg and the necessity for these interactions 
to occur in classic secondary lymphoid tissue T cell areas. 
                                                 
7 Data are excerpted from (361) where indicated. 
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 5.1. ABSTRACT 
The spleen is the draining lymphoid tissue of heterotypically-transplanted intra-abdominal 
cardiac allografts (343). CD8α+ and CD8α- mDC are poorly retained in the spleens of BALB/c 
plt/plt (H2d) mice after iv injection, and those DC that do remain are not detected in T cell areas 
with high frequency. Dorsal skin transplants, however, drain to local peripheral LN as well as 
spleen (343). While CD8α+ mDC exhibit poor migration to DLN after sc injection in plt mice, 
CD8α- mDC show no significant impairment (although they do not localize exclusively in T cell 
areas, as in wt recipients). As mDC/naïve T cell interactions are believed to be necessary for the 
initiation of allograft rejection, we employed these mice as the recipients of either heart or skin 
allografts from B10 (H2b) donors to investigate the influence of impairment of mDC migration in 
vivo on allograft survival. Whereas heart grafts in plt recipients survived significantly longer as 
compared with those in wt control recipients, skin transplants were rejected with the same 
rapidity on plt as on wt. Anti-CXCL9 (monokine induced by INFγ; Mig) antiserum was then 
used to determine whether simultaneous impairment of activated T cell migration could further 
prolong cardiac allograft survival. Graft survival in plt mice after anti-CXCL9 treatment was 
extended significantly compared to that in untreated plt mice, as well as wt controls, but this 
strategy did not elicit indefinite allograft survival. It is likely that therapies involving chemokine 
blockade may be most effective in combination with other strategies. 
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 5.2. INTRODUCTION 
As discussed previously, chemokines are essential for the regulation of innate and adaptive 
immune responses (159, 344-347). The release of specific chemokines in response to “danger” 
signals, such as TNFα and IL-1, by injured endothelia (for example) results in the recruitment of 
specific immune effector cells to the site of inflammation. The expression of certain 
inflammatory chemokines by endothelial and immune (both innate and adaptive) effector cells 
has been linked to allograft rejection in various rodent models and humans (165, 222, 223, 231, 
232, 234, 237, 249, 348-354). The CXC chemokine CXCL9, which specifically recruits activated 
T cells and is released in response to IFNγ expression, has been shown to be especially important 
in the rejection in murine heart and skin allografts (224, 225, 355). Treatment with anti-CXCL9 
polyAb, but not anti-CXCL10 (IFNγ-inducible protein of 10 kDa; IP-10) [another T cell-
recruiting, inflammatory chemokine thought to be important in acute rejection (165, 225, 228, 
234, 355)], significantly prolongs skin (355) and heart graft (248) survival in MHC class II-
disparate recipients.  
 
CCL21 and CCL19 are CC chemokines expressed constitutively by HEV and lymphatic vessels 
(184) and by the endothelia of secondary lymphoid tissues (183, 208), respectively. These 
chemokines in particular aid in the regulation of immune responses through recruitment of both 
mDC from the site of inflammation and naïve and memory T cells from the blood to T cell areas 
of secondary lymphoid tissues for the initiation of adaptive immune responses (159, 184, 200, 
311, 344, 346, 356-358).  
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 We have determined that iv- or sc-injected CD8α+ mDC are not retained in the T cell areas of 
either the spleen or DLN of plt mice (Figs 31 and 32). CD8α- mDC, on the other hand, while 
also not detected in the spleen after iv-injection into plt mice, appear to reach the DLN in normal 
numbers (by qualitative analysis; compare Figs 32 and 29) within 24 h after sc injection. Unlike 
in CCL19/CCL21-expressing recipients, these DC do not localize exclusively with T cells and 
were not observed 48 h after injection (Fig 31). We hypothesized that the impaired expression of 
CCL19 and CCL21, coupled with the absence of T cell areas in the spleen and the near total lack 
of DC and T cells in LN, would drastically reduce the number of alloAg-specific T cells that 
could reach the allograft post-transplant, allowing prolongation of allograft survival.  
 
Here we show that while heart graft rejection in plt mice is significantly delayed in an MHC-
mismatched model, the absence of CCL19 and CCL21 does not affect the rejection of skin 
allografts. Administration of anti-CXCL9 (polyAb) antiserum to plt heart allograft recipients 
further significantly prolonged graft survival, indicating that rejection is at least partially T cell-
mediated, but this combination strategy was not sufficient to induce indefinite graft 
survival/tolerance. 
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 5.3. MATERIALS & METHODS 
 
5.3.1. Immunostaining of tissue sections 
Tissue samples were embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, IN), snap-
frozen in isopentane (pre-chilled in liquid N2), and stored at -80°C until use. Eight µm cryostat 
sections were mounted on slides pretreated with Vectabond (Vector Laboratories Inc, 
Burlingame, CA), air-dried, and fixed in cold 4% PFA for 10 min. Sections were blocked with 
5% v/v normal goat serum, followed by avidin blocking solution (Vector Laboratories Inc). 
Biotinylated anti-Iab (donor MHC II+ cells) mAb (BD PharMingen) followed by Cy2-
streptavidin (Jackson Laboratories) were used to detect donor DC. DAPI labeling was performed 
to nuclei identification. 
 
5.3.2. Heterotopic heart transplantation 
 
Surgical procedures were performed under inhalation anesthesia using methoxyflurane (Pitman-
Moore, Atlanta, GA). Vascularized heterotopic cardiac transplants to an abdominal site were 
performed as described (359). Contraction of the donor heart was monitored daily by abdominal 
palpation. Total cessation of cardiac contraction was defined as rejection, and confirmed by 
histological analysis. 
 
5.3.3. Skin transplantation 
Skin grafting was performed as described (360). Briefly, square full-thickness skin grafts (1 cm2) 
were prepared from the tail skin of donors. Graft beds (1 cm2) were prepared on the right lateral 
thoracic wall of the recipient mice. The graft was fixed to the graft bed with eight interrupted 
sutures of 5-0 silk thread and covered with protective tape. The first inspection was conducted 7 
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 days post grafting, followed by daily inspection. Grafts were considered as rejected at the time of 
70% necrosis. Survival was expressed as the mean survival time ± 1 SD. 
 
5.3.4. Anti-CXCL9 treatment 
To test the role of CXCL9 in heart graft rejection in plt/plt mice, graft recipients received 0.5 ml 
aliquots of rabbit anti-CXCL9 antiserum (a kind gift from Dr. Robert Fairchild, Cleveland 
Clinic, OH) or normal rabbit serum (NRS) (Cedarlane Labs Limited, Hornby, Ontario, Canada) 
(as a control), ip. every other day from day 0 to day 9 and every 3 days from day 9 to day 14 
post-transplantation, as previously described (248). 
 
5.3.5. Statistical analysis 
Graft survival data were compared by Kaplan-Meier analysis and the log-rank test. A “P” value 
< 0.05 was considered to be significant. 
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 5.4. RESULTS 
 
5.4.1. Heart, but not skin, allograft survival, is prolonged significantly in 
CCL19/CCL21-deficient recipients 
Plt (H2b) or wt control BALB/c (H2b) mice received heterotopic heart transplants from B10 
(H2d) donors. Transplants in wt mice were rejected normally, with a mean survival time of 9.2 
days. Plt recipients, however, displayed a modest but significant (P < 0.05) extension of graft 
survival, with a mean of 13.8 days (Fig 34A).  
 
Fig 34. Plt recipients show significantly prolonged heart, but not skin, allograft survival.  
(A) Heart allografts in plt recipients (squares) had a modest but significant increase in mean survival time 
as compared to wt BALB/c recipients (circles). (B) Skin grafts were rejected with equal rapidity by both 
plt (squares) and wt BALB/c (circles) recipients (361). 
 
Plt and wt mice were then transplanted with trunk skin from B10 mice to ascertain whether this 
prolongation of graft survival could be extended to non-vascularized tissues. Skin graft survival 
was monitored daily, with 70% necrosis considered rejection. Skin transplants on experimental 
and wt recipients were rejected with nearly equal rapidity (12.3 days : wt vs 13.3 days : plt) (Fig 
34B).  
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 5.4.2. MHC II+ donor cell migration to the spleen is impaired in plt heart, but not skin, 
allograft recipients 
Migration of both mDC subsets to the spleen after their iv injection was impaired significantly in 
plt mice, but CD8α- mDC appeared to traffic normally to DLN after sc injection (Figs 32 and 
33). Thus it is conceivable that alloAg-laden (donor) DC from skin grafts on plt recipients traffic 
to DLN in numbers comparable to those emigrating from skin allografts on wt BALB/c 
recipients, while fewer DC overall may be successful in trafficking to the spleen from hearts 
transplanted in plt mice (as compared to wt control recipients). Therefore, we considered 
whether numbers of donor DC reaching the lymphoid tissue might be a factor in the difference in 
rejection time between skin and heart transplants. We excised the spleens and DLN of skin and 
heart recipient plt mice 48 h after transplant. In plt recipients of heart transplants, there were 
qualitatively fewer donor MHC II+ cells in both the spleen and DLN compared to wt BALB/c 
recipients (Fig 35A and B). In both plt and wt skin transplant recipients, however, similar 
numbers of donor MHC II+ cells were detected in the spleen (Fig 35C) and DLN (Fig 35D), and 
more donor (MHC II+) DC were detected in plt skin than in heart recipient secondary lymphoid 
tissues (Fig 35).  
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 Fig 35. MHC II+ cells in plt and wt BALB/c recipients of heart and skin allografts. 
Spleens (A and C) and DLN (B and D) of heart (A and B) or skin (C and D) allograft recipients were 
removed 48 h after transplant, snap frozen, sectioned, and stained for donor MHC II (IAb; red) and nuclei 
(DAPI; blue). Considerably fewer MHC II+ cells were detected in draining lymphoid tissues of plt heart 
allograft recipients as compared to wt (A and B). In contrast, a drastic increase in number of MHC II+ 
cells were detected in secondary lymphoid tissues of plt skin allograft recipients, with comparable MHC 
II+ cells visualized in both the spleen and DLN of wt recipients. Hearts were still beating and skin 
allografts showed no signs of necropsy in all/any of the recipients at the time of sacrifice for donor MHC 
II+ cell detection. 200x (361). 
 
5.4.3. Impairment of activated T cell migration is effective in prolongation of heart 
allograft survival only in combination with deficient DC trafficking 
CXCL9 has been reported by several groups to be expressed during the rejection of skin and 
heart transplants. CXCL9 is secreted by allograft endothelial cells and recipient graft-infiltrating 
Mφ and neutrophils as early as two days posttransplant in response to IFNγ secretion (220, 225, 
248, 355). Koga et al (220, 355) have reported that administration of anti-CXCL9 antiserum to 
skin transplant recipients significantly extends allograft survival in MHC class II disparate 
models. Further, other studies by the same group have revealed that the same therapy is equally 
effective in graft survival prolongation in a heterotopic heart transplant model (248). Since, in 
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 the present study, graft survival was not indefinite in plt heart allograft recipients, we thus 
evaluated whether the additional impairment of effector T cell recruitment to the allograft could 
further enhance the delay in heart allograft rejection in plt recipients. Anti-CXCL9 antiserum 
was administered to heart allograft recipients on the day of transplant, every other day for the 
first week, and then every third day for the second week. Plt mice received either anti-CXCL9 
antiserum or normal rabbit serum (NRS) as a control. Additionally, as studies with the antiserum 
originally were conducted with a different strain combination [A/J (H2a) cardiac grafts into 
C57BL/6 (H2b); performed by Miura et al (248)], wt BALB/c heart allograft recipients also 
received either anti-CXCL9 antiserum or NRS to control for the effect that inhibition of activated 
T cell migration alone would have on allograft survival (Fig 36). 
  
Fig 36. Impairment of activated 
T cell migration alone does not 
delay heart allograft survival in 
wt BALB/c recipients.  
Heart allografts in BALB/c 
recipients administered anti-
CXCL9 had a minimal increase in 
mean survival time as compared to 
control antiserum (normal rabbit 
serum; NRS)-treated recipients 
(361). 
 
 
Anti-CXCL9 antiserum did not extend heart graft survival in wt BALB/c recipients significantly 
compared to untreated wt BALB/c recipients. Dual inhibition of activated T cell (anti-CXCL9 
antiserum) and mDC (plt recipients) migration further enhanced the survival of donor hearts, but 
again the grafts were not accepted permanently (plt alone mean 13 days vs plt + anti-CXCL9 
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 mean 21 days). Mice that received NRS treatment rejected with the same time course as mice 
that received no treatment (Fig 37).  
 
Fig 37. Dual impairment of 
mDC and effector T cell 
migration further significantly 
prolongs heart allograft 
survival in plt recipients.  
Heart allografts in plt recipients 
administered anti-CXCL9 had a 
significant increase in mean 
survival time as compared to plt 
recipients treated with control 
polyAb (normal rabbit serum; 
NRS) (361). 
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 5.5. DISCUSSION 
We have investigated the roles of specific chemokines in promoting the immune response 
against vascularized and non-vascularized allografts. CCL19 and CCL21 are key to the 
recruitment of mature DC to secondary lymphoid tissues and are important in localizing Ag-
laden DC in T cell areas. CXCL9 is expressed early in the rejection process, eliciting activated T 
cell migration to the graft. Here we have shown that the near-absence of CCL19 and the total 
lack of CCL21 in secondary lymphoid tissues (plt mice) is enough to prolong allograft survival, 
but does not completely attenuate the rejection process (Fig 34). Although impaired mDC 
migration in plt mice did not result in indefinite graft survival, blocking of activated T cell 
migration alone (CXCL9 antagonist) had no effect whatsoever on graft survival (Fig 36). 
However, combining inhibition of activated T cell recruitment with reduced mDC migration (as 
occurs in plt mice) further prolonged transplant survival, although this too was not enough to 
prevent eventual rejection (Fig 37).  
 
Plt mice infected with MHV succumb to the virus at an LD50 that is 300-fold lower than that for 
wt BALB/c mice (LD50 of 5.67 pfu for plt mice vs LD50 of 1840 pfu for BALB/c) (200). 
However, when plt mice are immunized sc, they have a delayed but hyper response to the viral 
Ag (334). In these studies, DC and T cells were unable to colocalize in conventional T cell areas, 
but instead came together in the superficial cortex of LN and in splenic bridging channels (334). 
It is possible, then, that the recruitment of mDC by CCL21-leu expressed by lymphatic vessels 
allows co-localization of alloAg-bearing mDC with naïve alloAg-specific T cells outside 
“classical” T cell areas, thus initiating allograft rejection with equal rapidity to wt recipients.  
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 Another possibility as to why heart graft rejection in plt recipients is delayed and skin allografts 
are rejected with normal speed may have to do with the number of cells required to initiate and 
mediate graft rejection. While only a few DC bearing alloAg may reach naïve spleen T cells 
capable of recognizing alloMHC, the fact that T cells in plt mice have been reported to have 
delayed but enhanced proliferation in response to specific Ags (334) suggests that only a few DC 
may be required to initiate the process. The number of dermal and epidermal “passenger” DC 
may simply be more than enough to initiate rejection. Heart allografts may have a lower 
incidence of heart “passenger leukocytes”, and therefore, their rejection may be mediated by 
recipient DC. This also could account, at least partially, for the delay in rejection, as DC would 
first have to be recruited to the graft, mature, and then “find” alloAg-specific naïve T cells 
without the aid of “classic” T cell areas. The lower incidence of donor (MHC II+) DC detected in 
secondary lymphoid tissues of plt heart allograft recipients (Fig 35A and B) versus the 
apparently normal numbers detected in wt recipients (Fig 35A and B) appears to be consistent 
with this theory. In addition, comparable numbers of MHC II+ donor cells were detected in the 
DLN of both wt and plt skin allograft recipients (Fig 35D), suggesting equal ability of donor DC 
to emigrate out of skin transplants, enter lymphatics, and reach T cell areas [consistent with our 
in vivo migration data for CD8α- mDC migration after sc injection (Fig 32)].  
 
Lakkis et al (343), have reported that murine cardiac allografts can be rejected with either intact 
spleen or LN as the draining lymphoid tissue(s), while skin allografts rely solely on T cells from 
DLN (in the absence of LN, spleen T cells alone cannot reject skin allografts). Alymphoplastic 
mice have been reported to have a slight delay in cardiac allograft rejection compared to asplenic 
mice (343), perhaps similar to plt recipients which exhibited lower numbers of donor (MHC II+) 
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 DC in both their spleen and LN (Fig 35), but had significantly delayed rejection (compared to wt 
recipients) (Fig 34). Conversely, asplenic skin allograft recipients reject their grafts normally, but 
alymphoplastic do not (343). That plt recipients have similar numbers of detectable donor (MHC 
II+) DC in their LN (as compared to wt) (Fig 35) and reject their skin allografts with equal 
rapidity to wt controls also is perhaps similar in mechanism to the Lakkis data. 
 
In skin allograft recipients, we detected similar numbers of donor MHC II+ cells in the spleen of 
plt and wt mice. This appears to be inconsistent with our in vivo trafficking experiments (Fig 33), 
as neither subset of mDC efficiently migrated to the spleen after iv injection. As we did not 
examine the spleen for CMFDA-labeled DC after sc injection into either plt or wt recipients, we 
cannot completely rule out the possibility that sc-injected/skin allograft donor mDC traffic to 
both the spleen and DLN 48 h after injection/transplant. In our experiments with hepatic mDC 
(52), we found that DC, though few, were detected in the spleen after sc injection. 
 
It is possible that the donor MHC II (Iab) detected in the spleen and DLN of the allograft 
recipients (Fig 35) are not themselves donor DC, but only donor MHC II taken up and 
transported to secondary lymphoid tissues by recipient DC (Iad). However, as allografts are 
rejected by both the direct (donor DC alloAg presentation) and indirect (recipient DC alloAg 
presentation) pathways, that fewer MHC II-alloAg-bearing recipient DC are found in plt heart 
allograft recipients at 48 h than wt or plt skin allograft recipients still does not exclude the 
possibility that the delayed heart rejection of plt recipients is at least partly mediated by a delay 
in presentation of alloAg to recipient alloreactive T cells. 
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 As DC and T cells were found to assemble in “non-classical” T cell areas in MHV-infected plt 
mice (334), it would have been informative to localize MHC II+ donor cells with recipient B and 
T cell, Mφ, and DC as we have done previously in this work. However, due to the limits in 
available primary and secondary Abs, as well as the animals from which the antibodies were 
derived, we were unable to coordinate a combination that would allow dual-staining of both Iab 
and localizing Abs. 
 
It may be that impairment of mature DC migration from the graft is useful during the early 
“danger” phases of rejection, and that combination with other therapies such as suppression of T 
cell proliferation (e.g., rapamycin) may allow the inflammatory phase to pass, permitting any 
presentation of alloAg after inflammation to be treated as other “self” Ag, rendering the immune 
system tolerant to the foreign tissue. The extended graft survival seen coupling blockade of T 
cell migration with deficient DC (and naïve T cell) migration further confirms that regulation of 
leukocyte migration may be a valuable approach to preventing rejection. Further experimentation 
in this area likely also will reveal that effective DC/T cell migration targeting strategies will 
require allograft specificity, as we have shown leukocytes likely have unique trafficking patterns 
to and from different allografts (Fig 35). Thus, it is likely that DC- and T cell-targeted therapies 
will work best in combination, and may need to be regulated according to allograft model as well 
as in conjunction with conventional anti-rejection treatment.  
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 6. SUMMARY 
 
DC are the only APC to date reported to upregulate CCR7 expression in response to 
inflammatory signals, and they are the only APC capable of activating naïve T cells. Thus, the 
migration of Ag-bearing DC from the periphery to secondary lymphoid tissues is critical for both 
the initiation of an immune response and the maintenance of tolerance to self Ags. The CD8α-
expressing DC subset originally was purported to exhibit tolerogenic effects through Fas-
mediated (CD4+ T cells) (83) and IL-2-deprivation-mediated (CD8+ T cells) (84) apoptotic cell 
death. While these observations were not borne out by subsequent experiments by other 
investigators, the expression of IDO by CD8α+ DC (305), their ability to prolong allograft 
survival even when mature (47), and their superior ability (compared to CD8α- DC) to cross 
present Ag from apoptotic bodies for induction of T reg cells (32) suggests that CD8α+ DC do 
possess some tolerogenic abilities, although the mechanisms by which they exert them are yet 
unknown (and maybe be specific to each system). These studies provide ample material with 
which to devise methods to manipulate CD8α+ DC migration, in addition to having established a 
protocol for future studies with other DC of interest (i.e., the plasmacytoid or regulatory DC, the 
migratory patterns of which are understudied). 
 
We have determined herein that while CD8α+ mDC exhibit a decreased ability to migrate to 
CCR7 ligands in vitro compared to CD8α- mDC, both subsets migrate with equal agility to T cell 
areas of secondary lymphoid tissues in vivo (in normal wt recipients), regardless of route of 
injection. On the contrary, neither spleen iDC subset migrated in response to any of the CC 
chemokines tested (despite mRNA expression and protein production for several CCR) either in 
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 vitro or in vivo. Thus it is indeed likely disparate reports regarding the ability of CD8α+ DC to 
migrate in vivo are linked to their state of maturation rather than their phenotype. 
 
Interestingly, we found that although mDC traffic with equal competence in normal wt BALB/c 
recipients, when mice deficient in lymphoid tissue CCL19 and CCL21 expression are used as 
recipients, the difference seen in DC subset migration in vitro is apparent in vivo. We found that 
while both mDC subsets migrated to/remained in T cell areas of the spleen in low numbers after 
iv injection, only CD8α+ mDC were impaired in their ability to reach/be retained within lymph 
nodes draining the footpad of plt mice. These data, coupled with the poor prolongation of 
dendritic extensions of CD8α+ mDC in response to CCL19 and CCL21, suggest that these DC 
may require both ligation of CCL19 and/or CCL21 by CCR7 as well as other as yet unknown 
factors found only in vivo to elicit full extension of their dendrites for complete facilitation of 
transmigration. As 100 nM of chemokine is a physiologically high concentration, we did not 
carry out our in vitro chemotaxis or Ca++ studies with concentrations of 1000 nM or above. Had 
we done so, we may have seen an improved chemotactic/morphologic response in CD8α+ mDC. 
The lack of a reliable anti-mouse CCR7 mAb also prevented any conclusive data regarding the 
expression of CCR7 by these DC. The advent of this, as well as mAb against the other mouse 
CR, will provide valuable insight into the trafficking patterns of i and mDC from the various 
mouse tissues from which they may be isolated. 
 
Despite the low expression of CD11b on CD8α+ DC and its reported importance in facilitating 
DC adhesion to (and eventual transmigration through) EC in humans (278, 283), blocking of this 
adhesion molecule on CD8α- DC did not appear to effect their transendothelial migration in 
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 vitro. Nor did any of the adhesion molecules blocked in our experiments show a selective 
importance for murine spleen DC subset migration [blocking of CD54 elicited in a similar 
inhibition of CD8α- and CD8α+ mDC transendothelial migration (Fig 24)], in contrast to the 
differences reported (205) in human blood-isolated DC subsets. However, in those reports, the 
DC subsets were “myeloid” (CD11c+CD123-) and plasmacytoid (CD11c-CD123+) DC – it is 
possible murine plasmacytoid spleen DC will have different reliance on adhesion molecules than 
their CD8α+ and CD8α- counterparts. It is also possible [and more likely, given that murine 
spleen pDC have similar chemotactic abilities to murine CD8α- and CD8α+ DC as reported by 
Abe et al (54)] that more extensive investigations of the ability of murine blood i and mDC to 
migrate through EC will show different adhesion molecule requirements than do murine spleen 
DC, and these may be more similar to human blood DC. Indeed, with more investigations of DC 
from various tissues, it is probable that DC migratory requirements (i.e., chemokines which elicit 
their migration and essential adhesion molecules) will be found to be linked to their method of 
generation/tissue of isolation.  
 
That CD8α- DC showed no impairment in their ability to migrate to DLN after sc injection into 
the footpads of plt recipients may in part explain why skin transplants on CCL19/CCL21 
deficient mice rejected their allografts with the same rapidity as normal BALB/c recipients, as to 
date CD8α+ DC have not been identified in peripheral tissues [without addition of an exogenous 
growth factor (52, 190)]. Additionally, the increased number of donor (MHC II+) DC present in 
secondary lymphoid tissues of plt skin versus heart recipients (the number of donor DC detected 
in plt skin recipients is qualitatively comparable to the numbers detected in wt skin recipients) is 
consistent with this theory. The delayed cardiac allograft rejection witnessed in plt recipients was 
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 further prolonged with the addition of an activated T cell migratory blocking antiserum (e.g. anti-
CXCL9 Ab), suggesting that impairment of both mDC as well as activated T cell trafficking may 
act synergistically to the benefit of the patient, especially in combination with conventional 
pharmacologic immunosuppressants. 
 
These studies have brought to light several novel findings that will further our understanding of 
DC immunobiology: (i) unlike in vitro-derived and blood human and mouse iDC populations, 
freshly-isolated mouse spleen iDC do not respond to inflammatory CC chemokines, as 
determined both by chemotaxis and Ca++ flux assays; (ii) unlike human monocyte-derived and 
blood DC, mouse splenic mDC utilize the adhesion molecule CD54, but not CD11b, CD31, or 
CD62L, for their transendothelial migration; (iii) thus, the reduced migration of CD8α+ DC 
observed both in vitro and in vivo does not appear to be due to their low expression of CD11b, 
but may be related to the expression of functional CCR7/poor ability to lengthen their dendritic 
extensions; (iv) DC trafficking to T cell areas in vivo is dependent on the state of maturation, the 
route of administration, and the number of the injected DC; (v) mDC subset migration to T cells 
of secondary lymphoid tissues is directed, at least in part, by CCL19 and CCL21, as evidenced 
by their reduced detection in these areas in spleen and DLN of plt mice;  (vi) despite their 
inability to form proper T cell areas, endogenous DC subsets are found in the normal ratio in the 
spleen and LN of plt mice; (vii) an impaired ability of alloAg-bearing DC to reach T cell areas of 
secondary lymphoid tissues post transplant can delay, but not prevent mouse cardiac allograft 
rejection; (viii) the lack of significant impairment of donor MHC II+ cells to the spleen and DLN 
in skin allograft transplantation offers one explanation as to why skin allografts on plt recipients 
are rejected with the same rapidity on normal recipients; (ix) the conflicting reports regarding the 
151 
 ability of CD8α+ DC to migrate in vivo indeed are likely to be reflective of differences in 
protocols between groups, as (with the exception of migration to DLN after sc injection into plt 
mice) in our hands, CD8α+ and CD8α- DC appear to have similar trafficking ability in vivo. 
 
Thus the experiments discussed herein have provided insight into the field of DC/chemokine 
immunobiology. These studies have provided the impetus for investigations in our own 
laboratory of the migration of (CD8α-, CD8α+, and B220+) DC subsets directly isolated from the 
liver (54), kidney (42, 190), and blood (Yuk Yuen Lan, unpublished observations). Our 
discovery that tissue-isolated iDC do not exhibit as pluripotent an ability to respond to 
inflammatory CC chemokines as previously reported in vitro-generated iDC, as well as the 
preliminary investigations of the essential adhesion molecules necessary for mDC 
transendothelial migration, will aid future studies regarding the manipulation of specific i and 
mDC subsets. Further, our investigations regarding the importance of CCL19 and CCL21 in 
facilitating mDC migration in vivo and the impact that the lack of ability of mDC to migrate 
properly in the absence of their expression has on allograft survival, commence the first steps in 
understanding DC/chemokine immunobiology in the field of transplantation.  
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